Lung Neoplasms

• 

  Subject Areas on Research

  • "Anatomically-correct" dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics. 
  • "Crazy-paving" pattern at thin-section CT of the lungs: radiologic-pathologic overview. 
  • "I Already Know That Smoking Ain't Good for Me": Patient and Clinician Perspectives on Lung Cancer Screening Decision-Making Discussions as a Teachable Moment. 
  • "Tips" on acute arthritis and clubbing. 
  • #EBUSTwitter: Novel Use of Social Media for Conception, Coordination, and Completion of an International, Multicenter Pathology Study. 
  • 18F-EF5 PET imaging as an early response biomarker for the hypoxia-activated prodrug SN30000 combined with radiation treatment in a non-small cell lung cancer xenograft model. 
  • 18F-FDG PET/CT and lung cancer: value of fourth and subsequent posttherapy follow-up scans for patient management. 
  • 18F-FDG PET/CT: Therapy Response Assessment Interpretation (Hopkins Criteria) and Survival Outcomes in Lung Cancer Patients. 
  • 1999 plenary session: Friday imaging symposium : evaluation of focal pulmonary abnormalities with FDG PET. 
  • 27-Hydroxycholesterol links hypercholesterolemia and breast cancer pathophysiology. 
  • 4D radiomics: impact of 4D-CBCT image quality on radiomic analysis. 
  • 5' CpG island methylation of the FHIT gene is correlated with loss of gene expression in lung and breast cancer. 
  • 5-Fluorouracil in childhood solid tumors. 
  • 5-day methotrexate for women with metastatic gestational trophoblastic disease. 
  • 68Ga-DOTATATE PET/CT imaging of indeterminate pulmonary nodules and lung cancer. 
  • 70 Gy thoracic radiotherapy is feasible concurrent with chemotherapy for limited-stage small-cell lung cancer: analysis of Cancer and Leukemia Group B study 39808. 
  • 73.6 Gy and beyond: hyperfractionated, accelerated radiotherapy for non-small-cell lung cancer. 
  • A 10-gene progenitor cell signature predicts poor prognosis in lung adenocarcinoma. 
  • A 3D Poly(ethylene glycol)-based Tumor Angiogenesis Model to Study the Influence of Vascular Cells on Lung Tumor Cell Behavior. 
  • A 50-year-old woman with bilateral vocal cord paralysis and hilar mass. 
  • A 63-year-old woman with weight loss and multiple lung nodules. 
  • A 66-year-old man with prostate-specific antigen recurrence and lung mass after radical prostatectomy. 
  • A Cancer and Leukemia Group B phase II study of sunitinib malate in patients with previously treated metastatic pancreatic adenocarcinoma (CALGB 80603). 
  • A Circle RNA Regulatory Axis Promotes Lung Squamous Metastasis via CDR1-Mediated Regulation of Golgi Trafficking. 
  • A Cohort Study of Mortality in Individuals With and Without Schizophrenia After Diagnosis of Lung Cancer. 
  • A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • A Cyp2a polymorphism predicts susceptibility to NNK-induced lung tumorigenesis in mice. 
  • A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo. 
  • A Direct Comparative Study of Bronchoscopic Navigation Planning Platforms for Peripheral Lung Navigation: The ATLAS Study. 
  • A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC. 
  • A Geospatial Analysis of Factors Affecting Access to CT Facilities: Implications for Lung Cancer Screening. 
  • A Human Adult Stem Cell Signature Marks Aggressive Variants across Epithelial Cancers. 
  • A Minimally Invasive Approach to Lobectomy After Induction Therapy Does Not Compromise Survival. 
  • A Multi-Institutional Study to Evaluate Automated Whole Slide Scoring of Immunohistochemistry for Assessment of Programmed Death-Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer. 
  • A National Analysis of Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Stage I Non-small-cell Lung Cancer. 
  • A National Analysis of Minimally Invasive Vs Open Segmentectomy for Stage IA Non-Small-Cell Lung Cancer. 
  • A National Analysis of Short-term Outcomes and Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Clinical Stage II Non-Small-Cell Lung Cancer. 
  • A National Survey of Pulmonologists' Views on Low-Dose Computed Tomography Screening for Lung Cancer. 
  • A Nomogram for Predicting Cancer-Specific Survival of TNM 8th Edition Stage I Non-small-cell Lung Cancer. 
  • A Novel Genetic Variant in Long Non-coding RNA Gene NEXN-AS1 is Associated with Risk of Lung Cancer. 
  • A Phase 1-2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC. 
  • A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC. 
  • A Phase II trial of Denileukin Diftitox in patients with previously treated advanced non-small cell lung cancer. 
  • A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute-International Association for the Study of Lung Cancer-Mesothelioma Applied Research Foundation Taskforce. 
  • A Randomized, Open-Label, Phase II Study Comparing Pemetrexed Plus Cisplatin Followed by Maintenance Pemetrexed versus Pemetrexed Alone in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Non-small Cell Lung Cancer after Failure of First-Line EGFR Tyrosine Kinase Inhibitor: KCSG-LU12-13. 
  • A Risk Score to Assist Selecting Lobectomy Versus Sublobar Resection for Early Stage Non-Small Cell Lung Cancer. 
  • A SMAP in the face for cancer. 
  • A TAZ-AXL-ABL2 Feed-Forward Signaling Axis Promotes Lung Adenocarcinoma Brain Metastasis. 
  • A Technique for Generating Volumetric Cine-Magnetic Resonance Imaging. 
  • A Therapeutic Antibody for Cancer, Derived from Single Human B Cells. 
  • A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers. 
  • A central role for Foxp3+ regulatory T cells in K-Ras-driven lung tumorigenesis. 
  • A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. 
  • A common polymorphism in the 3'UTR of cyclooxygenase 2/prostaglandin synthase 2 gene and risk of lung cancer in a Chinese population. 
  • A comparative analysis of EGFR-targeting antibodies for gold nanoparticle CT imaging of lung cancer. 
  • A comparison of two methodologies for radiotherapy treatment plan optimization and QA for clinical trials. 
  • A computer simulated phantom study of tomotherapy dose optimization based on probability density functions (PDF) and potential errors caused by low reproducibility of PDF. 
  • A cost analysis of hematopoietic colony-stimulating factors. 
  • A cost-minimisation analysis of lobectomy: thoracoscopic versus posterolateral thoracotomy. 
  • A dose-volume-based tool for evaluating and ranking IMRT treatment plans. 
  • A feasibility study of extended chemotherapy for locally advanced non-small cell lung cancer: a phase II trial of cancer and leukemia group B. 
  • A functional variant (-1304T>G) in the MKK4 promoter contributes to a decreased risk of lung cancer by increasing the promoter activity. 
  • A functional variant of tandem repeats in human telomerase gene was associated with survival of patients with early stages of non-small cell lung cancer. 
  • A genetic algorithm for variable selection in logistic regression analysis of radiotherapy treatment outcomes. 
  • A genomic approach to identify molecular pathways associated with chemotherapy resistance. 
  • A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. 
  • A hypothesis: indirect cell death in the radiosurgery era. 
  • A longitudinal study of quality of life in advanced non-small cell lung cancer: Cancer and Leukemia Group B (CALGB) 8931. 
  • A methodology for selecting the beam arrangement to reduce the intensity-modulated radiation therapy (IMRT) dose to the SPECT-defined functioning lung. 
  • A methodology for using SPECT to reduce intensity-modulated radiation therapy (IMRT) dose to functioning lung. 
  • A methylthioadenosine phosphorylase (MTAP) fusion transcript identifies a new gene on chromosome 9p21 that is frequently deleted in cancer. 
  • A model for morbidity after lung resection in octogenarians. 
  • A modern review of the uncertainties in volumetric imaging of respiratory-induced target motion in lung radiotherapy. 
  • A modified host-cell reactivation assay to measure repair of alkylating DNA damage for assessing risk of lung adenocarcinoma. 
  • A multi-center phase II study of weekly topotecan as second-line therapy for small cell lung cancer. 
  • A multi-scale framework with unsupervised joint training of convolutional neural networks for pulmonary deformable image registration. 
  • A multiple testing procedure to associate gene expression levels with survival. 
  • A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. 
  • A national analysis of wedge resection versus stereotactic body radiation therapy for stage IA non-small cell lung cancer. 
  • A neural network to predict symptomatic lung injury. 
  • A novel T-77C polymorphism in DNA repair gene XRCC1 contributes to diminished promoter activity and increased risk of non-small cell lung cancer. 
  • A novel classification of lung cancer into molecular subtypes. 
  • A novel polymorphism in human cytosine DNA-methyltransferase-3B promoter is associated with an increased risk of lung cancer. 
  • A pan-cancer mycobiome analysis reveals fungal involvement in gastrointestinal and lung tumors. 
  • A pencil beam dose calculation model for CyberKnife system. 
  • A perioperative strategy for the placement of a thoracic epidural catheter in a pediatric patient on high-dose enoxaprin. 
  • A phase 2 randomized trial of paclitaxel and carboplatin with or without panitumumab for first-line treatment of advanced non-small-cell lung cancer. 
  • A phase 3 trial of whole brain radiation therapy and stereotactic radiosurgery alone versus WBRT and SRS with temozolomide or erlotinib for non-small cell lung cancer and 1 to 3 brain metastases: Radiation Therapy Oncology Group 0320. 
  • A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer. 
  • A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. 
  • A phase I/II trial of TAC-101, an oral synthetic retinoid, in patients with advanced hepatocellular carcinoma. 
  • A phase I/II trial of etoposide and cisplatin in extensive small cell lung cancer: a cancer and leukemia group B study. 
  • A phase II study evaluating the efficacy of carboplatin, etoposide, and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer. 
  • A phase II study of carboplatin, etoposide, and exisulind in patients with extensive small cell lung cancer: CALGB 30104. 
  • A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer. 
  • A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602). 
  • A phase II study of induction chemotherapy followed by thoracic radiotherapy and erlotinib in poor-risk stage III non-small-cell lung cancer: results of CALGB 30605 (Alliance)/RTOG 0972 (NRG). 
  • A phase II study of paclitaxel and granulocyte colony-stimulating factor in previously untreated patients with extensive-stage small cell lung cancer: a study of the North Central Cancer Treatment Group. 
  • A phase II study of recombinant beta-interferon at maximum tolerated dose in patients with advanced non-small cell lung cancer: a cancer and leukemia group B study. 
  • A phase II study of recombinant interferon-gamma following combination chemotherapy for patients with extensive small cell lung cancer. CALGB. 
  • A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with relapsed or refractory non-small cell lung cancer. 
  • A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. 
  • A phase II trial of high dose carboplatin and paclitaxel with G-CSF and peripheral blood stem cell support followed by surgery and/or chest radiation in patients with stage III non-small cell lung cancer: CALGB 9531. 
  • A phase III study of surgical resection and paclitaxel/carboplatin chemotherapy with or without adjuvant radiation therapy for resected stage III non-small-cell lung cancer: Cancer and Leukemia Group B 9734. 
  • A phase III trial evaluating the combination of cisplatin, etoposide, and radiation therapy with or without tamoxifen in patients with limited-stage small cell lung cancer: Cancer and Leukemia Group B Study (9235). 
  • A pilot study investigating the utility of the cognitive-behavioral model of insomnia in early-stage lung cancer patients. 
  • A polymorphism within the promoter of the TGFβ1 gene is associated with radiation sensitivity using an objective radiologic endpoint. 
  • A pooled analysis of individual patient data from National Clinical Trials Network clinical trials of concurrent chemoradiotherapy for limited-stage small cell lung cancer in elderly patients versus younger patients. 
  • A pooled analysis of limited-stage small-cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. 
  • A population-based model of respiratory cancer incidence, progression, diagnosis, treatment, and mortality. 
  • A portable ventilator with integrated physiologic monitoring for hyperpolarized 129Xe MRI in rodents. 
  • A practical molecular assay to predict survival in resected non-squamous, non-small-cell lung cancer: development and international validation studies. 
  • A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology, and oncoprotein expression. 
  • A promoter polymorphism (-77T>C) of DNA repair gene XRCC1 is associated with risk of lung cancer in relation to tobacco smoking. 
  • A prospective comparison of fiberoptic transbronchial needle aspiration and bronchial biopsy for bronchoscopically visible lung carcinoma. 
  • A prospective study of plasma Selenoprotein P and lung cancer risk among low-income adults. 
  • A randomized phase II study of ifosfamide/mesna/cisplatin plus G-CSF or etoposide/cisplatin plus G-CSF in advanced non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer. 
  • A randomized trial comparing immediate versus delayed treatment of anemia with once-weekly epoetin alfa in patients with non-small cell lung cancer scheduled to receive first-line chemotherapy. 
  • A randomized trial to compare intravenous and oral etoposide in combination with cisplatin for the treatment of small cell lung cancer. 
  • A rare endobronchial neurilemmoma (Schwannoma). 
  • A reevaluation of CD22 expression in human lung cancer. 
  • A review of glioblastoma immunotherapy. 
  • A semiparametric empirical likelihood method for biased sampling schemes with auxiliary covariates. 
  • A single-arm phase II trial of pazopanib in patients with advanced non-small cell lung cancer with non-squamous histology with disease progression on bevacizumab containing therapy. 
  • A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations. 
  • A singular value decomposition linear programming (SVDLP) optimization technique for circular cone based robotic radiotherapy. 
  • A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer. 
  • A somatic TSHR mutation in a patient with lung adenocarcinoma with bronchioloalveolar carcinoma, coronary artery disease and severe chronic obstructive pulmonary disease. 
  • A stitch (or scan) in time saves nine. 
  • A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. 
  • A study of filgrastim (rG-CSF) priming of etoposide/cisplatin in advanced non-small cell lung cancer. 
  • A synthetic matrix with independently tunable biochemistry and mechanical properties to study epithelial morphogenesis and EMT in a lung adenocarcinoma model. 
  • A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer. 
  • A technique for estimating 4D-CBCT using prior knowledge and limited-angle projections. 
  • A technique of automating compensator design for lung inhomogeneity correction using an electron portal imaging device. 
  • A technique of using gated-CT images to determine internal target volume (ITV) for fractionated stereotactic lung radiotherapy. 
  • A variance components approach to categorical data models with heterogeneous cell populations: analysis of spatial gradients in lung cancer mortality rates in North Carolina counties. 
  • A variant in the CHEK2 promoter at a methylation site relieves transcriptional repression and confers reduced risk of lung cancer. 
  • ABL allosteric inhibitors synergize with statins to enhance apoptosis of metastatic lung cancer cells. 
  • ACR Appropriateness Criteria® Lung Cancer Screening. 
  • ACR Appropriateness Criteria® Noninvasive Clinical Staging of Primary Lung Cancer. 
  • APOB Genotypes and CDH13 Haplotypes in the Cholesterol-Related Pathway Genes Predict Non-Small Cell Lung Cancer Survival. 
  • ATM polymorphisms predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. 
  • Aberrant p53 staining does not predict cisplatin resistance in locally advanced non-small cell lung cancer. 
  • Aberrant promoter methylation of multiple genes in non-small cell lung cancers. 
  • Ablative Approaches for Pulmonary Metastases. 
  • Abrogation of the RB-p16 tumor suppressor pathway in human lung cancer. 
  • Absence of correlation between nuclear morphometry and survival in stage I non-small cell lung carcinoma. 
  • Accelerated decline in lung function in cigarette smokers is associated with TP53/HDM2 polymorphisms. 
  • Accelerating volumetric cine MRI (VC-MRI) using undersampling for real-time 3D target localization/tracking in radiation therapy: a feasibility study. 
  • Accentuation of differentially expressed proteins using phage technology. 
  • Accuracy of Pulmonary Nodule Sampling Using Robotic Assisted Bronchoscopy with Shape Sensing, Fluoroscopy, and Radial Endobronchial Ultrasound (The ACCURACY Study). 
  • Accuracy of clinicians and models for estimating the probability that a pulmonary nodule is malignant. 
  • Accuracy of positron emission tomography in identifying hilar (N1) lymph node involvement in non-small cell lung cancer: Implications for stereotactic body radiation therapy. 
  • Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors. 
  • Adaptation and applications of a realistic digital phantom based on patient lung tumor trajectories. 
  • Adaptation and selection shape clonal evolution of tumors during residual disease and recurrence. 
  • Adaptive border marching algorithm: automatic lung segmentation on chest CT images. 
  • Adaptive planning using positron emission tomography for locally advanced lung cancer: A feasibility study. 
  • Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints. 
  • Adaptive stereotactic body radiation therapy planning for lung cancer. 
  • Adding radiation to induction chemotherapy does not improve survival of patients with operable clinical N2 non-small cell lung cancer. 
  • Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs. 
  • Adenomas induced by polycyclic aromatic hydrocarbons in strain A/J mouse lung correlate with time-integrated DNA adduct levels. 
  • Adenovirus-mediated antisense urokinase-type plasminogen activator receptor gene transfer reduces tumor cell invasion and metastasis in non-small cell lung cancer cell lines. 
  • Adherence to Radiology Recommendations in a Clinical CT Lung Screening Program. 
  • Adjuvant Chemotherapy After Lobectomy for T1-2N0 Non-Small Cell Lung Cancer: Are the Guidelines Supported? 
  • Adjuvant Chemotherapy Does Not Confer Superior Survival in Patients With Atypical Carcinoid Tumors. 
  • Adjuvant Therapy for Patients With Early Large Cell Lung Neuroendocrine Cancer: A National Analysis. 
  • Adjuvant chemotherapy for non-small cell lung cancer. 
  • Adjuvant chemotherapy for osteosarcoma of the extremity. Long-term results of two consecutive prospective protocol studies. 
  • Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. 
  • Adjuvant therapies for non-small cell lung cancer: introduction. 
  • Adoption of Extended-Interval Dosing of Single-Agent Pembrolizumab and Comparative Effectiveness vs Standard Dosing in Time-to-Treatment Discontinuation. 
  • Adrenal insufficiency secondary to metastatic lung carcinoma: CT aided diagnosis. 
  • Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. 
  • Adult respiratory distress syndrome after limited thoracic radiotherapy. 
  • Advanced Diagnostic and Therapeutic Bronchoscopy: Technology and Reimbursement. 
  • Advanced imaging and hospice use in end-of-life cancer care. 
  • Advanced prostatic carcinoma: pulmonary manifestations. 
  • Advances in Lung Cancer Imaging. 
  • Adverse events among the elderly receiving chemotherapy for advanced non-small-cell lung cancer. 
  • Afatinib induces apoptosis in NSCLC without EGFR mutation through Elk-1-mediated suppression of CIP2A. 
  • Age differences in care practices and outcomes for hospitalized patients with cancer. 
  • Age- and sex-specific genomic profiles in non-small cell lung cancer. 
  • Aging and neoplasia. 
  • Air pollution and lung cancer mortality in Harris County, Texas, 1979-1981. 
  • Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. 
  • Akt1 deletion prevents lung tumorigenesis by mutant K-ras. 
  • All evidence points to the need for collaborative care. 
  • Alliance A082002 -a randomized phase II/III trial of modern immunotherapy-based systemic therapy with or without SBRT for PD-L1-negative, advanced non-small cell lung cancer. 
  • Alterations of LKB1 and KRAS and risk of brain metastasis: comprehensive characterization by mutation analysis, copy number, and gene expression in non-small-cell lung carcinoma. 
  • Altered protein kinase C (PKC) isoforms in non-small cell lung cancer cells: PKCdelta promotes cellular survival and chemotherapeutic resistance. 
  • Alternating irradiation and chemotherapy in stage III A and B nonsmall cell lung cancer: report of a cancer and Leukemia Group B phase II study 8636. 
  • Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. 
  • Alternatives to Lobectomy for High-Risk Patients With Early-Stage Non-Small Cell Lung Cancer. 
  • Alveolar cell carcinoma of the lung: a retrospective analysis of 205 patients. 
  • Ameloblastic carcinoma of the mandible with metastasis to the skull and lung: advanced imaging appearance including computed tomography, magnetic resonance imaging and positron emission tomography computed tomography. 
  • American Cancer Society lung cancer screening guidelines. 
  • American College of Surgeons Oncology Group and the community surgeon. 
  • An ERCC4 regulatory variant predicts grade-3 or -4 toxicities in patients with advanced non-small cell lung cancer treated by platinum-based therapy. 
  • An Exploratory Radiomics Approach to Quantifying Pulmonary Function in CT Images. 
  • An Investigation of Cancer-Directed Surgery for Different Histologic Subtypes of Malignant Pleural Mesothelioma. 
  • An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancer. 
  • An analysis of single nucleotide polymorphisms of 125 DNA repair genes in the Texas genome-wide association study of lung cancer with a replication for the XRCC4 SNPs. 
  • An epidemiological study of the role of chrysotile asbestos fibre dimensions in determining respiratory disease risk in exposed workers. 
  • An expanded risk prediction model for lung cancer. 
  • An overview of lung cancer genomics and proteomics. 
  • An unusual cause of late pain and effusion after total knee arthroplasty: pulmonary hypertrophic osteoarthropathy. A case report. 
  • Analysis of 945 cases of pulmonary metastatic melanoma. 
  • Analysis of Factors Associated With In-hospital Mortality in Lung Cancer Chemotherapy Patients With Neutropenia. 
  • Analysis of a Real-World Progression Variable and Related Endpoints for Patients with Five Different Cancer Types. 
  • Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies. 
  • Analysis of multi-arm tumor growth trials in xenograft animals using phase change adaptive piecewise quadratic models. 
  • Analysis of neuroendocrine markers, HER2 and CEA before and after chemotherapy in patients with stage IIIA non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Analysis of single nucleotide polymorphisms and radiation sensitivity of the lung assessed with an objective radiologic endpoin. 
  • Anemia and lung cancer. 
  • Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer. 
  • Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer. 
  • Angiogenesis in non-small cell lung cancer. 
  • Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. 
  • Antibodies to the GABA(B) receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. 
  • Anticancer antibodies for lung cancer. 
  • Antigen retrieval, blocking, detection and visualisation systems in immunohistochemistry: a review and practical evaluation of tyramide and rolling circle amplification systems. 
  • Antitumor activity of a monoclonal antibody directed against gastrin-releasing peptide in patients with small cell lung cancer. 
  • Archetype tasks link intratumoral heterogeneity to plasticity and cancer hallmarks in small cell lung cancer. 
  • Are discordant positron emission tomography and pathological assessments of the mediastinum in non-small cell lung cancer significant? 
  • Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1). 
  • Asbestos bodies in fine needle aspirates of the lung. 
  • Asbestos bodies in pulmonary hilar lymph nodes. 
  • Asbestos content of lung tissue and carcinoma of the lung: a clinicopathologic correlation and mineral fiber analysis of 234 cases. 
  • Asbestos content of lung tissue in asbestos associated diseases: a study of 110 cases. 
  • Asbestos content of lung tissue in patients with malignant peritoneal mesothelioma: A study of 42 cases. 
  • Asbestos fiber concentrations in the lungs of brake repair workers: commercial amphiboles levels are predictive of chrysotile levels. 
  • Asbestos fiber type in malignant mesothelioma: an analytical scanning electron microscopic study of 94 cases. 
  • Asbestos fibre dimensions and lung cancer mortality among workers exposed to chrysotile. 
  • Asbestos standards: Impact of currently uncounted chrysotile asbestos fibers on lifetime lung cancer risk. 
  • Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. 
  • Asbestos-related disease associated with exposure to asbestiform tremolite. 
  • Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies. 
  • Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury. 
  • Assessment of objective responses using volumetric evaluation in advanced thymic malignancies and metastatic non-small cell lung cancer. 
  • Assessment of pleural invasion and adhesion of lung tumors with dynamic chest radiography: A virtual clinical imaging study. 
  • Assessment of spatial variation of risks in small populations. 
  • Assessment of the impact of adjunctive proactive telephone counseling to promote smoking cessation among lung cancer patients' social networks. 
  • Assessment of the psychometric properties of an English version of the cancer dyspnea scale in people with advanced lung cancer. 
  • Assessment of the scope and quality of clinical practice guidelines in lung cancer. 
  • Association between Adult Height and Risk of Colorectal, Lung, and Prostate Cancer: Results from Meta-analyses of Prospective Studies and Mendelian Randomization Analyses. 
  • Association between CASP8 and CASP10 polymorphisms and toxicity outcomes with platinum-based chemotherapy in Chinese patients with non-small cell lung cancer. 
  • Association between RT-induced changes in lung tissue density and global lung function. 
  • Association between a rare novel TP53 variant (rs78378222) and melanoma, squamous cell carcinoma of head and neck and lung cancer susceptibility in non-Hispanic Whites. 
  • Association between glutathione S-transferase p1 polymorphisms and lung cancer risk in Caucasians: a case-control study. 
  • Association between p21 Ser31Arg polymorphism and cancer risk: a meta-analysis. 
  • Association between polymorphisms in the GSTA4 gene and risk of lung cancer: a case-control study in a Southeastern Chinese population. 
  • Association between single nucleotide polymorphisms of the transforming growth factor β1 gene and the risk of severe radiation esophagitis in patients with lung cancer. 
  • Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. 
  • Association of CASP7 polymorphisms and survival of patients with non-small cell lung cancer with platinum-based chemotherapy treatment. 
  • Association of Financial Strain With Symptom Burden and Quality of Life for Patients With Lung or Colorectal Cancer. 
  • Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. 
  • Association of a novel functional promoter variant (rs2075533 C>T) in the apoptosis gene TNFSF8 with risk of lung cancer--a finding from Texas lung cancer genome-wide association study. 
  • Association of area-level socioeconomic status and non-small cell lung cancer stage by race/ethnicity and health care-level factors: Analysis of the National Cancer Database. 
  • Association of genetic variants of O6-methylguanine-DNA methyltransferase with risk of lung cancer in non-Hispanic Whites. 
  • Association of human aryl hydrocarbon receptor gene polymorphisms with risk of lung cancer among cigarette smokers in a Chinese population. 
  • Association of plasma micronutrient levels and urinary isoprostane with risk of lung cancer: the multiethnic cohort study. 
  • Association of polymorphisms in one-carbon metabolizing genes and lung cancer risk: a case-control study in Chinese population. 
  • Association of pre-treatment radiomic features with lung cancer recurrence following stereotactic body radiation therapy. 
  • Association of tumor genomic factors and efficacy for metastasis-directed stereotactic body radiotherapy for oligometastatic colorectal cancer. 
  • Association study of nicotinic acetylcholine receptor genes identifies a novel lung cancer susceptibility locus near CHRNA1 in African-Americans. 
  • Associations between body mass index, weight loss and overall survival in patients with advanced lung cancer. 
  • Associations between genetic variants in mRNA splicing-related genes and risk of lung cancer: a pathway-based analysis from published GWASs. 
  • Associations of county-level cumulative environmental quality with mortality of chronic obstructive pulmonary disease and mortality of tracheal, bronchus and lung cancers. 
  • Asymptomatic profound sinus bradycardia (heart rate ≤45) in non-small cell lung cancer patients treated with crizotinib. 
  • Attachment styles in patients with lung cancer and their spouses: associations with patient and spouse adjustment. 
  • Atypical Localized Scleroderma Development During Nivolumab Therapy for Metastatic Lung Adenocarcinoma. 
  • Atypical metaplasia and incidence of bronchogenic carcinoma. 
  • Augmentation of CBCT Reconstructed From Under-Sampled Projections Using Deep Learning. 
  • Authors' Reply. 
  • Autocrine growth factors and neuroendocrine markers in the development of small-cell lung cancer. 
  • Automated detection of lung nodules and coronary artery calcium using artificial intelligence on low-dose CT scans for lung cancer screening: accuracy and prognostic value. 
  • Automated lung segmentation in digital chest tomosynthesis. 
  • Automated measurement of microcirculatory blood flow velocity in pulmonary metastases of rats. 
  • Autosomal dominant multiple cylindromas associated with solitary lung cylindroma. 
  • Axin gene methylation status correlates with radiosensitivity of lung cancer cells. 
  • BET Inhibitors Target the SCLC-N Subtype of Small-Cell Lung Cancer by Blocking NEUROD1 Transactivation. 
  • BW2258U89: a GRP receptor antagonist which inhibits small cell lung cancer growth. 
  • Balance of proinflammatory and antiinflammatory cytokines at thoracic cancer operation. 
  • Barriers to Prescribing Targeted Therapies for Patients With NSCLC With Highly Actionable Gene Variants in the Veterans Affairs National Precision Oncology Program. 
  • Barriers to mental health service use and preferences for addressing emotional concerns among lung cancer patients. 
  • Basic Bronchoscopy: Technology, Techniques, and Professional Fees. 
  • Basic mechanisms of therapeutic resistance to radiation and chemotherapy in lung cancer. 
  • Bayesian analysis of proportional hazards models built from monotone functions. 
  • Bayesian models for multivariate current status data with informative censoring. 
  • Behavior of patients with lung cancer: description and associations with oncologic and pain variables. 
  • Benefit of adjuvant chemotherapy after resection of stage II (T1-2N1M0) non-small cell lung cancer in elderly patients. 
  • Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. 
  • Benign metastasizing leiomyoma: a rare cause of multiple pulmonary nodules. 
  • Benzo(a)pyrene diol epoxide-induced chromosomal aberrations and risk of lung cancer. 
  • Beta-2 adrenergic receptor gene (ADRB2) polymorphism and risk for lung adenocarcinoma: a case-control study in a Chinese population. 
  • Bevacizumab-associated fistula formation in postoperative colorectal cancer patients. 
  • Bias-adjusted Kaplan-Meier survival curves for marginal treatment effect in observational studies. 
  • Bilateral pulmonary nodules in a 37-year-old woman with malignant melanoma. Pulmonary Langerhans cell histiocytosis (eosinophilic granuloma). 
  • Bilateral vocal cord paresis as a presenting sign of paraneoplastic syndrome: case report. 
  • Bimodal liquid biopsy for cancer immunotherapy based on peptide engineering and nanoscale analysis. 
  • Bioactuarial models of national mortality time series data. 
  • Biology of small cell lung cancer. 
  • Biomarkers and correlative endpoints for immunotherapy trials. 
  • Biomarkers to help guide management of patients with pulmonary nodules. 
  • Biopsy first: Lessons learned from Cancer and Leukemia Group B (CALGB) 140503. 
  • Biopsy of enlarging lesions after stereotactic radiosurgery for brain metastases frequently reveals radiation necrosis. 
  • Biplane correlation imaging: a feasibility study based on phantom and human data. 
  • Black Patients Experience Highest Rates of Cancer-associated Venous Thromboembolism. 
  • Black cohosh increases metastatic mammary cancer in transgenic mice expressing c-erbB2. 
  • Brain Metastases in Lung Cancer With Targetable Mutations-Reply. 
  • Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. 
  • Brain metastases in patients with EGFR-mutated or ALK-rearranged non-small-cell lung cancers. 
  • Bridging the translational gap: Implementation of multimodal small animal imaging strategies for tumor burden assessment in a co-clinical trial. 
  • Brief report: idiopathic diffuse hyperplasia of pulmonary neuroendocrine cells and airways disease. 
  • Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer? 
  • Bronchioloalveolar carcinoma and lung adenocarcinoma: the clinical importance and research relevance of the 2004 World Health Organization pathologic criteria. 
  • Bronchogenic carcinoma after lung transplantation: frequency, clinical characteristics, and imaging findings. 
  • C-Raf antagonizes apoptosis induced by IFN-alpha in human lung cancer cells by phosphorylation and increase of the intracellular content of elongation factor 1A. 
  • CALGB 30704 (Alliance): A randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small-cell lung cancer. 
  • CD10/NEP in non-small cell lung carcinomas. Relationship to cellular proliferation. 
  • CD10/neutral endopeptidase 24.11 hydrolyzes bombesin-like peptides and regulates the growth of small cell carcinomas of the lung. 
  • CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activation. 
  • CHML promotes liver cancer metastasis by facilitating Rab14 recycle. 
  • CIP2A mediates erlotinib-induced apoptosis in non-small cell lung cancer cells without EGFR mutation. 
  • CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer. 
  • CT for detection of malignant posterior intercostal lymph nodes in patients undergoing pre-operative staging for malignant pleural mesothelioma. 
  • CT of localized lucent lung lesions. 
  • CT of the lung: patterns of calcification and other high-attenuation abnormalities. 
  • CT screening and follow-up of lung nodules: effects of tube current-time setting and nodule size and density on detectability and of tube current-time setting on apparent size. 
  • CT screening for lung cancer: not ready for routine practice. 
  • CXCR4 enhances adhesion of B16 tumor cells to endothelial cells in vitro and in vivo via beta(1) integrin. 
  • CYFRA 21-1 as a prognostic and predictive marker in advanced non-small-cell lung cancer in a prospective trial: CALGB 150304. 
  • Calcification in pulmonary metastases. 
  • Calcitonin driven v-Ha-ras induces multilineage pulmonary epithelial hyperplasias and neoplasms. 
  • Calcitonin elevation in small cell lung cancer without ectopic production. 
  • Can we predict radiation-induced changes in pulmonary function based on the sum of predicted regional dysfunction? 
  • Cancer cachexia: Are we ready to take a step forward? 
  • Cancer chemotherapeutic response and intravenous hyperalimentaion. 
  • Cancer incidence among patients of the U.S. Veterans Affairs Health Care System. 
  • Cancer-Associated Fibroblasts Induce a Collagen Cross-link Switch in Tumor Stroma. 
  • Cancer-related fatigue. 
  • Capillary isoelectric-focusing immunoassays to study dynamic oncoprotein phosphorylation and drug response to targeted therapies in non-small cell lung cancer. 
  • Carbonic anhydrase IX in early-stage non-small cell lung cancer. 
  • Carboplatin and vinblastine in advanced non-small-cell lung cancer: a phase II study. 
  • Carboplatin, etoposide, and radiotherapy, followed by surgery, for the treatment of marginally resectable non-small cell lung cancer. 
  • Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium. 
  • Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium. 
  • Carcinogenicity of chrysotile asbestos: a case control study of textile workers. 
  • Carcinogenicity of chrysotile asbestos: evidence from cohort studies. 
  • Carcinoma of the lung in the absence of asbestosis: The value of lung fiber burden analysis. 
  • Carcinoma of the lung with osseous stromal metaplasia. 
  • Cardiac tamponade complicating trimodal therapy for malignant mesothelioma. 
  • Cardiovascular Risk in the Lung Cancer Screening Population: A Multicenter Study Evaluating the Association Between Coronary Artery Calcification and Preventive Statin Prescription. 
  • Cardiovascular comorbidities and survival of lung cancer patients: Medicare data based analysis. 
  • Caregiver-assisted coping skills training for lung cancer: results of a randomized clinical trial. 
  • Caring for Caregivers-A New Integrative Care Path for Advanced Lung Cancer Patients and Their Caregivers. 
  • Case 2: acute respiratory failure secondary to lymphangitic carcinomatosis. 
  • Case-control analysis of thymidylate synthase polymorphisms and risk of lung cancer. 
  • Caspase-2 impacts lung tumorigenesis and chemotherapy response in vivo. 
  • Causal effects of time-dependent treatments in older patients with non-small cell lung cancer. 
  • Cell motility as a prognostic factor in Stage I nonsmall cell lung carcinoma: the role of gelsolin expression. 
  • Ceramide mediates nanovesicle shedding and cell death in response to phosphatidylinositol ether lipid analogs and perifosine. 
  • Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. 
  • Challenging 30-day mortality as a site-specific quality metric in non-small cell lung cancer. 
  • Change in four measures of physical function among older adults during lung cancer treatment: A mixed methods cohort study. 
  • Changes in older adults' life space during lung cancer treatment: A mixed methods cohort study. 
  • Characteristics of lung cancer in elderly patients. 
  • Characterization of delta opioid receptors in lung cancer using a novel nonpeptidic ligand. 
  • Characterizing search, recognition, and decision in the detection of lung nodules on CT scans: elucidation with eye tracking. 
  • Characterizing the Feasibility and Performance of Real-World Tumor Progression End Points and Their Association With Overall Survival in a Large Advanced Non-Small-Cell Lung Cancer Data Set. 
  • Characterizing the developmental pathways TTF-1, NKX2-8, and PAX9 in lung cancer. 
  • Chemokine receptors and melanoma metastasis. 
  • Chemoradiation treatment patterns among United States Veteran Health Administration patients with unresectable stage III non-small cell lung cancer. 
  • Chemoradiotherapy and gefitinib in stage III non-small cell lung cancer with epidermal growth factor receptor and KRAS mutation analysis: cancer and leukemia group B (CALEB) 30106, a CALGB-stratified phase II trial. 
  • Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). 
  • Chemotherapy and high dose radiotherapy followed by resection for locally advanced nonsmall cell lung cancers. 
  • Chest case of the day. Bronchoalveolar carcinoma of the lung. 
  • Chest wall volume receiving >30 Gy predicts risk of severe pain and/or rib fracture after lung stereotactic body radiotherapy. 
  • Chromosomal aberrations of primary lung adenocarcinomas in nonsmokers. 
  • Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer. 
  • Chronic inflammation and risk of lung cancer in older adults in the health, aging and body composition cohort study. 
  • Cigarette smoking associated with lung adenocarcinoma in situ in a large case-control study (SFBALCS). 
  • Circulating mutational portrait of cancer: manifestation of aggressive clonal events in both early and late stages. 
  • Circulating vitamin D concentration and risk of seven cancers: Mendelian randomisation study. 
  • Cisplatin and etoposide versus carboplatin and paclitaxel with concurrent radiotherapy for stage III non-small-cell lung cancer: an analysis of Veterans Health Administration data. 
  • Cisplatin plus etoposide consolidation following cyclophosphamide, doxorubicin, and vincristine in limited small-cell lung cancer. 
  • Cisplatin versus carboplatin-based regimens for the treatment of patients with metastatic lung cancer. An analysis of Veterans Health Administration data. 
  • Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. 
  • Cisplatin, vinblastine, and hydrazine sulfate in advanced, non-small-cell lung cancer: a randomized placebo-controlled, double-blind phase III study of the Cancer and Leukemia Group B. 
  • Class IIb HDAC6 regulates endothelial cell migration and angiogenesis by deacetylation of cortactin. 
  • Clear-cell adenocarcinoma of the vagina and cervix in young females: analysis of 37 tumors that persisted or recurred after primary therapy. 
  • Clinical Decision Support for Symptom Management in Lung Cancer Patients: A Group RCT. 
  • Clinical Outcomes and Toxic Effects of Single-Agent Immune Checkpoint Inhibitors Among Patients Aged 80 Years or Older With Cancer: A Multicenter International Cohort Study. 
  • Clinical Significance of Lung-RADS Category 3 Lesions in the National Lung Screening Trial. 
  • Clinical and dosimetric predictors of radiation-induced esophageal toxicity. 
  • Clinical and radiographic predictors of the etiology of pulmonary nodules in HIV-infected patients. 
  • Clinical applications of PET in oncology. 
  • Clinical decisions surrounding genomic and proteomic testing among United States veterans treated for lung cancer within the Veterans Health Administration. 
  • Clinical practice. Lung cancer screening. 
  • Clinical prognostic model for older patients with advanced non-small cell lung cancer. 
  • Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer. 
  • Clinical stage I non-small cell lung cancer including FDG-PET Imaging: sites and time to recurrence. 
  • Clinical utility of serum amyloid A and macrophage migration inhibitory factor as serum biomarkers for the detection of nonsmall cell lung carcinoma. 
  • Clinical validation and utility of Percepta GSC for the evaluation of lung cancer. 
  • Clinico-pathologic conference: 12-year-old girl with fatigue, anemia, weight loss, abdominal distention, and occasional nausea and vomiting. 
  • Clonality of combined tumors. 
  • Clustering gene expression time series data using an infinite Gaussian process mixture model. 
  • Co-amplification of a novel cyclophilin-like gene (PPIE) with L-myc in small cell lung cancer cell lines. 
  • Co-clinical trials demonstrate superiority of crizotinib to chemotherapy in ALK-rearranged non-small cell lung cancer and predict strategies to overcome resistance. 
  • Codon bias imposes a targetable limitation on KRAS-driven therapeutic resistance. 
  • Colorectal Cancer Liver Metastases and Concurrent Extrahepatic Disease Treated With Resection. 
  • Combination chemotherapy and radiation therapy of undifferentiated small cell bronchogenic carcinoma. 
  • Combination chemotherapy with or without thoracic radiotherapy in limited-stage small-cell lung cancer: a randomized trial of the Southeastern Cancer Study Group. 
  • Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). 
  • Combination of flavor enhancement and chemosensory education improves nutritional status in older cancer patients. 
  • Combination regimens and dose intensification in non-small cell lung cancer: a panel discussion (Part 1). 
  • Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. 
  • Combined T2* and T1 measurements for improved perfusion and permeability studies in high field using dynamic contrast enhancement. 
  • Combined effects of the p53 and p73 polymorphisms on lung cancer risk. 
  • Combined modality trials of the Cancer and Leukemia Group B in stage III non-small-cell lung cancer: analysis of factors influencing survival and toxicity. 
  • Combining Nelfinavir With Chloroquine Inhibits In Vivo Growth of Human Lung Cancer Xenograft Tumors. 
  • Combining immunotherapy and radiotherapy for the STAR treatment. 
  • Combining multiple models to generate consensus: application to radiation-induced pneumonitis prediction. 
  • Commentary on imaging of bronchogenic carcinoma. 
  • Commentary: Breaking down non-small cell lung cancer tumor microenvironment heterogeneity and predicting response to immune checkpoint inhibitors. 
  • Commentary: Epidermal growth factor receptor mutations in resectable lung cancer: What is the prognostic importance? 
  • Commentary: New players in epidermal growth factor receptor tyrosine kinase inhibitor resistance. 
  • Commentary: Safety first! 
  • Commentary: Surgery for small cell lung cancer: This is the way. 
  • Commentary: Survival after small cell lung cancer resection: Small opportunity? 
  • Community Size and Lung Cancer Resection Outcomes: Studying The Society of Thoracic Surgeons Database. 
  • Comorbidity Profiles and Lung Cancer Screening among Older Adults: U.S. Behavioral Risk Factor Surveillance System 2017-2019. 
  • Comparative Efficacy of Treatments for Brain Metastases from Non-Small Cell Lung Cancer without an EGFR-Mutation/ALK-Rearrangement: A Systematic Review and Network Meta-Analysis. 
  • Comparative effectiveness of stereotactic radiosurgery versus whole-brain radiation therapy for patients with brain metastases from breast or non-small cell lung cancer. 
  • Comparative effectiveness research in cancer genomics and precision medicine: current landscape and future prospects. 
  • Comparative effectiveness: 18F-FDG-PET/CT versus CT for post-treatment follow-up of patients with lung cancer. 
  • Comparing a medical records-based and a claims-based index for measuring comorbidity in patients with lung or colon cancer. 
  • Comparison of CT localization radiography and high-kilovoltage chest radiography. 
  • Comparison of demographic characteristics, surgical resection patterns, and survival outcomes for veterans and nonveterans with non-small cell lung cancer in the Pacific Northwest. 
  • Comparison of liquid-based to tissue-based biopsy analysis by targeted next generation sequencing in advanced non-small cell lung cancer: a comprehensive systematic review. 
  • Comparison of performance status with peak oxygen consumption in operable patients with non-small-cell lung cancer. 
  • Comparison of plain radiography, conventional tomography, and computed tomography in detecting intrathoracic lymph node metastases from lung carcinoma. 
  • Comparison of sputum and lung asbestos body counts in former asbestos workers. 
  • Comparison of temporal changes in U.S. and Swedish lung cancer, 1950-51 to 1981-82. 
  • Comparison of whole-body FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer. 
  • Compartment model approaches for estimating the parameters of a chronic disease process under changing risk factor exposures. 
  • Complement Factor H Antibodies from Lung Cancer Patients Induce Complement-Dependent Lysis of Tumor Cells, Suggesting a Novel Immunotherapeutic Strategy. 
  • Complement factor H autoantibodies are associated with early stage NSCLC. 
  • Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis. 
  • Complications (excluding hyperinflation) involving the native lung after single-lung transplantation: incidence, radiologic features, and clinical importance. 
  • Complications Following Therapeutic Bronchoscopy for Malignant Central Airway Obstruction: Results of the AQuIRE Registry. 
  • Complications of thoracoscopic pulmonary resection. 
  • Compound haploinsufficiency of Dok2 and Dusp4 promotes lung tumorigenesis. 
  • Comprehensive Molecular and Pathologic Evaluation of Transitional Mesothelioma Assisted by Deep Learning Approach: A Multi-Institutional Study of the International Mesothelioma Panel from the MESOPATH Reference Center. 
  • Computed tomography fluoroscopy versus conventional computed tomography guidance for biopsy of intrathoracic lesions: a retrospective review of 1143 consecutive procedures. 
  • Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. 
  • Computed tomography scanning for lung cancer screening: an update. 
  • Computed tomography screening for lung cancer: where are we now? 
  • Computed tomography screening for the early detection of lung cancer. 
  • Computer-aided detection (CAD) of lung nodules in CT scans: radiologist performance and reading time with incremental CAD assistance. 
  • Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study. 
  • Concurrent chemoradiotherapy for unresectable stage III non-small cell lung cancer. 
  • Concurrent molecular alterations in tumors with germ line epidermal growth factor receptor T790M mutations. 
  • Conditional expression of the mutant Ki-rasG12C allele results in formation of benign lung adenomas: development of a novel mouse lung tumor model. 
  • Cone-beam CT localization of internal target volumes for stereotactic body radiotherapy of lung lesions. 
  • Conflict of interest disclosures. 
  • Congenital pulmonary capillary hemangiomatosis: Report of two cases and review of the literature. 
  • Congressional update: Report from the biomedical imaging program of the National Cancer Institute. Research recommendations from a lung cancer screening workshop. 
  • Consensus for Thoracoscopic Left Upper Lobectomy-Essential Components and Targets for Simulation. 
  • Consensus for Thoracoscopic Lower Lobectomy: Essential Components and Targets for Simulation. 
  • Consensus on medical treatment of non-small cell lung cancer. 
  • Consensus report IASLC workshop Bruges, September 2002: pretreatment minimal staging for non-small cell lung cancer. 
  • Consensus report of a joint NCI thoracic malignancies steering committee: FDA workshop on strategies for integrating biomarkers into clinical development of new therapies for lung cancer leading to the inception of "master protocols" in lung cancer. 
  • Consensus statement on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. 
  • Conserved transcription factor binding sites of cancer markers derived from primary lung adenocarcinoma microarrays. 
  • Contemplating genetic feedback regarding lung cancer susceptibility. 
  • Continuation of clozapine during chemotherapy: a case report and review of literature. 
  • Continuous somatosensory evoked potential monitoring during brain tumor resection. Report of four cases and review of the literature. 
  • Contouring variations and the role of atlas in non-small cell lung cancer radiation therapy: Analysis of a multi-institutional preclinical trial planning study. 
  • Contribution of environmental fibers to respiratory cancer. 
  • Control of PD-L1 Expression by Oncogenic Activation of the AKT-mTOR Pathway in Non-Small Cell Lung Cancer. 
  • Controlled aspiration of subretinal fluid in the diagnosis of carcinoma metastatic to the choroid. 
  • Controlling cancer-induced inflammation with a nucleic acid scavenger prevents lung metastasis in murine models of breast cancer. 
  • Controlling symptoms in elderly lung cancer patients. 
  • Controversial issues regarding the use of induction chemotherapy for lung cancer. 
  • Conversion to Thoracotomy During Thoracoscopic vs Robotic Lobectomy: Predictors and Outcomes. 
  • Coordinated activation of candidate proto-oncogenes and cancer testes antigens via promoter demethylation in head and neck cancer and lung cancer. 
  • Coping Skills Practice and Symptom Change: A Secondary Analysis of a Pilot Telephone Symptom Management Intervention for Lung Cancer Patients and Their Family Caregivers. 
  • Coping strategies of patients with lung cancer-related pain. 
  • Copper is required for oncogenic BRAF signalling and tumorigenesis. 
  • Correction for Systematic Bias in Radiomics Measurements Due to Variation in Imaging Protocols. 
  • Correlation between erythrocyte CR1 reduction and other blood proteinase markers in patients with malignant and inflammatory disorders. 
  • Correlation of FDG-PET imaging with Glut-1 and Glut-3 expression in early-stage non-small cell lung cancer. 
  • Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. 
  • Correlation of Regional Lung Ventilation and Gas Transfer to Red Blood Cells: Implications for Functional-Avoidance Radiation Therapy Planning. 
  • Correlation of [18F]-2-fluoro-deoxy-D-glucose positron emission tomography standard uptake values with the cellular composition of stage I nonsmall cell lung cancer. 
  • Correlation of abnormal RB, p16ink4a, and p53 expression with 3p loss of heterozygosity, other genetic abnormalities, and clinical features in 103 primary non-small cell lung cancers. 
  • Correlation of expression of bombesin-like peptides and receptors with growth inhibition by an anti-bombesin antibody in small-cell lung cancer cell lines. 
  • Correlation of tumor size and survival in patients with stage IA non-small cell lung cancer. 
  • Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. 
  • Cost-effectiveness of collecting routine cytologic specimens during fiberoptic bronchoscopy for endoscopically visible lung tumor. 
  • Cost-effectiveness of epidermal growth factor receptor mutation testing and first-line treatment with gefitinib for patients with advanced adenocarcinoma of the lung. 
  • Cost-effectiveness of follow-up of pulmonary nodules incidentally detected on cardiac computed tomographic angiography in patients with suspected coronary artery disease. 
  • Costs Associated With Lobectomy for Lung Cancer: An Analysis Merging STS and Medicare Data. 
  • County-level cumulative environmental quality associated with cancer incidence. 
  • Criterion validity of Medicare chemotherapy claims in Cancer and Leukemia Group B breast and lung cancer trial participants. 
  • Cross Cancer Genomic Investigation of Inflammation Pathway for Five Common Cancers: Lung, Ovary, Prostate, Breast, and Colorectal Cancer. 
  • Cross-Cancer Genome-Wide Analysis of Lung, Ovary, Breast, Prostate, and Colorectal Cancer Reveals Novel Pleiotropic Associations. 
  • Cross-ancestry genome-wide meta-analysis of 61,047 cases and 947,237 controls identifies new susceptibility loci contributing to lung cancer. 
  • Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. 
  • Cyclocreatine in cancer chemotherapy. 
  • Cyclooxygenase-2 (COX-2) as a predictive marker for the use of COX-2 inhibitors in advanced non-small-cell lung cancer. 
  • Cytokine profiling for prediction of symptomatic radiation-induced lung injury. 
  • Cytologic studies of glucose-6-phosphate dehydrogenase in malignancy. 
  • Cytomorphology of primary small-cell (Merkel-cell) carcinoma of the skin in fine needle aspirates. 
  • Cytosolic TMEM88 promotes invasion and metastasis in lung cancer cells by binding DVLS. 
  • DEK expression in Merkel cell carcinoma and small cell carcinoma. 
  • DNA repair capacity and lung cancer risk in never smokers. 
  • DNA repair capacity in peripheral lymphocytes predicts survival of patients with non-small-cell lung cancer treated with first-line platinum-based chemotherapy. 
  • DNA repair gene XPC genotypes/haplotypes and risk of lung cancer in a Chinese population. 
  • DNA repair gene XPD polymorphism and lung cancer risk: a meta-analysis. 
  • DOK2 inhibits EGFR-mutated lung adenocarcinoma. 
  • Data analysis: evaluation of nanoscale contrast agent enhanced CT scan to differentiate between benign and malignant lung cancer in mouse model. 
  • Dataset for Reporting of Malignant Mesothelioma of the Pleura or Peritoneum: Recommendations From the International Collaboration on Cancer Reporting (ICCR). 
  • De-escalating adjuvant durvalumab treatment duration in stage III non-small cell lung cancer. 
  • Decision tree classification of proteins identified by mass spectrometry of blood serum samples from people with and without lung cancer. 
  • Decreased tumorigenesis in mice with a Kras point mutation at C118. 
  • Deep learning model to quantify left atrium volume on routine non-contrast chest CT and predict adverse outcomes. 
  • Deep learning-based motion compensation for four-dimensional cone-beam computed tomography (4D-CBCT) reconstruction. 
  • Defining Proficiency for The Society of Thoracic Surgeons Participants Performing Thoracoscopic Lobectomy. 
  • Defining and improving postoperative care. 
  • Defining the role of adjuvant chemotherapy after lobectomy for typical bronchopulmonary carcinoid tumors. 
  • Definition and assessment of high risk in patients considered for lobectomy for stage I non-small cell lung cancer: The American Association for Thoracic Surgery expert panel consensus document. 
  • Definitive Radiotherapy for Inoperable Stage IIB Non-small-cell Lung Cancer: Patterns of Care and Comparative Effectiveness. 
  • Deletion of Atm in Tumor but not Endothelial Cells Improves Radiation Response in a Primary Mouse Model of Lung Adenocarcinoma. 
  • Delivery efficiency of an Elekta linac under gated operation. 
  • Dendriform pulmonary ossification. Report of two cases with unique findings. 
  • Depression after successful treatment for nonsmall cell lung carcinoma. 
  • Depression and Health Care Utilization at End of Life Among Older Adults With Advanced Non-Small-Cell Lung Cancer. 
  • Depression may mediate the relationship between sense of coherence and quality of life in lung cancer patients. 
  • Derlin-1 is overexpressed in non-small cell lung cancer and promotes cancer cell invasion via EGFR-ERK-mediated up-regulation of MMP-2 and MMP-9. 
  • Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung Cancer: The AEGEAN Trial. 
  • Design and inference for cancer biomarker study with an outcome and auxiliary-dependent subsampling. 
  • Design of a prospective, multicenter, global, cohort study of electromagnetic navigation bronchoscopy. 
  • Detection of Lung Nodules in Micro-CT Imaging Using Deep Learning. 
  • Detection of Occult Micrometastases in Patients With Clinical Stage I Non-Small-Cell Lung Cancer: A Prospective Analysis of Mature Results of CALGB 9761 (Alliance). 
  • Detection of human telomerase reverse transcriptase mRNA in cells obtained by lavage of the pleura is not associated with worse outcome in patients with stage I/II non-small cell lung cancer: results from Cancer and Leukemia Group B 159902. 
  • Detection of metastatic disease from carcinoma of the breast: limited value of full lung tomography. 
  • Detection of occult N2 disease with molecular techniques. 
  • Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET). 
  • Determining the optimal block margin on the planning target volume for extracranial stereotactic radiotherapy. 
  • Development and clinical evaluation of a three-dimensional cone-beam computed tomography estimation method using a deformation field map. 
  • Development of a Metastatic Spinal Tumor Frailty Index (MSTFI) Using a Nationwide Database and Its Association with Inpatient Morbidity, Mortality, and Length of Stay After Spine Surgery. 
  • Development of a virtual multidisciplinary lung cancer tumor board in a community setting. 
  • Development of bilateral acquired toxoplasmic retinochoroiditis during erlotinib therapy. 
  • Development of methods for beam angle optimization for IMRT using an accelerated exhaustive search strategy. 
  • Developmental History Provides a Roadmap for the Emergence of Tumor Plasticity. 
  • Diagnosis and treatment of stage-III peripheral squamous cell carcinoma of right upper lung. 
  • Diagnosis of lung adenocarcinoma in resected specimens: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. 
  • Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. 
  • Diagnosis of metastatic malignant melanoma by fine needle aspiration biopsy: a clinical and pathologic correlation of 298 cases. 
  • Diagnosis of metastatic renal cell carcinoma on fine-needle aspiration cytology. 
  • Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. 
  • Diagnostic Accuracy and Performance of Artificial Intelligence in Detecting Lung Nodules in Patients With Complex Lung Disease: A Noninferiority Study. 
  • Dietary folate intake and lung cancer risk in former smokers: a case-control analysis. 
  • Dietary magnesium and DNA repair capacity as risk factors for lung cancer. 
  • Differences in Active and Passive Smoking Exposures and Lung Cancer Incidence Between Veterans and Non-Veterans in the Women's Health Initiative. 
  • Differential diagnosis of pulmonary nodule. 
  • Differential effects of operative complications on survival after surgery for primary lung cancer. 
  • Differential inactivation of CDKN2 and Rb protein in non-small-cell and small-cell lung cancer cell lines. 
  • Differential prognostic significance of extralobar and intralobar nodal metastases in patients with surgically resected stage II non-small cell lung cancer. 
  • Differential screening of a human chromosome 3 library identifies hepatocyte growth factor-like/macrophage-stimulating protein and its receptor in injured lung. Possible implications for neuroendocrine cell survival. 
  • Differentiation of benign from malignant pulmonary nodules with digitized chest radiographs. 
  • Diffuse Idiopathic Pulmonary Neuroendocrine Cell Hyperplasia: Imaging and Clinical Features of a Frequently Delayed Diagnosis. 
  • Diffuse cystic lung disease at high-resolution CT. 
  • Diffuse malignant mesothelioma and synchronous lung cancer: A clinicopathological study of 18 cases. 
  • Digital synthesis of lung nodules. 
  • Digital tomosynthesis of the chest. 
  • Dimensions of elongated mineral particles: a study of more than 570 fibers from more than 90 cases with implications for pathogenicity and classification as asbestiform vs. cleavage fragments. 
  • Dinucleotide polymorphism of p73 gene is associated with a reduced risk of lung cancer in a Chinese population. 
  • Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. 
  • Dishevelled-3 activates p65 to upregulate p120-catenin transcription via a p38-dependent pathway in non-small cell lung cancer. 
  • Disparities in cancer funding. 
  • Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery. 
  • Disparities in stage at diagnosis for five common cancers in China: a multicentre, hospital-based, observational study. 
  • Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis. 
  • Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features. 
  • Distinguishing benign from malignant pulmonary nodules by computed tomography. 
  • Distress and motivation for smoking cessation among lung cancer patients' relatives who smoke. 
  • Dithiolethione compounds inhibit Akt signaling in human breast and lung cancer cells by increasing PP2A activity. 
  • Diurnal cortisol rhythm as a predictor of lung cancer survival. 
  • Divergent Interpretations of Imaging After Stereotactic Body Radiation Therapy for Lung Cancer. 
  • Do Patients Regret Having Received Systemic Treatment for Advanced Non-Small Cell Lung Cancer: A Prospective Evaluation. 
  • Do neuroendocrine cells come up large in small cell lung cancer? 
  • Do older patients with non-small cell lung cancer also benefit from first-line platinum-based doublet chemotherapy? Observations from a pooled analysis of 730 prospectively-treated patients (Alliance Study A151622). 
  • Does asbestos or asbestosis cause carcinoma of the lung? 
  • Does change in health-related quality of life score predict survival? Analysis of EORTC 08975 lung cancer trial. 
  • Does computed tomography or positron emission tomography response after neoadjuvant chemotherapy for resectable non-small-cell lung cancer predict survival? 
  • Does pneumonectomy have a role in the treatment of stage IIIA non-small cell lung cancer? 
  • Dose as a function of lung volume and planned treatment volume in helical tomotherapy intensity-modulated radiation therapy-based stereotactic body radiation therapy for small lung tumors. 
  • Dosimetric Analysis of Microscopic Disease in SBRT for Lung Cancers. 
  • Dosimetric comparison of treatment plans based on free breathing, maximum, and average intensity projection CTs for lung cancer SBRT. 
  • Dosimetric effects of rotational offsets in stereotactic body radiation therapy (SBRT) for lung cancer. 
  • Dosimetric feasibility of cone-beam CT-based treatment planning compared to CT-based treatment planning. 
  • Dosimetric verification of lung cancer treatment using the CBCTs estimated from limited-angle on-board projections. 
  • Double-blind, placebo-controlled, randomized phase 2 study of the proapoptotic agent AT-101 plus docetaxel, in second-line non-small cell lung cancer. 
  • Dual-energy micro-CT functional imaging of primary lung cancer in mice using gold and iodine nanoparticle contrast agents: a validation study. 
  • Dual-targeted hybrid nanoparticles of synergistic drugs for treating lung metastases of triple negative breast cancer in mice. 
  • Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply. 
  • Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study. 
  • Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial. 
  • Dynamic prognostication using conditional survival analysis for patients with operable lung adenocarcinoma. 
  • Dysphagia prevalence and associated survival differences in older patients with lung cancer: A SEER-Medicare population-based study. 
  • Dysregulated cholesterol homeostasis results in resistance to ferroptosis increasing tumorigenicity and metastasis in cancer. 
  • EBUS-FNA cytologic-histologic correlation of PD-L1 immunohistochemistry in non-small cell lung cancer. 
  • EGFR mutation testing and TKI treatment patterns among veterans with stage III and IV non-small cell lung cancer. 
  • ERCC6/CSB gene polymorphisms and lung cancer risk. 
  • EURACAN/IASLC Proposals for Updating the Histologic Classification of Pleural Mesothelioma: Towards a More Multidisciplinary Approach. 
  • Early Reduction in ctDNA Predicts Survival in Patients with Lung and Bladder Cancer Treated with Durvalumab. 
  • Early changes in tumor size in patients treated for advanced stage nonsmall cell lung cancer do not correlate with survival. 
  • Early detection of lung cancer in a population at high risk due to occupation and smoking. 
  • Early detection of pemetrexed-induced inhibition of thymidylate synthase in non-small cell lung cancer with FLT-PET imaging. 
  • Early pulmonary toxicity following lung stereotactic body radiation therapy delivered in consecutive daily fractions. 
  • Eaton-Lambert syndrome: a clinical and electrophysiological study of a patient treated with 4-aminopyridine. 
  • Economic burden for informal caregivers of lung and colorectal cancer patients. 
  • Effect of Lymph Node Assessment on Outcomes in Surgery for Limited Stage Small Cell Lung Cancer. 
  • Effect of adriamycin and Corynebacterium parvum in tumor-bearing mice: modulation of response to sheep red blood cells. 
  • Effect of age on the efficacy of adjuvant chemotherapy for resected non-small cell lung cancer. 
  • Effect of amifostine on survival among patients treated with radiotherapy: a meta-analysis of individual patient data. 
  • Effect of exposure to light-at-night on life span and spontaneous carcinogenesis in female CBA mice. 
  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. 
  • Effect of machine learning methods on predicting NSCLC overall survival time based on Radiomics analysis. 
  • Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients. 
  • Effect of prior antibiotic or chemotherapy treatment on immunotherapy response in non-small cell lung cancer. 
  • Effect of synthetic thymic and pineal peptides on biomarkers of ageing, survival and spontaneous tumour incidence in female CBA mice. 
  • Effect of virtual reality on time perception in patients receiving chemotherapy. 
  • Effects and tolerability of exercise therapy modality on cardiorespiratory fitness in lung cancer: a randomized controlled trial. 
  • Effects of aerobic training on oxidative status in postsurgical non-small cell lung cancer patients: a pilot study. 
  • Effects of breathing variation on gating window internal target volume in respiratory gated radiation therapya). 
  • Effects of downregulated HDAC6 expression on the proliferation of lung cancer cells. 
  • Effects of hyperthermia and irradiation on the growth of mouse melanoma tumors following immunotherapy. 
  • Effects of image processing on nodule detection rates in digitized chest radiographs: ROC study of observer performance. 
  • Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer. 
  • Efficacy and Safety of Rovalpituzumab Tesirine in Third-Line and Beyond Patients with DLL3-Expressing, Relapsed/Refractory Small-Cell Lung Cancer: Results From the Phase II TRINITY Study. 
  • Efficacy and pharmacokinetics of a modified acid-labile docetaxel-PRINT(®) nanoparticle formulation against non-small-cell lung cancer brain metastases. 
  • Efficacy and safety of virtual bronchoscopic navigation with fused fluoroscopy and vessel mapping for access of pulmonary lesions. 
  • Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. 
  • Efficacy of bevacizumab plus erlotinib versus erlotinib alone in advanced non-small-cell lung cancer after failure of standard first-line chemotherapy (BeTa): a double-blind, placebo-controlled, phase 3 trial. 
  • Efficacy of mediastinal lymph node dissection during lobectomy for lung cancer by thoracoscopy and thoracotomy. 
  • Efficacy of radiographic chest imaging in patients with testicular cancer. 
  • Eicosanoid modulation in advanced lung cancer: cyclooxygenase-2 expression is a positive predictive factor for celecoxib + chemotherapy--Cancer and Leukemia Group B Trial 30203. 
  • Elastic image mapping for 4-D dose estimation in thoracic radiotherapy. 
  • Elective nodal irradiation for locally advanced non-small-cell lung cancer: it's called cancer for a reason. 
  • Electromagnetic navigation bronchoscopy to access lung lesions in 1,000 subjects: first results of the prospective, multicenter NAVIGATE study. 
  • Electron microscopy in selection of patients with small cell carcinoma of the lung for medical versus surgical therapy. 
  • Elevated Risk of Radiation Therapy-Associated Second Malignant Neoplasms in Young African-American Women Survivors of Stage I-IIIA Breast Cancer. 
  • Endobronchial fiducial to guide stereotactic body radiotherapy. 
  • Endobronchial interstitial Au-198 implantation in the treatment of recurrent bronchogenic carcinoma. 
  • Endobronchial ultrasound versus mediastinoscopy for mediastinal nodal staging of non-small-cell lung cancer. 
  • Endoscopic ultrasound-guided fine-needle aspiration for non-small cell lung cancer staging: A systematic review and metaanalysis. 
  • Enrollment Trends and Disparity Among Patients With Lung Cancer in National Clinical Trials, 1990 to 2012. 
  • Enrollment of patients with lung and colorectal cancers onto clinical trials. 
  • Environmental malignant mesothelioma in southern Anatolia: a study of fifty cases. 
  • Environmental tobacco smoke and lung cancer risk in nonsmoking women. 
  • Eosinophilic intracytoplasmic globules in pulmonary adenocarcinomas: a histochemical, immunohistochemical, and ultrastructural study of six cases. 
  • Epidemiology of asbestos-related diseases. 
  • Epidermal Growth Factor Receptor Mutational Testing and Erlotinib Treatment Among Veterans Diagnosed With Lung Cancer in the United States Department of Veterans Affairs. 
  • Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors combined with chemotherapy in first-line treatment in an advanced non-small cell lung cancer patient with EGFR sensitive mutation. 
  • Epidermal growth factor receptor gene analysis in renal cell carcinoma. 
  • Epidermal growth factor receptor inhibitors and their role in non-small-cell lung cancer. 
  • Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer. 
  • Epidermal growth factor receptor-tyrosine kinase inhibitors in advanced squamous cell carcinoma of the lung: a meta-analysis. 
  • Epigenetic silencing of Kruppel like factor-3 increases expression of pro-metastatic miR-182. 
  • Epstein-Barr-associated leiomyomatosis and T-cell chimerism after haploidentical bone marrow transplantation for severe combined immunodeficiency disease. 
  • Equivalent Survival Between Lobectomy and Segmentectomy for Clinical Stage IA Lung Cancer. 
  • Eradication of melanoma pulmonary metastases by immunotherapy with tumor cells engineered to secrete interleukin-2 or gamma interferon. 
  • Erk/MAP kinase signaling pathway and neuroendocrine differentiation of non-small-cell lung cancer. 
  • Establishing the diagnosis of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. 
  • Establishing the feasibility of the dosimetric compliance criteria of RTOG 1308: phase III randomized trial comparing overall survival after photon versus proton radiochemotherapy for inoperable stage II-IIIB NSCLC. 
  • Estimate of lung cancer mortality from low-dose spiral computed tomography screening trials: implications for current mass screening recommendations. 
  • Estimating 4D-CBCT from prior information and extremely limited angle projections using structural PCA and weighted free-form deformation for lung radiotherapy. 
  • Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA). 
  • Estimating hidden morbidity via its effect on mortality and disability. 
  • Estimating overdiagnosis in lung cancer screening--reply. 
  • Estimating the Impact of Extended Delay to Surgery for Stage I Non-small-cell Lung Cancer on Survival. 
  • Estimating the annual frequency of synchronous brain metastasis in the United States 2010-2013: a population-based study. 
  • Estimating the magnitude and field-size dependence of radiotherapy-induced mortality and tumor control after postoperative radiotherapy for non-small-cell lung cancer: calculations from clinical trials. 
  • Estimation of error in maximal intensity projection-based internal target volume of lung tumors: a simulation and comparison study using dynamic magnetic resonance imaging. 
  • Estimation of the effects of smoking and DNA repair capacity on coefficients of a carcinogenesis model for lung cancer. 
  • Estrogen metabolism within the lung and its modulation by tobacco smoke. 
  • Etoposide (VP-16) and cisplatin at maximum tolerated dose in non-small cell lung carcinoma: a Cancer and Leukemia Group B study. 
  • Etoposide (VP-16) and cytosine arabinoside in the treatment of relapsed small-cell lung cancer. 
  • Evaluating the clinical trends and benefits of low-dose computed tomography in lung cancer patients. 
  • Evaluating the number of stages in development of squamous cell and adenocarcinomas across cancer sites using human population-based cancer modeling. 
  • Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenib. 
  • Evaluation of Safety of Stereotactic Body Radiotherapy for the Treatment of Patients With Multiple Metastases: Findings From the NRG-BR001 Phase 1 Trial. 
  • Evaluation of Simulated Lesions as Surrogates to Clinical Lesions for Thoracic CT Volumetry: The Results of an International Challenge. 
  • Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. 
  • Evaluation of primary pulmonary carcinoid tumors using FDG PET. 
  • Evaluation of two phosphorylation sites improves the prognostic significance of Akt activation in non-small-cell lung cancer tumors. 
  • Evidence for a role of Met-HGF/SF during Ras-mediated tumorigenesis/metastasis. 
  • Evidence for the treatment of patients with pulmonary nodules: when is it lung cancer?: ACCP evidence-based clinical practice guidelines (2nd edition). 
  • Evidence for type II cells as cells of origin of K-Ras-induced distal lung adenocarcinoma. 
  • Evidence that SOX2 overexpression is oncogenic in the lung. 
  • Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. 
  • Examining the role of access to care: Racial/ethnic differences in receipt of resection for early-stage non-small cell lung cancer among integrated system members and non-members. 
  • Expanding Beyond Maximum Grade: Chemotherapy Toxicity over Time by Age and Performance Status in Advanced Non-Small Cell Lung Cancer in CALGB 9730 (Alliance A151729). 
  • Experience with a CT screening program for individuals at high risk for developing lung cancer. 
  • Expert opinion: United States Preventive Services Task Force recommendation on screening for lung cancer. 
  • Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer. 
  • Exploratory thoracotomy for nonresectable lung cancer. 
  • Exploring Radiotherapy Targeting Strategy and Dose: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Stage III NSCLC. 
  • Exponential models for analyses of time-related factors, illustrated with asbestos textile worker mortality data. 
  • Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. 
  • Exposure to radon and heavy particulate pollution and incidence of brain tumors. 
  • Expression of CXC chemokine receptor-4 enhances the pulmonary metastatic potential of murine B16 melanoma cells. 
  • Expression of HIF-1alpha, CA IX, VEGF, and MMP-9 in surgically resected non-small cell lung cancer. 
  • Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells. 
  • Expression of heterogeneous nuclear ribonucleoprotein A2/B1 changes with critical stages of mammalian lung development. 
  • Expression of mutated epidermal growth factor receptor by non-small cell lung carcinomas. 
  • Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. 
  • Expression profiling of non-small cell lung carcinoma identifies metastatic genotypes based on lymph node tumor burden. 
  • Expression signatures of the lipid-based Akt inhibitors phosphatidylinositol ether lipid analogues in NSCLC cells. 
  • Extensive disease small cell lung cancer dose-response relationships: implications for resistance mechanisms. 
  • Extensive invasion of the left atrium by lung cancer. 
  • Extent of Surgery for Stage IA Non-Small-Cell Lung Cancer. Reply. 
  • Extracellular matrix protein betaig-h3/TGFBI promotes metastasis of colon cancer by enhancing cell extravasation. 
  • Extrapulmonary Findings and Malignancies in Participants Screened With Chest CT in the National Lung Screening Trial. 
  • F-18 FDG PET/CT imaging of submandibular gland oncocytoma. 
  • FDG PET of pleural effusions in patients with non-small cell lung cancer. 
  • FDG PET/CT for Primary Staging of Lung Cancer and Mesothelioma. 
  • FDG Uptake on Positron Emission Tomography Correlates with Survival and Time to Recurrence in Patients with Stage I Non-Small-Cell Lung Cancer. 
  • FDG-PET imaging in patients with paraneoplastic syndromes and suspected small cell lung cancer. 
  • FDG-PET imaging in patients with pulmonary carcinoid tumor. 
  • FHIT and FRA3B 3p14.2 allele loss are common in lung cancer and preneoplastic bronchial lesions and are associated with cancer-related FHIT cDNA splicing aberrations. 
  • FOXO transcription factors control E2F1 transcriptional specificity and apoptotic function. 
  • Facilitatory effects of 4-aminopyridine on neuromuscular transmission in disease states. 
  • Factors Associated With Successful Postoperative Day One Discharge After Anatomic Lung Resection. 
  • Factors affecting selection of operative approach and subsequent short-term outcomes after anatomic resection for lung cancer. 
  • Factors associated with the development of brain metastases: analysis of 975 patients with early stage nonsmall cell lung cancer. 
  • Failure to induce apoptosis via BCL-2 family proteins underlies lack of efficacy of combined MEK and PI3K inhibitors for KRAS-mutant lung cancers. 
  • False-negative findings for primary lung tumors on FDG positron emission tomography: staging and prognostic implications. 
  • Family matters: How MYC family oncogenes impact small cell lung cancer. 
  • Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. 
  • Fast and Furious: New Data Examining Accelerated Radiation Therapy for Limited-Stage Small Cell Lung Cancer. 
  • Fast four-dimensional cone-beam computed tomography reconstruction using deformable convolutional networks. 
  • Fatal esorubicin-induced cardiomyopathy: report of a case and review of the literature. 
  • Feasibility of Patient Reporting of Symptomatic Adverse Events via the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) in a Chemoradiotherapy Cooperative Group Multicenter Clinical Trial. 
  • Feasibility of hybrid thoracoscopic lobectomy and en-bloc chest wall resection. 
  • Feasibility of optimizing the dose distribution in lung tumors using fluorine-18-fluorodeoxyglucose positron emission tomography and single photon emission computed tomography guided dose prescriptions. 
  • Feasibility of sparing lung and other thoracic structures with intensity-modulated radiotherapy for non-small-cell lung cancer. 
  • Feasibility of using algorithm-based clinical decision support for symptom assessment and management in lung cancer. 
  • Fetal constrictive pericardial defect with pulmonary capillary hemangiomatosis. 
  • Fewer complications result from a video-assisted approach to anatomic resection of clinical stage I lung cancer. 
  • Fibrous glass and cancer. 
  • Fibulin-2 is a driver of malignant progression in lung adenocarcinoma. 
  • Final overall survival and safety update for durvalumab in third- or later-line advanced NSCLC: The phase II ATLANTIC study. 
  • Finding diagnostic biomarkers in proteomic spectra. 
  • Findings on Chest CT Performed in the Emergency Department in Patients Receiving Immune Checkpoint Inhibitor Therapy: Single-Institution 8-Year Experience in 136 Patients. 
  • Fine needle aspiration biopsy of metastatic melanoma. A morphologic analysis of 174 cases. 
  • Fine needle aspiration cytology of mucinous cystadenocarcinoma of the lung: report of a case with radiographic and histologic correlation. 
  • Fine needle aspiration of osteogenic sarcoma metastatic to the lung. A report of four cases. 
  • Fine-mapping of the 5p15.33, 6p22.1-p21.31, and 15q25.1 regions identifies functional and histology-specific lung cancer susceptibility loci in African-Americans. 
  • First clinical retrospective investigation of limited projection CBCT for lung tumor localization in patients receiving SBRT treatment. 
  • First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. 
  • First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. 
  • First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. 
  • First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743. 
  • First-line systemic therapy practice patterns and concordance with NCCN guidelines for patients diagnosed with metastatic NSCLC treated at NCCN institutions. 
  • Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer. 
  • Focal F-18 fluoro-deoxy-glucose accumulation in the lung parenchyma in the absence of CT abnormality in PET/CT. 
  • Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning. 
  • Follow-up or Surveillance (18)F-FDG PET/CT and Survival Outcome in Lung Cancer Patients. 
  • Follow-up study of chrysotile asbestos textile workers: cohort mortality and case-control analyses. 
  • Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. 
  • Forecasting health: data needs and implications for model structure. 
  • Formation of a bronchoesophageal fistula following concurrent radiation and chemotherapy for lung cancer in the setting of Behçet's disease. 
  • Four-dimensional image-based treatment planning: Target volume segmentation and dose calculation in the presence of respiratory motion. 
  • Four-dimensional magnetic resonance imaging (4D-MRI) using image-based respiratory surrogate: a feasibility study. 
  • Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis. 
  • Fractal texture analysis in computer-aided diagnosis of solitary pulmonary nodules. 
  • Free-riding and the prisoner's dilemma: problems in funding economic analyses of phase III cancer clinical trials. 
  • Frequency and prognostic significance of preoperatively detected enlarged regional lymph nodes in patients with pathological stage I non-small cell lung cancer following resection. 
  • Frequent Mutations of POT1 Distinguish Pulmonary Sarcomatoid Carcinoma From Other Lung Cancer Histologies. 
  • Frequent loss of KAI1 expression in squamous and lymphoid neoplasms. An immunohistochemical study of archival tissues. 
  • Function of the secretory immune system in bronchogenic carcinoma. Immunoglobulin A levels in respiratory secretions. 
  • Functional FLT1 Genetic Variation is a Prognostic Factor for Recurrence in Stage I-III Non-Small-Cell Lung Cancer. 
  • Functional airway obstruction observed with hyperpolarized 129 Xenon-MRI. 
  • Functional characterization of a promoter polymorphism in APE1/Ref-1 that contributes to reduced lung cancer susceptibility. 
  • Functional imaging in lung cancer. 
  • Functional polymorphisms of CHRNA3 predict risks of chronic obstructive pulmonary disease and lung cancer in Chinese. 
  • Functional polymorphisms of base excision repair genes XRCC1 and APEX1 predict risk of radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. 
  • Functional polymorphisms of matrix metalloproteinase-9 are associated with risk of occurrence and metastasis of lung cancer. 
  • Functional promoter rs2868371 variant of HSPB1 associates with radiation-induced esophageal toxicity in patients with non-small-cell lung cancer treated with radio(chemo)therapy. 
  • Functional promoter variant rs2868371 of HSPB1 is associated with risk of radiation pneumonitis after chemoradiation for non-small cell lung cancer. 
  • Functional status declines among cancer survivors: trajectory and contributing factors. 
  • Functional variants in DCAF4 associated with lung cancer risk in European populations. 
  • Future trends in lung cancer diagnosis. 
  • GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. 
  • GLUT1 Expression in Tumor-Associated Neutrophils Promotes Lung Cancer Growth and Resistance to Radiotherapy. 
  • Gastrin-releasing peptide gene expression in small cell and large cell undifferentiated lung carcinomas. 
  • Gefitinib (Iressa, ZD1839) and tyrosine kinase inhibitors: the wave of the future in cancer therapy. 
  • Gefitinib for refractory advanced non-small-cell lung cancer. 
  • Gefitinib therapy for non-small cell lung cancer. 
  • Gene by Environment Investigation of Incident Lung Cancer Risk in African-Americans. 
  • Gene therapy for lung cancer. 
  • Generalizability of trial results to elderly Medicare patients with advanced solid tumors (Alliance 70802). 
  • Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC. 
  • Genetic analysis of second primary lung cancers in patients surviving small cell lung cancer. 
  • Genetic analysis of the beta-tubulin gene, TUBB, in non-small-cell lung cancer. 
  • Genetic and environmental determinants of postthoracotomy pain syndrome. 
  • Genetic changes in contralateral bronchioloalveolar carcinomas of the lung. 
  • Genetic predisposition to lung adenocarcinoma among never-smoking Chinese with different epidermal growth factor receptor mutation status. 
  • Genetic susceptibility for lung cancer: interactions with gender and smoking history and impact on early detection policies. 
  • Genetic susceptibility of lung cancer associated with common variants in the 3' untranslated regions of the adenosine triphosphate-binding cassette B1 (ABCB1) and ABCC1 candidate transporter genes for carcinogen export. 
  • Genetic susceptibility to lung cancer: the role of DNA damage and repair. 
  • Genetic susceptibility to tobacco carcinogenesis. 
  • Genetic variant in DNA repair gene GTF2H4 is associated with lung cancer risk: a large-scale analysis of six published GWAS datasets in the TRICL consortium. 
  • Genetic variant of IRAK2 in the toll-like receptor signaling pathway and survival of non-small cell lung cancer. 
  • Genetic variants in DDO and PEX5L in peroxisome-related pathways predict non-small cell lung cancer survival. 
  • Genetic variants in ERCC1 and XPC predict survival outcome of non-small cell lung cancer patients treated with platinum-based therapy. 
  • Genetic variants in GTF2H1 and risk of lung cancer: a case-control analysis in a Chinese population. 
  • Genetic variants in MGMT and risk of lung cancer in Southeastern Chinese: a haplotype-based analysis. 
  • Genetic variants in RUNX3, AMD1 and MSRA in the methionine metabolic pathway and survival in nonsmall cell lung cancer patients. 
  • Genetic variants in peroxisome proliferator-activated receptor-gamma gene are associated with risk of lung cancer in a Chinese population. 
  • Genetic variants in the MDM2 promoter and lung cancer risk in a Chinese population. 
  • Genetic variants in the human leukocyte antigen region and survival of Chinese patients with non-small cell lung carcinoma. 
  • Genetic variants of CHEK1, PRIM2 and CDK6 in the mitotic phase-related pathway are associated with nonsmall cell lung cancer survival. 
  • Genetic variants of GADD45A, GADD45B and MAPK14 predict platinum-based chemotherapy-induced toxicities in Chinese patients with non-small cell lung cancer. 
  • Genetic variants of JNK and p38α pathways and risk of non-small cell lung cancer in an Eastern Chinese population. 
  • Genetic variants of PTPN2 are associated with lung cancer risk: a re-analysis of eight GWASs in the TRICL-ILCCO consortium. 
  • Genetic variants of genes in the Notch signaling pathway predict overall survival of non-small cell lung cancer patients in the PLCO study. 
  • Genetic variants of the LIN28B gene predict severe radiation pneumonitis in patients with non-small cell lung cancer treated with definitive radiation therapy. 
  • Genetic variants of the nonhomologous end joining gene LIG4 and severe radiation pneumonitis in nonsmall cell lung cancer patients treated with definitive radiotherapy. 
  • Genome-Wide Analysis of Sex Disparities in the Genetic Architecture of Lung and Colorectal Cancers. 
  • Genome-wide association study reveals novel genetic determinants of DNA repair capacity in lung cancer. 
  • Genome-wide gene-environment interaction analysis for asbestos exposure in lung cancer susceptibility. 
  • Genomic analysis of early-stage lung cancer reveals a role for TP53 mutations in distant metastasis. 
  • Genomic profiles specific to patient ethnicity in lung adenocarcinoma. 
  • Genomic signatures in non-small-cell lung cancer: targeting the targeted therapies. 
  • Genotypes and haplotypes of the VEGF gene and survival in locally advanced non-small cell lung cancer patients treated with chemoradiotherapy. 
  • Geographic Access to CT for Lung Cancer Screening: A Census Tract-Level Analysis of Cigarette Smoking in the United States and Driving Distance to a CT Facility. 
  • Geographic Variations in Lung Cancer Lobectomy Outcomes: The General Thoracic Surgery Database. 
  • Geriatric Assessment as a Predictor of Tolerance, Quality of Life, and Outcomes in Older Patients With Head and Neck Cancers and Lung Cancers Receiving Radiation Therapy. 
  • Global and regional burden of cancer in 2016 arising from occupational exposure to selected carcinogens: a systematic analysis for the Global Burden of Disease Study 2016. 
  • Glucocorticoid receptor triggers a reversible drug-tolerant dormancy state with acquired therapeutic vulnerabilities in lung cancer. 
  • Graded Prognostic Assessment (GPA) for Patients With Lung Cancer and Brain Metastases: Initial Report of the Small Cell Lung Cancer GPA and Update of the Non-Small Cell Lung Cancer GPA Including the Effect of Programmed Death Ligand 1 and Other Prognostic Factors. 
  • Gray-scale inversion radiographic display for the detection of pulmonary nodules on chest radiographs. 
  • Gremlin is overexpressed in lung adenocarcinoma and increases cell growth and proliferation in normal lung cells. 
  • Growth inhibition of a human lung adenocarcinoma cell line by genetic complementation with chromosome 11. 
  • Guanosine triphosphate links MYC-dependent metabolic and ribosome programs in small-cell lung cancer. 
  • Guidelines for Management of Incidental Pulmonary Nodules Detected on CT Images: From the Fleischner Society 2017. 
  • Guidelines for Pathologic Diagnosis of Malignant Mesothelioma 2017 Update of the Consensus Statement From the International Mesothelioma Interest Group. 
  • Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. 
  • Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. 
  • HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. 
  • HSPB1 gene polymorphisms predict risk of mortality for US patients after radio(chemo)therapy for non-small cell lung cancer. 
  • Haptoglobin and posttranslational glycan-modified derivatives as serum biomarkers for the diagnosis of nonsmall cell lung cancer. 
  • Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy. 
  • Heart rate decrease during crizotinib treatment and potential correlation to clinical response. 
  • Hedgehog-GLI signaling inhibition suppresses tumor growth in squamous lung cancer. 
  • Helical tomotherapy planning for lung cancer based on ventilation magnetic resonance imaging. 
  • Helping patients take control of their medical records. A case study of a personal health organizer. 
  • Hemidesmosome-like intercellular specializations in human meningiomas. 
  • High frequency of bronchogenic carcinoma after single-lung transplantation. 
  • High resolution analysis of genomic aberrations by metaphase and array comparative genomic hybridization identifies candidate tumour genes in lung cancer cell lines. 
  • High-Dose Once-Daily Thoracic Radiotherapy in Limited-Stage Small-Cell Lung Cancer: CALGB 30610 (Alliance)/RTOG 0538. 
  • High-LET Radiation Increases Tumor Progression in a K-Ras-Driven Model of Lung Adenocarcinoma. 
  • High-affinity inhibitors of dihydrofolate reductase: antimicrobial and anticancer activities of 7,8-dialkyl-1,3-diaminopyrrolo[3,2-f]quinazolines with small molecular size. 
  • High-capacity poly(2-oxazoline) formulation of TLR 7/8 agonist extends survival in a chemo-insensitive, metastatic model of lung adenocarcinoma. 
  • High-dose, hyperfractionated, accelerated radiotherapy using a concurrent boost for the treatment of nonsmall cell lung cancer: unusual toxicity and promising early results. 
  • High-grade neuroendocrine carcinomas of the lung highly express enhancer of zeste homolog 2, but carcinoids do not. 
  • Higher Use of Surgery Confers Superior Survival in Stage I Non-Small Cell Lung Cancer. 
  • Histochemical characterization of non-neuroendocrine tumors and neuroendocrine cell hyperplasia induced in hamster lung by 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone with or without hyperoxia. 
  • Histologic classification of lung cancers. Factors affecting its variability. 
  • Histologic considerations for individualized systemic therapy approaches for the management of non-small cell lung cancer. 
  • Historical perspectives of The American Association for Thoracic Surgery: Evarts A. Graham (1883-1957). 
  • Home surveillance program prevents interstage mortality after the Norwood procedure. 
  • Hope in the context of lung cancer: relationships of hope to symptoms and psychological distress. 
  • Hospital-level compliance with the commission on cancer's quality of care measures and the association with patient survival. 
  • How Good Is Positron Emission Tomography at Detecting Previously-Occult Metastatic Lung Cancer at Diagnosis? 
  • How much have adverse occupational health outcomes among construction workers improved over time? Evidence from 25 years of medical screening. 
  • How well does the new lung cancer staging system predict for local/regional recurrence after surgery?: A comparison of the TNM 6 and 7 systems. 
  • Human disease consequences of fiber exposures: a review of human lung pathology and fiber burden data. 
  • Human lung cancer cell lines exhibit resistance to retinoic acid treatment. 
  • Human recombinant stem-cell factor induces melanocytic hyperplasia in susceptible patients. 
  • Hyperbaric oxygen as a chemotherapy adjuvant in the treatment of metastatic lung tumors in a rat model. 
  • Hyperpolarized 129 Xe gas transfer MRI: the transition from 1.5T to 3T. 
  • Hyperpolarized 129Xe Magnetic Resonance Imaging for Functional Avoidance Treatment Planning in Thoracic Radiation Therapy: A Comparison of Ventilation- and Gas Exchange-Guided Treatment Plans. 
  • Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. 
  • Hypoxia, angiogenesis, and lung cancer. 
  • IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain. 
  • Identification and validation of a potential lung cancer serum biomarker detected by matrix-assisted laser desorption/ionization-time of flight spectra analysis. 
  • Identification of a highly effective rapamycin schedule that markedly reduces the size, multiplicity, and phenotypic progression of tobacco carcinogen-induced murine lung tumors. 
  • Identification of a serum microRNA expression signature for detection of lung cancer, involving miR-23b, miR-221, miR-148b and miR-423-3p. 
  • Identification of distant metastases with PET-CT in patients with suspected recurrent head and neck cancer. 
  • Identification of distant metastases with positron-emission tomography-computed tomography in patients with previously untreated head and neck cancer. 
  • Identification of risk loci and a polygenic risk score for lung cancer: a large-scale prospective cohort study in Chinese populations. 
  • Identification of small lung nodules at autopsy: implications for lung cancer screening and overdiagnosis bias. 
  • Identifying symptomatic adverse events using the patient-reported outcomes version of the common terminology criteria for adverse events in patients with non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations. 
  • If at First You Don't Succeed-Stereotactic Body Radiation Therapy for Recurrent Non-Small Cell Lung Cancer. 
  • If histology matters.. 
  • Image acquisition optimization of a limited-angle intrafraction verification (LIVE) system for lung radiotherapy. 
  • Images in clinical medicine. Malignant pericardial effusion. 
  • Imaging bronchogenic carcinoma. 
  • Imaging genotyping of functional signaling pathways in lung squamous cell carcinoma using a radiomics approach. 
  • Imaging lung cancer. 
  • Imaging of mediastinal lymph nodes: CT, MR, and FDG PET. 
  • Immunohistochemical and ultrastructural markers suggest different origins for cuboidal and polygonal cells in pulmonary sclerosing hemangioma. 
  • Immunohistochemical detection of occult lymph node metastases in non-small cell lung cancer: anatomical pathology results from Cancer and Leukemia Group B Trial 9761. 
  • Immunostaining in lung cancer for the clinician. Commonly used markers for differentiating primary and metastatic pulmonary tumors. 
  • Immunotherapy Utilization Among Patients With Metastatic NSCLC: Impact of Comorbidities. 
  • Immunotherapy for Resected Pulmonary Metastases. 
  • Immunotherapy of surgical malignancies. 
  • Immunotoxin Therapy for Lung Cancer. 
  • Immunotoxins that target an oncogenic mutant epidermal growth factor receptor expressed in human tumors. 
  • Impact of Age on Long-Term Outcomes of Surgery for Malignant Pleural Mesothelioma. 
  • Impact of Chest Wall Resection on Mortality After Lung Resection for Non-Small Cell Lung Cancer. 
  • Impact of Esophageal Motion on Dosimetry and Toxicity With Thoracic Radiation Therapy. 
  • Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non-Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry. 
  • Impact of HIV on lung tumorigenesis in an animal model. 
  • Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC Study. 
  • Impact of Pulmonary Function Measurements on Long-Term Survival After Lobectomy for Stage I Non-Small Cell Lung Cancer. 
  • Impact of Race on Treatment and Survival among U.S. Veterans with Early-Stage Lung Cancer. 
  • Impact of Surveillance After Lobectomy for Lung Cancer on Disease Detection and Survival. 
  • Impact of T status and N status on perioperative outcomes after thoracoscopic lobectomy for lung cancer. 
  • Impact of Timing of Lobectomy on Survival for Clinical Stage IA Lung Squamous Cell Carcinoma. 
  • Impact of a multidisciplinary thoracic oncology clinic on the timeliness of care. 
  • Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. 
  • Impact of computed tomography-positron emission tomography fusion in staging patients with thoracic malignancies. 
  • Impact of dose calculation accuracy during optimization on lung IMRT plan quality. 
  • Impact of image quality, radiologists, lung segments, and Gunnar eyewear on detectability of lung nodules in chest CT. 
  • Impact of mesothelioma histologic subtype on outcomes in the Surveillance, Epidemiology, and End Results database. 
  • Impact of patient selection and treatment strategies on outcomes after lobectomy for biopsy-proven stage IIIA pN2 non-small cell lung cancer. 
  • Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. 
  • Impact of the Percepta Genomic Classifier on Clinical Management Decisions in a Multicenter Prospective Study. 
  • Implementation and Effectiveness of a Veterans Affairs-Based Comprehensive Lung Cancer Survivorship Program. 
  • Implementation of Lung Cancer Screening in the Veterans Health Administration. 
  • Implementation of new clinical programs in the VHA healthcare system: the importance of early collaboration between clinical leadership and research. 
  • Implementing Lung Cancer Screening Using Low-Dose Computed Tomography: Recommendations From an Expert Panel. 
  • Importance of integrating nanotechnology with pharmacology and physiology for innovative drug delivery and therapy - an illustration with firsthand examples. 
  • Improved Survival of Stage I Non-Small Cell Lung Cancer: A VA Central Cancer Registry Analysis. 
  • Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. 
  • Improved survival with pulmonary metastasectomy: an analysis of 1720 patients with pulmonary metastatic melanoma. 
  • Improving DNA double-strand repair inhibitor KU55933 therapeutic index in cancer radiotherapy using nanoparticle drug delivery. 
  • In Reply to "Malignant Mesothelioma and Its Nonasbestos Causes". 
  • In Reply to Giron et al. 
  • In reply to Kumar et al. 
  • In reply to Robins et al. 
  • In situ detection of Epstein-Barr virus in non-small cell lung carcinomas. 
  • In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. 
  • In vitro determination of thymidine-3H labeling index in human solid tumors. 
  • In vitro induction of benzo(a)pyrene diol epoxide-DNA adducts in peripheral lymphocytes as a susceptibility marker for human lung cancer. 
  • Incidental findings on cardiac multidetector row computed tomography among healthy older adults: prevalence and clinical correlates. 
  • Incidental, subsolid pulmonary nodules at CT: etiology and management. 
  • Incorporating single-nucleotide polymorphisms into the Lyman model to improve prediction of radiation pneumonitis. 
  • Increased lung cancer mortality among chrysotile asbestos textile workers is more strongly associated with exposure to long thin fibres. 
  • Increased microvascular density predicts relapse in Wilms' tumor. 
  • Increased type III TGF-β receptor shedding decreases tumorigenesis through induction of epithelial-to-mesenchymal transition. 
  • Increasing PET Use in Small Cell Lung Cancer: Survival Improvement and Stage Migration in the VA Central Cancer Registry. 
  • Induction Chemotherapy is Not Superior to a Surgery-First Strategy for Clinical N1 Non-Small Cell Lung Cancer. 
  • Induction and spontaneous regression of intense pulmonary neuroendocrine cell differentiation in a model of preneoplastic lung injury. 
  • Induction and spontaneous regression of pulmonary neuroendocrine cell hyperplasia in a hamster model. 
  • Induction chemoradiation is not superior to induction chemotherapy alone in stage IIIA lung cancer. 
  • Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III Non-small-cell lung cancer: Cancer and Leukemia Group B. 
  • Induction chemotherapy for T3N0M0 non-small-cell lung cancer increases the rate of complete resection but does not confer improved survival. 
  • Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. 
  • Induction of preneoplastic lung lesions in guinea pigs by cigarette smoke inhalation and their exacerbation by high dietary levels of vitamins C and E. 
  • Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. 
  • Induction of wild-type p53 activity in human cancer cells by ribozymes that repair mutant p53 transcripts. 
  • Induction or consolidation systemic therapy in the multimodality treatment of unresectable locally advanced non-small cell lung cancer. 
  • Induction paclitaxel/carboplatin followed by concurrent chemoradiation therapy for unresectable stage III non-small-cell lung cancer: a limited-access study--CALGB 9534. 
  • Influence of comorbidity on racial differences in receipt of surgery among US veterans with early-stage non-small-cell lung cancer. 
  • Inherent variability of CT lung nodule measurements in vivo using semiautomated volumetric measurements. 
  • Inhibiting the inhibitor: targeting vascular endothelial protein tyrosine phosphatase to promote tumor vascular maturation. 
  • Inhibition of Karyopherin β1-Mediated Nuclear Import Disrupts Oncogenic Lineage-Defining Transcription Factor Activity in Small Cell Lung Cancer. 
  • Inhibition of haematogenous metastasis of colon cancer in mice by a selective COX-2 inhibitor, JTE-522. 
  • Inhibition of the epidermal growth factor receptor in combined modality treatment for locally advanced non-small cell lung cancer. 
  • Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody. 
  • Inhibition of the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway but not the MEK/ERK pathway attenuates laminin-mediated small cell lung cancer cellular survival and resistance to imatinib mesylate or chemotherapy. 
  • Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. 
  • Initial and Longitudinal Cost of Surgical Resection for Lung Cancer. 
  • Inosine Monophosphate Dehydrogenase Dependence in a Subset of Small Cell Lung Cancers. 
  • Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors. 
  • Integrated cistromic and expression analysis of amplified NKX2-1 in lung adenocarcinoma identifies LMO3 as a functional transcriptional target. 
  • Integration of biomarkers and imaging. 
  • Integration of immunotherapy into adjuvant therapy for resected non-small-cell lung cancer: ALCHEMIST chemo-IO (ACCIO). 
  • Integration of peripheral blood biomarkers with computed tomography to differentiate benign from malignant pulmonary opacities. 
  • Integrative Molecular Characterization of Malignant Pleural Mesothelioma. 
  • Intensive etoposide and carboplatin chemotherapy for advanced non-small-cell lung cancer. A phase II trial of the Cancer and Leukemia Group B. 
  • Intercellular junctions and tumor behavior in lung cancer. 
  • Intercellular junctions and tumor stage in small cell carcinoma of the lung. 
  • Interest in testing for genetic susceptibility to lung cancer among Black college students "at risk" of becoming cigarette smokers. 
  • Interhospital variability in localization techniques for small pulmonary nodules in children: A pediatric surgical oncology research collaborative study. 
  • Interinstitutional variation in management decisions for treatment of 4 common types of cancer: A multi-institutional cohort study. 
  • Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. 
  • Interleukin-2 reverses CD8(+) T cell exhaustion in clinical malignant pleural effusion of lung cancer. 
  • Internally administered isotopes in the treatment of solid malignancy. 
  • International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. 
  • International practice survey on palliative lung radiotherapy: third international consensus workshop on palliative radiotherapy and symptom control. 
  • Interpathologist Diagnostic Agreement for Non-Small Cell Lung Carcinomas Using Current and Recent Classifications. 
  • Interpretation of genetic risk feedback among African American smokers with low socioeconomic status. 
  • Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery. 
  • Interruptions of once-daily thoracic radiotherapy do not correlate with outcomes in limited stage small cell lung cancer: analysis of CALGB phase III trial 9235. 
  • Interventions designed to increase the uptake of lung cancer screening and implications for priority populations: a scoping review protocol. 
  • Interventions to improve lung cancer screening among racially and ethnically minoritized groups: A scoping review. 
  • Intraoperative electron beam radiation therapy for retroperitoneal soft tissue sarcoma. 
  • Intraoperative radioisotope sentinel lymph node mapping in non-small cell lung cancer. 
  • Intraoperative sentinel node mapping with technitium-99 in lung cancer: results of CALGB 140203 multicenter phase II trial. 
  • Intrathoracic metastasis from an extrathoracic malignancy: a radiographic approach to patient evaluation. 
  • Intravascular bronchioloalveolar tumor of the lung presenting as pulmonary thromboembolic disease and pulmonary hypertension. 
  • Intravascular location of breast cancer cells after spontaneous metastasis to the lung. 
  • Intravenous 6-thioguanine or cisplatin, fluorouracil and leucovorin for advanced non-small cell lung cancer: a randomized phase II study of the cancer and leukemia group B. 
  • Invasive Mediastinal Staging for Lung Cancer by The Society of Thoracic Surgeons Database Participants. 
  • Invasive staging of non-small cell lung cancer: a review of the current evidence. 
  • Investigating the prognostic ability of health-related quality of life on survival: a prospective cohort study of adults with lung cancer. 
  • Investigations of new drugs in combination with cisplatin in stage III non-small cell lung cancer. 
  • Invited Commentary. 
  • Invited Commentary. 
  • Invited Commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Invited commentary. 
  • Irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Is follow-up CT imaging of the chest and abdomen necessary after preoperative neoadjuvant therapy in rectal cancer patients without evidence of metastatic disease at diagnosis? 
  • Is quality of life predictive of the survival of patients with advanced nonsmall cell lung carcinoma? 
  • Isoform-Specific Effects of Wild-Type Ras Genes on Carcinogen-Induced Lung Tumorigenesis in Mice. 
  • Issues with implementing a high-quality lung cancer screening program. 
  • Joint effects of dietary trace metals and DNA repair capacity in lung cancer risk. 
  • Just buckle up. 
  • KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors. 
  • Kaposi sarcoma after bilateral lung transplantation. 
  • Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. 
  • Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis. 
  • Killing SCLC: insights into how to target a shapeshifting tumor. 
  • LY2109761, a novel transforming growth factor beta receptor type I and type II dual inhibitor, as a therapeutic approach to suppressing pancreatic cancer metastasis. 
  • Lack of correlation between short- and long-term performance after lung cancer surgery. 
  • Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B. 
  • Lambert-Eaton myasthenic syndrome (LEMS). Clinical and electrodiagnostic features and response to therapy in 59 patients. 
  • Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. 
  • Lambert-Eaton myasthenic syndrome: pathogenesis and treatment. 
  • Lambert-Eaton myasthenic syndrome: the lack of short-term in vitro effects of serum factors on neuromuscular transmission. 
  • Large clinical databases for the study of lung cancer: Making up for the failure of randomized trials. 
  • Laryngeal transplantation in the setting of cancer: a rat model. 
  • Late pulmonary metastases from hemangiopericytoma of the mandible: unusual findings on CT and MR imaging. 
  • Latency analysis in occupational epidemiology. 
  • Less is more: a shift in the surgical approach to non-small-cell lung cancer. 
  • Less is sometimes less. 
  • Letter to the editor: "Comparing milled fiber, Quebec ore, and textile factory dust: has another piece of the asbestos puzzle fallen into place?" by D. Wayne Berman. 
  • Letters of Correspondence: Telehealth, Post-Acute Sequelae of COVID-19, Lung Cancer Screening Rates. 
  • Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. 
  • Lifetime Occurrence of Brain Metastases Arising from Lung, Breast, and Skin Cancers in the Elderly: A SEER-Medicare Study. 
  • Limited-stage small-cell lung cancer (stages I-III): observations from the National Cancer Data Base. 
  • Lithium carbonate in patients with small cell lung cancer receiving combination chemotherapy. 
  • Lobar or Sublobar Resection for Peripheral Stage IA Non-Small-Cell Lung Cancer. 
  • Lobectomy by Video-Assisted Thoracic Surgery or Muscle-Sparing Thoracotomy for Stage 1 Lung Cancer: Could Cost-Effectiveness Give the Answer? 
  • Local control without resection. 
  • Local failure in resected N1 lung cancer: implications for adjuvant therapy. 
  • Local mutational diversity drives intratumoral immune heterogeneity in non-small cell lung cancer. 
  • Local recurrence after surgery for early stage lung cancer: an 11-year experience with 975 patients. 
  • Local recurrence after surgery for non-small cell lung cancer: a recursive partitioning analysis of multi-institutional data. 
  • Local recurrence following initial resection of NSCLC: salvage is possible with radiation therapy. 
  • Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. 
  • Localization of occult bronchogenic carcinoma by bronchography. 
  • Localized adenocarcinoma of the lung: oncogene expression of erbB-2 and p53 in 150 patients. 
  • Localized peribronchial thickening: a CT sign of occult bronchogenic carcinoma. 
  • Location of the Tumor is a "Central" Predictor of Nodal (N1) Upstaging. 
  • Long-Term Outcomes of Lobectomy for Non-Small Cell Lung Cancer After Definitive Radiation Treatment. 
  • Long-term Survival After Surgery Compared With Concurrent Chemoradiation for Node-negative Small Cell Lung Cancer. 
  • Long-term outcomes after lobectomy for non-small cell lung cancer when unsuspected pN2 disease is found: A National Cancer Data Base analysis. 
  • Long-term outcomes of surgical resection for stage IV non-small-cell lung cancer: A national analysis. 
  • Long-term outcomes of thoracoscopic lobectomy. 
  • Long-term survival follow-up of atezolizumab in combination with platinum-based doublet chemotherapy in patients with advanced non-small-cell lung cancer. 
  • Long-term survival following open versus thoracoscopic lobectomy after preoperative chemotherapy for non-small cell lung cancer. 
  • Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis. 
  • Longitudinal Follow-up of Lung Cancer Resection From the Society of Thoracic Surgeons General Thoracic Surgery Database in Patients 65 Years and Older. 
  • Longitudinal monitoring of EGFR mutations in plasma predicts outcomes of NSCLC patients treated with EGFR TKIs: Korean Lung Cancer Consortium (KLCC-12-02). 
  • Loss of Fhit expression in non-small-cell lung cancer: correlation with molecular genetic abnormalities and clinicopathological features. 
  • Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. 
  • Loss of cytoplasmic CDK1 predicts poor survival in human lung cancer and confers chemotherapeutic resistance. 
  • Loss of heterozygosity at the mannose 6-phosphate insulin-like growth factor 2 receptor (M6P/IGF2R) locus predisposes patients to radiation-induced lung injury. 
  • Low morbidity and mortality for bronchoplastic procedures with and without induction therapy. 
  • Low-Dose Computed Tomography: Effects of Oncology Nurse Navigation on Lung Cancer Screening. 
  • Low-dose computed tomographic screening for lung cancer. 
  • Low-dose spiral computed tomography screening for lung cancer: not ready for prime time. 
  • Lung Cancer Diagnosed Through Screening, Lung Nodule, and Neither Program: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta Cohort. 
  • Lung Cancer Recurrence: 18F-FDG PET/CT in Clinical Practice. 
  • Lung Cancer Risk Associated with Regulated and Unregulated Chrysotile Asbestos Fibers. 
  • Lung Cancer Screening Eligibility and Use: A Population Health Perspective of One Community. 
  • Lung Cancer Screening in Never Smokers: Counterpoint-Cannot Identify Which Never Smokers Are at Sufficient Risk to Balance the Potential Harms of Screening. 
  • Lung Cancer Screening with Chest CT: Efficacy Confirmed. 
  • Lung Cancer Screening, Version 3.2018, NCCN Clinical Practice Guidelines in Oncology. 
  • Lung Cancers Associated With Cystic Airspaces: Natural History, Pathologic Correlation, and Mutational Analysis. 
  • Lung IMRT planning with automatic determination of beam angle configurations. 
  • Lung cancer and positron emission tomography with fluorodeoxyglucose. 
  • Lung cancer chemoprevention: ACCP evidence-based clinical practice guidelines (2nd Edition). 
  • Lung cancer heterogeneity. Prognostic implications. 
  • Lung cancer heterogeneity: a blinded and randomized study of 100 consecutive cases. 
  • Lung cancer in Florida. Risks associated with residence in the central Florida phosphate mining region. 
  • Lung cancer in North Carolina. 
  • Lung cancer in the elderly. 
  • Lung cancer in the elderly. 
  • Lung cancer in women. 
  • Lung cancer incidence and mortality in National Lung Screening Trial participants who underwent low-dose CT prevalence screening: a retrospective cohort analysis of a randomised, multicentre, diagnostic screening trial. 
  • Lung cancer incidence trends by gender, race and histology in the United States, 1973-2010. 
  • Lung cancer management in 2010. 
  • Lung cancer mortality among asbestos textile workers: a review and update. 
  • Lung cancer mortality among construction workers: implications for early detection. 
  • Lung cancer mortality and fibre exposures among North Carolina asbestos textile workers. 
  • Lung cancer mortality in North Carolina and South Carolina chrysotile asbestos textile workers. 
  • Lung cancer screening, overdiagnosis bias, and reevaluation of the Mayo Lung Project. 
  • Lung cancer screening: No more excuses. 
  • Lung cancer staging and management: comparison of contrast-enhanced and nonenhanced helical CT of the thorax. 
  • Lung cancer staging: proteomics. 
  • Lung nodule and cancer detection in computed tomography screening. 
  • Lung nodule enhancement at CT: multicenter study. 
  • Lung nodules: dual-kilovolt peak analysis with CT--multicenter study. 
  • Lung transplantation for lymphangioleiomyomatosis: role of imaging in the assessment of complications related to the underlying disease. 
  • Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. 
  • Lung-RADS Version 1.1: Challenges and a Look Ahead, From the AJR Special Series on Radiology Reporting and Data Systems. 
  • Lung-cancer screening. 
  • Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial. 
  • Lymph node evaluation by open or video-assisted approaches in 11,500 anatomic lung cancer resections. 
  • Lymphangioleiomyomatosis. 
  • Lymphangitic carcinomatosis: A common radiographic manifestation of local failure following extended pleurectomy/decortication in patients with malignant pleural mesothelioma. 
  • Lymphatic mapping and sentinel node analysis: current concepts and applications. 
  • Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. 
  • Lysyl oxidase is essential for hypoxia-induced metastasis. 
  • MDM2 gene promoter polymorphisms and risk of lung cancer: a case-control analysis. 
  • MEN1 gene mutation analysis of high-grade neuroendocrine lung carcinoma. 
  • MET and phosphorylated MET as potential biomarkers in lung cancer. 
  • MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. 
  • MMTV-PyMT and Derived Met-1 Mouse Mammary Tumor Cells as Models for Studying the Role of the Androgen Receptor in Triple-Negative Breast Cancer Progression. 
  • MYC Drives Progression of Small Cell Lung Cancer to a Variant Neuroendocrine Subtype with Vulnerability to Aurora Kinase Inhibition. 
  • MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. 
  • MYC paralog-dependent apoptotic priming orchestrates a spectrum of vulnerabilities in small cell lung cancer. 
  • MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. 
  • Macrophage-stimulating protein and its receptor in non-small-cell lung tumors: induction of receptor tyrosine phosphorylation and cell migration. 
  • Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). 
  • Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. 
  • Major and massive hemoptysis: reassessment of conservative management. 
  • Malignancy after solid organ transplantation: an overview. 
  • Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases. 
  • Malignant Diffuse Mesothelioma in Women: A Study of 354 Cases. 
  • Malignant Mesothelioma and Its Non-Asbestos Causes. 
  • Malignant Mesothelioma in Individuals With Nonmesothelial Neoplasms. 
  • Malignant giant cell tumor of soft parts. 
  • Malignant mesothelioma associated with low pulmonary tissue asbestos burdens: a light and scanning electron microscopic analysis of 18 cases. 
  • Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure. 
  • Malignant mesothelioma in the jewelry industry. 
  • Malignant peritoneal mesothelioma and Crohn disease. 
  • Malignant peritoneal mesothelioma in patients with endometriosis. 
  • Management of unresectable non-small cell carcinoma of the lung (NSCLC). 
  • Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer. 
  • Manassantin A inhibits tumour growth under hypoxia through the activation of chaperone-mediated autophagy by modulating Hsp90 activity. 
  • Markerless lung tumor tracking and trajectory reconstruction using rotational cone-beam projections: a feasibility study. 
  • Maximizing the motivational impact of feedback of lung cancer susceptibility on smokers' desire to quit. 
  • Maximum likelihood estimation of a stochastic compartment model of cancer latency: lung cancer mortality among white females in the U.S. 
  • Maximum-Intensity-Projection and Computer-Aided-Detection Algorithms as Stand-Alone Reader Devices in Lung Cancer Screening Using Different Dose Levels and Reconstruction Kernels. 
  • Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection. 
  • Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies. Psychometric assessment of the Lung Cancer Symptom Scale. 
  • Measuring EMPs in the lung what can be measured in the lung: Asbestiform minerals and cleavage fragments. 
  • Mechanism of inactivation of CDKN2 and MTS2 in non-small cell lung cancer and association with advanced stage. 
  • Mect1-Maml2 fusion oncogene linked to the aberrant activation of cyclic AMP/CREB regulated genes. 
  • Mediastinal Lymphadenopathy in the National Lung Screening Trial (NLST) Is Associated with Interval Lung Cancer. 
  • Mendelian randomization study of adiposity-related traits and risk of breast, ovarian, prostate, lung and colorectal cancer. 
  • Mesenchymal stem cells promote metastasis through activation of an ABL-MMP9 signaling axis in lung cancer cells. 
  • Mesothelioma in the age of "Omics": Before and after The Cancer Genome Atlas. 
  • Mesothelioma of the tunica vaginalis testis. 
  • Mesothelioma vs. adenocarcinoma. 
  • Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. 
  • Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. 
  • Metabolism of benzo[a]pyrene by cultured tracheobronchial tissues from mice, rats, hamsters, bovines and humans. 
  • Metastasis dynamics for non-small-cell lung cancer: effect of patient and tumor-related factors. 
  • Metastasis of Lung Adenocarcinoma to the Lacrimal Sac. 
  • Metastatic Lung Cancer and Distress: Use of the Distress Thermometer for Patient Assessment. 
  • Metastatic carcinoma of the iris. 
  • Metastatic dedifferentiated chordoma with elevated beta-hCG: a case report. 
  • Metastatic hemangiopericytoma with prolonged survival. 
  • Metastatic intracardiac tumour from liposarcoma. 
  • Metastatic melanoma in the thorax: report of 130 patients. 
  • Metastatic squamous cell carcinoma of the nasal tip: a case report. 
  • Metformin exposure is associated with improved progression-free survival in diabetic patients after resection for early-stage non-small cell lung cancer. 
  • Metformin prevents tobacco carcinogen--induced lung tumorigenesis. 
  • Methodology for lung cancer evidence review and guideline development: ACCP evidence-based clinical practice guidelines (2nd Edition). 
  • Methyl-CpG binding domain 1 gene polymorphisms and lung cancer risk in a Chinese population. 
  • MiR-148a functions to suppress metastasis and serves as a prognostic indicator in triple-negative breast cancer. 
  • MicroRNA-182 drives metastasis of primary sarcomas by targeting multiple genes. 
  • Midlife Cardiorespiratory Fitness, Incident Cancer, and Survival After Cancer in Men: The Cooper Center Longitudinal Study. 
  • Mind-mapping for lung cancer: towards a personalized therapeutics approach. 
  • Minimal important differences for interpreting health-related quality of life scores from the EORTC QLQ-C30 in lung cancer patients participating in randomized controlled trials. 
  • Minimally Invasive Approaches Do Not Compromise Outcomes for Pneumonectomy: A Comparison Using the National Cancer Database. 
  • Minimally Invasive Lung Cancer Surgery Performed by Thoracic Surgeons as Effective as Thoracotomy. 
  • Minimally Invasive Thoracic Surgery 3.0: Lessons Learned From the History of Lung Cancer Surgery. 
  • Minimum perceivable size difference: how well can radiologists visually detect a change in lung nodule size from CT images? 
  • Mitomycin C and menadione for the treatment of lung cancer: a phase II trial. 
  • Mitophagy defects arising from BNip3 loss promote mammary tumor progression to metastasis. 
  • Modeling disease incidence data with spatial and spatio temporal dirichlet process mixtures. 
  • Modeling killing and repopulation kinetics of subclinical cancer: direct calculations from clinical data. 
  • Moderately Hypofractionated Proton Beam Therapy for Locally Advanced Non-Small Cell Lung Cancer: A New Way Forward for Dose Escalation? 
  • Modern Management of Pulmonary Metastases. 
  • Modified uniportal video-assisted thoracoscopic lobectomy: Duke approach. 
  • Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. 
  • Modulation of specific active immunization against murine melanoma using recombinant cytokines. 
  • Molecular Analysis of a Patient With Neurofibromatosis 2 (NF2) and Peritoneal Malignant Mesothelioma. 
  • Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations. 
  • Molecular MRI for sensitive and specific detection of lung metastases. 
  • Molecular analysis of synchronous and metachronous tumors of the lung: impact on management and prognosis. 
  • Molecular analysis-based treatment strategies for the management of non-small cell lung cancer. 
  • Molecular and genetic markers in thoracic surgery. 
  • Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung. 
  • Molecular biologic staging of lung cancer. 
  • Molecular biologic substaging of non-small cell lung cancer. 
  • Molecular biologic substaging of stage I NSCLC through immunohistochemistry performed on formalin-fixed, paraffin-embedded tissue. 
  • Molecular biologic substaging of stage I lung cancer according to gender and histology. 
  • Molecular characterization of the human delta opioid receptor in lung cancer. 
  • Molecular classification and molecular genetics of human lung cancers. 
  • Molecular margin analysis predicts local recurrence after sublobar resection of lung cancer. 
  • Molecular markers for incidence, prognosis, and response to therapy. 
  • Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. 
  • Molecular staging and the selection of therapy for non-small cell lung cancer. 
  • Molecular staging of lung and esophageal cancer. 
  • Molecular staging of lung cancer: real-time polymerase chain reaction estimation of lymph node micrometastatic tumor cell burden in stage I non-small cell lung cancer--preliminary results of Cancer and Leukemia Group B Trial 9761. 
  • Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. 
  • Monoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomas. 
  • Morbidity and mortality after treatment of Ewing sarcoma: A single-institution experience. 
  • Morbidity and mortality of major pulmonary resections in patients with early-stage lung cancer: initial results of the randomized, prospective ACOSOG Z0030 trial. 
  • Morphological changes in smokers' lungs. 
  • Morphometric quantitation of tumor necrosis in stage 1 non-small cell carcinoma of lung: prognostic implications. 
  • Mortality among sheet metal workers participating in a medical screening program. 
  • Mortality among sheet metal workers participating in a respiratory screening program. 
  • Mortality of older construction and craft workers employed at department of energy nuclear sites: Follow-up through 2016. 
  • Mortality patterns among female and male chrysotile asbestos textile workers. 
  • Mosaic Attenuation: Etiology, Methods of Differentiation, and Pitfalls. 
  • Motivations for genetic testing for lung cancer risk among young smokers. 
  • Mouse pulmonary interstitial macrophages mediate the pro-tumorigenic effects of IL-9. 
  • Mucinous (colloid) adenocarcinoma of the lung. 
  • Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). 
  • Multi-omics to predict acute radiation esophagitis in patients with lung cancer treated with intensity-modulated radiation therapy. 
  • Multi-scale gradual integration CNN for false positive reduction in pulmonary nodule detection. 
  • Multidisciplinary approach to treatment of radiation-induced chest wall sarcoma. 
  • Multimodality nuclear medicine imaging in three-dimensional radiation treatment planning for lung cancer: challenges and prospects. 
  • Multinational Randomized Phase III Trial With or Without Consolidation Chemotherapy Using Docetaxel and Cisplatin After Concurrent Chemoradiation in Inoperable Stage III Non-Small-Cell Lung Cancer: KCSG-LU05-04. 
  • Multiparametric Data-driven Imaging Markers: Guidelines for Development, Application and Reporting of Model Outputs in Radiomics. 
  • Multiple local minima in IMRT optimization based on dose-volume criteria. 
  • Multiple pulmonary nodules in AIDS: usefulness of CT in distinguishing among potential causes. 
  • Multiple testing for gene sets from microarray experiments. 
  • Multiple, thin-walled cystic lesions of the lung. 
  • Multiprojection correlation imaging for improved detection of pulmonary nodules. 
  • Multitrial Evaluation of Progression-Free Survival as a Surrogate End Point for Overall Survival in First-Line Extensive-Stage Small-Cell Lung Cancer. 
  • Mutational Landscapes of Smoking-Related Cancers in Caucasians and African Americans: Precision Oncology Perspectives at Wake Forest Baptist Comprehensive Cancer Center. 
  • Mutational hotspots in the mitochondrial genome of lung cancer. 
  • Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer. 
  • Myogenic transcription factors regulate pro-metastatic miR-182. 
  • N-terminal 1-54 amino acid sequence and Armadillo repeat domain are indispensable for P120-catenin isoform 1A in regulating E-cadherin. 
  • NCCN Guidelines Insights: Malignant Pleural Mesothelioma, Version 3.2016. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 1.2020. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 4.2016. 
  • NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018. 
  • NCCN Guidelines as a Model of Extended Criteria for Lung Cancer Screening. 
  • NCCN Guidelines® Insights: Lung Cancer Screening, Version 1.2022. 
  • NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. 
  • Nanoparticle delivery of chemosensitizers improve chemotherapy efficacy without incurring additional toxicity. 
  • Nanoparticle delivery of chemotherapy combination regimen improves the therapeutic efficacy in mouse models of lung cancer. 
  • National Cancer Institute initiative: Lung image database resource for imaging research. 
  • National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers. 
  • National Lung Screening Trial findings by age: Medicare-eligible versus under-65 population. 
  • National Trends in End-of-Life Care for Veterans With Advanced Cancer in the Veterans Health Administration: 2009 to 2016. 
  • Neighborhood-level socioeconomic determinants impact outcomes in nonsmall cell lung cancer patients in the Southeastern United States. 
  • Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors. 
  • Neoadjuvant chemotherapy and radiotherapy followed by surgery in stage IIIA non-small-cell carcinoma of the lung: report of a Cancer and Leukemia Group B phase II study. 
  • Neuroendocrine differentiation is an independent prognostic factor in chemotherapy-treated nonsmall cell lung carcinoma. 
  • Neuroendocrine lung tumors and disorders of the neuromuscular junction. 
  • Neuropsychological effects of cranial radiation: current knowledge and future directions. 
  • Neutrophil elastase increases MUC5AC mRNA and protein expression in respiratory epithelial cells. 
  • New Approaches to SCLC Therapy: From the Laboratory to the Clinic. 
  • New Insights on Diagnostic Reproducibility of Biphasic Mesotheliomas: A Multi-Institutional Evaluation by the International Mesothelioma Panel From the MESOPATH Reference Center. 
  • New murine cell line derived from a spontaneous lung tumor induces paraneoplastic syndromes. 
  • New radiotherapy and chemoradiotherapy approaches for non-small-cell lung cancer. 
  • New targeted therapies for non-small-cell lung cancer: a focus on the epidermal growth factor receptor. 
  • Next-generation Tumor-homing Induced Neural Stem Cells as an Adjuvant to Radiation for the Treatment of Metastatic Lung Cancer. 
  • Nicotine does not enhance tumorigenesis in mutant K-ras-driven mouse models of lung cancer. 
  • Nine-year single center experience with cervical mediastinoscopy: complications and false negative rate. 
  • Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort. 
  • Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer. 
  • Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057). 
  • Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. 
  • Nivolumab and Ipilimumab as Maintenance Therapy in Extensive-Disease Small-Cell Lung Cancer: CheckMate 451. 
  • Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. 
  • Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. 
  • Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. 
  • Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. 
  • No evidence of an association of ERCC1 and ERCC2 polymorphisms with clinical outcomes of platinum-based chemotherapies in non-small cell lung cancer: a meta-analysis. 
  • No heroic measures: how soon is too soon to stop? 
  • Nodal downstaging predicts survival following induction chemotherapy for stage IIIA (N2) non-small cell lung cancer in CALGB protocol #8935. 
  • Nodal stage of surgically resected non-small cell lung cancer and its effect on recurrence patterns and overall survival. 
  • Nomogram Predicting Overall Survival Benefit of Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancer. 
  • Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 
  • Non-canonical genomic driver mutations of urethane carcinogenesis. 
  • Non-small cell lung cancer clinical practice guidelines in oncology. 
  • Non-small cell lung cancer, version 2.2013. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer. 
  • Non-small cell lung cancer: FDG PET for nodal staging in patients with stage I disease. 
  • Non-small cell lung cancer: FDG-PET imaging. 
  • Noncanonical agonist PPARγ ligands modulate the response to DNA damage and sensitize cancer cells to cytotoxic chemotherapy. 
  • Noninvasive clinical staging modalities for lung cancer. 
  • Noninvasive imaging and quantification of epidermal growth factor receptor kinase activation in vivo. 
  • Noninvasive staging of non-small cell lung cancer: a review of the current evidence. 
  • Nonoperative management of non-small cell lung cancer: the current cancer and leukemia group B experience. 
  • Notch-1 regulates pulmonary neuroendocrine cell differentiation in cell lines and in transgenic mice. 
  • Novel PI analogues selectively block activation of the pro-survival serine/threonine kinase Akt. 
  • Novel Variants of ELP2 and PIAS1 in the Interferon Gamma Signaling Pathway Are Associated with Non-Small Cell Lung Cancer Survival. 
  • Novel genetic variants in HDAC2 and PPARGC1A of the CREB-binding protein pathway predict survival of non-small-cell lung cancer. 
  • Novel genetic variants in KIF16B and NEDD4L in the endosome-related genes are associated with nonsmall cell lung cancer survival. 
  • Novel genetic variants in the P38MAPK pathway gene ZAK and susceptibility to lung cancer. 
  • Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. 
  • Number of Ribs Resected is Associated with Respiratory Complications Following Lobectomy with en bloc Chest Wall Resection. 
  • Oligometastatic breast cancer: where are we now and where are we headed?-a narrative review. 
  • Oligoreview of Non-Small Cell Lung Cancer Oligometastases. 
  • On Enrichment Strategies for Biomarker Stratified Clinical Trials. 
  • On Goldilocks, care coordination, and palliative care: making it 'just right'. 
  • Oncogenic KRAS is dependent upon an EFR3A-PI4KA signaling axis for potent tumorigenic activity. 
  • Oncogenic pathway signatures in human cancers as a guide to targeted therapies. 
  • Oncologic Equivalence of Minimally Invasive Lobectomy: The Scientific and Practical Arguments. 
  • Operative techniques in early-stage lung cancer. 
  • Optimal weight in estimating and comparing areas under the receiver operating characteristic curve using longitudinal data. 
  • Organ doses from CT localizer radiographs: Development, validation, and application of a Monte Carlo estimation technique. 
  • Organizing disparate, seemingly chaotic data into a meaningful and useful order. 
  • Organs at Risk Considerations for Thoracic Stereotactic Body Radiation Therapy: What Is Safe for Lung Parenchyma? 
  • Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. 
  • Osimertinib for Patients With Leptomeningeal Metastases Associated With EGFR T790M-Positive Advanced NSCLC: The AURA Leptomeningeal Metastases Analysis. 
  • Osteogenic sarcoma of the head and neck. The UCLA experience. 
  • Outcome and prognostic factors after adrenalectomy for patients with distant adrenal metastasis. 
  • Outcomes after surgical management of synchronous bilateral primary lung cancers. 
  • Outcomes after treatment of 17,378 patients with locally advanced (T3N0-2) non-small-cell lung cancer. 
  • Outcomes among African-American/non-African-American patients with advanced non-small-cell lung carcinoma: report from the Cancer and Leukemia Group B. 
  • Outcomes of Major Lung Resection After Induction Therapy for Non-Small Cell Lung Cancer in Elderly Patients. 
  • Outcomes of surgery versus chemoradiotherapy in patients with clinical or pathologic stage N3 non-small cell lung cancer. 
  • Outcomes of tracheobronchial stents in patients with malignant airway disease. 
  • Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial. 
  • Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. 
  • Overdiagnosis in low-dose computed tomography screening for lung cancer. 
  • Overestimating the influence of the 1999 WHO classification of lung tumors on survival in bronchioloalveloar carcinoma. 
  • Overexpression of CRKL correlates with poor prognosis and cell proliferation in non-small cell lung cancer. 
  • Overexpression of tropomysin-related kinase B in metastatic human pancreatic cancer cells. 
  • Overview of genetic and molecular events in the pathogenesis of lung cancer. 
  • Overview of methodology for lung cancer evidence review and guideline development. 
  • Overview of stereotactic body radiotherapy and the nursing role. 
  • P120-catenin isoforms 1 and 3 regulate proliferation and cell cycle of lung cancer cells via β-catenin and Kaiso respectively. 
  • PD-L1 Assay Concordance in Metastatic Renal Cell Carcinoma and Metastatic Urothelial Carcinoma. 
  • PET with 62Cu-ATSM and 62Cu-PTSM is a useful imaging tool for hypoxia and perfusion in pulmonary lesions. 
  • PET-CT: current applications and new developments in the thorax. 
  • PET-based primary tumor volumetric parameters and survival of patients with non-small cell lung carcinoma. 
  • PPARgamma agonists follow an unknown TRAIL in lung cancer. 
  • Paclitaxel by 96-hour continuous infusion in combination with cisplatin: a phase I trial in patients with advanced lung cancer. 
  • Paclitaxel/ifosfamide or navelbine/ifosfamide chemotherapy for advanced non-small cell lung cancer: CALGB 9532. 
  • Pain Intensity and Pain Interference in Patients With Lung Cancer: A Pilot Study of Biopsychosocial Predictors. 
  • Palliative thoracic radiotherapy in advanced lung cancer: A single institution experience. 
  • Pancreatoblastoma in a teenage patient. 
  • Panel of serum biomarkers for the diagnosis of lung cancer. 
  • Parietal pleural plaques, asbestos bodies, and neoplasia. A clinical, pathologic, and roentgenographic correlation of 25 consecutive cases. 
  • Partitioning of time trends in prevalence and mortality of lung cancer. 
  • Pathologic complete response of a malignant peripheral nerve sheath tumor in the lung treated with neoadjuvant Ifosfamide and radiation therapy. 
  • Pathologic quiz case: a 54-year-old man with multiple pulmonary nodules. 
  • Pathologic response after neoadjuvant carboplatin and weekly paclitaxel for early-stage lung cancer: a Brown University oncology group phase II study. 
  • Pathologic response rates following definitive dose image-guided chemoradiotherapy and resection for locally advanced non-small cell lung cancer. 
  • Pathologic staging of the mediastinum: when and how? 
  • Pathway-analysis of published genome-wide association studies of lung cancer: A potential role for the CYP4F3 locus. 
  • Patient Burden and Real-World Management of Chemotherapy-Induced Myelosuppression: Results from an Online Survey of Patients with Solid Tumors. 
  • Patient Preferences for Features of Health Care Delivery Systems: A Discrete Choice Experiment. 
  • Patient Preferences in Treatment Choices for Early-Stage Lung Cancer. 
  • Patient education level as a predictor of survival in lung cancer clinical trials. 
  • Patient expectations of benefit from phase I clinical trials: linguistic considerations in diagnosing a therapeutic misconception. 
  • Patient's lung cancer diagnosis as a cue for relatives' smoking cessation: evaluating the constructs of the teachable moment. 
  • Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study. 
  • Patient-reported distress as an early warning sign of unmet palliative care needs and increased healthcare utilization in patients with advanced cancer. 
  • Patient-specific deep learning model to enhance 4D-CBCT image for radiomics analysis. 
  • Patients with cancer and their spouse caregivers. Perceptions of the illness experience. 
  • Patterns of Distant Metastases After Surgical Management of Non-Small-cell Lung Cancer. 
  • Patterns of Failure After Surgery for Non-Small-cell Lung Cancer Invading the Chest Wall. 
  • Patterns of Treatment and Outcomes for Definitive Therapy of Early Stage Non-Small Cell Lung Cancer. 
  • Patterns of disease failure after trimodality therapy of nonsmall cell lung carcinoma pathologic stage IIIA (N2). Analysis of Cancer and Leukemia Group B Protocol 8935. 
  • Patterns of failure after resection of non-small-cell lung cancer: implications for postoperative radiation therapy volumes. 
  • Pazopanib maintenance after first-line etoposide and platinum chemotherapy in patients with extensive disease small-cell lung cancer: a multicentre, randomised, placebo-controlled Phase II study (KCSG-LU12-07). 
  • Peak oxygen consumption and long-term all-cause mortality in nonsmall cell lung cancer. 
  • Pediatric MDCT: towards assessing the diagnostic influence of dose reduction on the detection of small lung nodules. 
  • Pemetrexed Plus Cisplatin Versus Gemcitabine Plus Cisplatin According to Thymidylate Synthase Expression in Nonsquamous Non-Small-Cell Lung Cancer: A Biomarker-Stratified Randomized Phase II Trial. 
  • Penetration, Completeness, and Representativeness of The Society of Thoracic Surgeons General Thoracic Surgery Database for Lobectomy. 
  • Peptidyl membrane-interactive molecules are cytotoxic to prostatic cancer cells in vitro. 
  • Perceptions of patients' self-efficacy for managing pain and lung cancer symptoms: correspondence between patients and family caregivers. 
  • Percutaneous image-guided thermal ablation and radiation therapy: outcomes of combined treatment for 41 patients with inoperable stage I/II non-small-cell lung cancer. 
  • Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. 
  • Performance evaluation of automatic anatomy segmentation algorithm on repeat or four-dimensional computed tomography images using deformable image registration method. 
  • Performance of a Machine Learning Algorithm Using Electronic Health Record Data to Identify and Estimate Survival in a Longitudinal Cohort of Patients With Lung Cancer. 
  • Perioperative Outcomes and 5-year Survival After Open versus Thoracoscopic Sleeve Resection for Lung Cancer. 
  • Perioperative Outcomes and Survival After Preoperative Immunotherapy for Non-Small Cell Lung Cancer. 
  • Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). 
  • Perioperative outcomes of pulmonary resection after neoadjuvant pembrolizumab in patients with non-small cell lung cancer. 
  • Persistent N2 disease after neoadjuvant chemotherapy for non-small-cell lung cancer. 
  • Persistent Pure Ground-Glass Nodules Larger Than 5 mm: Differentiation of Invasive Pulmonary Adenocarcinomas From Preinvasive Lesions or Minimally Invasive Adenocarcinomas Using Texture Analysis. 
  • Persistent or recurrent bronchogenic carcinoma: detection with PET and 2-[F-18]-2-deoxy-D-glucose. 
  • Persistent pulmonary subsolid nodules with solid portions of 5 mm or smaller: Their natural course and predictors of interval growth. 
  • Persistent smoking after a diagnosis of lung cancer is associated with higher reported pain levels. 
  • Personalized treatment of lung cancer. 
  • Pharmacoeconomics, quality of life, and combination modalities in non-small cell lung cancer: a panel discussion (Part 2). 
  • Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. 
  • Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosis. 
  • Pharmacokinetics of combined gene therapy expressing constitutive human GM-CSF and hyperthermia-regulated human IL-12. 
  • Phase 1 Dose Escalation Study of Accelerated Radiation Therapy With Concurrent Chemotherapy for Locally Advanced Lung Cancer. 
  • Phase 1 Study of Accelerated Hypofractionated Radiation Therapy With Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance). 
  • Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. 
  • Phase I Study Evaluating Glesatinib (MGCD265), An Inhibitor of MET and AXL, in Patients with Non-small Cell Lung Cancer and Other Advanced Solid Tumors. 
  • Phase I Study of 2- or 3-Week Dosing of Telisotuzumab Vedotin, an Antibody-Drug Conjugate Targeting c-Met, Monotherapy in Patients with Advanced Non-Small Cell Lung Carcinoma. 
  • Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. 
  • Phase I study of 5-day continuous infusion fluorodeoxyuridine and high-dose folinic acid with oral hydroxyurea. 
  • Phase I study of Tomudex and Doxorubicin in patients with locally advanced, inoperable or metastatic cancer (IND.98). 
  • Phase I study of a five-day dose schedule of 4-Ipomeanol in patients with non-small cell lung cancer. 
  • Phase I study of accelerated conformal radiotherapy for stage I non-small-cell lung cancer in patients with pulmonary dysfunction: CALGB 39904. 
  • Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. 
  • Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/epidermal growth factor receptor mutation double-positive lung cancer. 
  • Phase I study to determine the maximum-tolerated dose of radiation in standard daily and hyperfractionated-accelerated twice-daily radiation schedules with concurrent chemotherapy for limited-stage small-cell lung cancer. 
  • Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832). 
  • Phase I trial of interleukin-2 plus gamma-interferon. 
  • Phase II Study of Dasatinib in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer. 
  • Phase II evaluation of aclarubicin in lung cancer: a Southeastern Cancer Study Group Trial. 
  • Phase II multicenter trial of voreloxin as second-line therapy in chemotherapy-sensitive or refractory small cell lung cancer. 
  • Phase II randomized study of dose-dense docetaxel and cisplatin every 2 weeks with pegfilgrastim and darbepoetin alfa with and without the chemoprotector BNP7787 in patients with advanced non-small cell lung cancer (CALGB 30303). 
  • Phase II study of carboplatin, irinotecan, and thalidomide combination in patients with extensive stage small-cell lung cancer. 
  • Phase II study of durvalumab plus tremelimumab as therapy for patients with previously treated anti-PD-1/PD-L1 resistant stage IV squamous cell lung cancer (Lung-MAP substudy S1400F, NCT03373760). 
  • Phase II study of induction cisplatin and irinotecan followed by concurrent carboplatin, etoposide, and thoracic radiotherapy for limited-stage small-cell lung cancer, CALGB 30206. 
  • Phase II study of irinotecan plus cisplatin in patients with advanced non-small-cell lung cancer. 
  • Phase II study of neoadjuvant chemotherapy and radiation therapy with thoracotomy in the treatment of clinically staged IIIA non-small cell lung cancer. 
  • Phase II study of stereotactic radiosurgery for the treatment of patients with oligoprogression on erlotinib. 
  • Phase II study of the histone deacetylase inhibitor Romidepsin in relapsed small cell lung cancer (Cancer and Leukemia Group B 30304). 
  • Phase II study of troxacitabine (BCH-4556) in patients with advanced non-small-cell lung cancer. 
  • Phase II trial of irinotecan/gemcitabine as second-line therapy for relapsed and refractory small-cell lung cancer: Cancer and Leukemia Group B Study 39902. 
  • Phase II trial of karenitecin in patients with relapsed or refractory non-small cell lung cancer (CALGB 30004). 
  • Phase II trial of lymphoblastoid interferon in metastatic colon carcinoma. 
  • Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430. 
  • Phase II trial of paclitaxel-topotecan-etoposide followed by consolidation chemoradiotherapy for limited-stage small cell lung cancer: CALGB 30002. 
  • Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy. 
  • Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332. 
  • Phase II trial of weekly dose-dense paclitaxel in extensive-stage small cell lung cancer: cancer and leukemia group B study 39901. 
  • Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. 
  • Phase III Randomized, Placebo-Controlled, Double-Blind Trial of Celecoxib in Addition to Standard Chemotherapy for Advanced Non-Small-Cell Lung Cancer With Cyclooxygenase-2 Overexpression: CALGB 30801 (Alliance). 
  • Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small-cell lung cancer. 
  • Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors. 
  • Phase Ib Study of Telisotuzumab Vedotin in Combination With Erlotinib in Patients With c-Met Protein-Expressing Non-Small-Cell Lung Cancer. 
  • Phosphatidylinositol ether lipid analogues induce AMP-activated protein kinase-dependent death in LKB1-mutant non small cell lung cancer cells. 
  • Phosphorylated epidermal growth factor receptor and cyclooxygenase-2 expression in localized non-small cell lung cancer. 
  • Pilot Study of the Performance of 19-G Needle in Endobronchial Ultrasound-guided Transbronchial Aspiration for the Diagnosis and Testing of Molecular Markers in Lung Cancer. 
  • Placebo-controlled randomized study of hydrazine sulfate in lung cancer. 
  • Plasma Metabolites and Risk of Radiation-induced Esophagitis: A Secondary Analysis from a Prospective Study. 
  • Point/Counterpoint. A 3D-conformal technique is better than IMRT or VMAT for lung SBRT. 
  • Point: Should UItrasonographic Endoscopy Be the Preferred Modality for Staging of Lung Cancer? Yes. 
  • Pollution and regional variations of lung cancer mortality in the United States. 
  • Polymorphism of DNA ligase I and risk of lung cancer--a case-control analysis. 
  • Polymorphisms in DNA base excision repair genes ADPRT and XRCC1 and risk of lung cancer. 
  • Polymorphisms in DNA damage binding protein 2 (DDB2) and susceptibility of primary lung cancer in the Chinese: a case-control study. 
  • Polymorphisms in MicroRNAs are associated with survival in non-small cell lung cancer. 
  • Polymorphisms in excision repair cross-complementing group 4 (ERCC4) and susceptibility to primary lung cancer in a Chinese Han population. 
  • Polymorphisms in hMLH1 and risk of early-onset lung cancer in a southeast Chinese population. 
  • Polymorphisms in the two helicases ERCC2/XPD and ERCC3/XPB of the transcription factor IIH complex and risk of lung cancer: a case-control analysis in a Chinese population. 
  • Polymorphisms of CAK genes and risk for lung cancer: a case-control study in Chinese population. 
  • Polymorphisms of cytosolic serine hydroxymethyltransferase and risk of lung cancer: a case-control analysis. 
  • Polymorphisms of homologous recombination genes and clinical outcomes of non-small cell lung cancer patients treated with definitive radiotherapy. 
  • Polymorphisms of methionine synthase and methionine synthase reductase and risk of lung cancer: a case-control analysis. 
  • Polymorphisms of methylene-tetrahydrofolate reductase and risk of lung cancer: a case-control study. 
  • Polymorphisms of the DNA repair gene XPD and risk of lung cancer in a Chinese population. 
  • Polymorphisms of the centrosomal gene (FGFR1OP) and lung cancer risk: a meta-analysis of 14,463 cases and 44,188 controls. 
  • Polymorphisms of the vascular endothelial growth factor gene and severe radiation pneumonitis in non-small cell lung cancer patients treated with definitive radiotherapy. 
  • Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies. 
  • Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: results from CALGB 9761, a prospective trial. 
  • Population-based assessment of cancer survivors' financial burden and quality of life: a prospective cohort study. 
  • Positive Interaction between Prophylactic Cranial Irradiation and Maintenance Sunitinib for Untreated Extensive-Stage Small Cell Lung Cancer Patients After Standard Chemotherapy: A Secondary Analysis of CALGB 30504 (ALLIANCE). 
  • Positron emission tomographic imaging with fluorodeoxyglucose isefficacious in evaluating malignant pulmonary disease. 
  • Positron emission tomography combined with diagnostic chest computed tomography enhances detection of regional recurrence after stereotactic body radiation therapy for early stage non-small cell lung cancer. 
  • Positron emission tomography detection of metastatic penile squamous cell carcinoma. 
  • Positron emission tomography imaging in the thorax. 
  • Positron emission tomography imaging of the thorax. 
  • Positron emission tomography in the pretreatment evaluation and follow-up of non-small cell lung cancer patients treated with radiotherapy: preliminary findings. 
  • Positron emission tomography: brain tumors and lung cancer. 
  • Post-operative smoking status in lung and head and neck cancer patients: association with depressive symptomatology, pain, and fatigue. 
  • Postoperative atrophy of posterolateral chest wall musculature: CT demonstration. 
  • Postoperative radiation therapy for lung cancer: where do we stand? 
  • Potential conflict of interest. 
  • Potential underestimation of the internal target volume (ITV) from free-breathing CBCT. 
  • Potentially Functional Variants of ATG16L2 Predict Radiation Pneumonitis and Outcomes in Patients with Non-Small Cell Lung Cancer after Definitive Radiotherapy. 
  • Potentially functional genetic variants in PLIN2, SULT2A1 and UGT1A9 genes of the ketone pathway and survival of nonsmall cell lung cancer. 
  • Potentially functional genetic variants in the TNF/TNFR signaling pathway genes predict survival of patients with non-small cell lung cancer in the PLCO cancer screening trial. 
  • Potentially functional genetic variants in the complement-related immunity gene-set are associated with non-small cell lung cancer survival. 
  • Potentially functional genetic variants of VAV2 and PSMA4 in the immune-activation pathway and non-small cell lung cancer survival. 
  • Potentially functional polymorphisms of EXO1 and risk of lung cancer in a Chinese population: A case-control analysis. 
  • Potentially functional variants of ERAP1, PSMF1 and NCF2 in the MHC-I-related pathway predict non-small cell lung cancer survival. 
  • Potentially functional variants of HBEGF and ITPR3 in GnRH signaling pathway genes predict survival of non-small cell lung cancer patients. 
  • Potentiation of paclitaxel cytotoxicity in lung and esophageal cancer cells by pharmacologic inhibition of the phosphoinositide 3-kinase/protein kinase B (Akt)-mediated signaling pathway. 
  • Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial. 
  • Precision treatment for metastatic non-small cell lung cancer: A conceptual overview. 
  • Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. 
  • Predicting lung radiotherapy-induced pneumonitis using a model combining parametric Lyman probit with nonparametric decision trees. 
  • Predicting risk of chemotherapy-induced severe neutropenia: A pooled analysis in individual patients data with advanced lung cancer. 
  • Predicting the sites of metastases from lung cancer using molecular biologic markers. 
  • Predicting toxicity from radiation therapy--it's genetic, right? 
  • Prediction of Long-Term Survival After Lung Cancer Surgery for Elderly Patients in The Society of Thoracic Surgeons General Thoracic Surgery Database. 
  • Prediction of clinical outcome in multiple lung cancer cohorts by integrative genomics: implications for chemotherapy selection. 
  • Prediction of lung malignancy progression and survival with machine learning based on pre-treatment FDG-PET/CT. 
  • Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. 
  • Predictive value of the EphA2 receptor tyrosine kinase in lung cancer recurrence and survival. 
  • Predictors of Physical and Functional Loss in Advanced-Stage Lung Cancer Patients Receiving Platinum Chemotherapy. 
  • Predictors of Survival in 211 Patients with Stage IV Pulmonary and Gastroenteropancreatic MIBG-Positive Neuroendocrine Tumors Treated with 131I-MIBG. 
  • Predictors of adverse smoking outcomes in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial. 
  • Predictors of prolonged length of stay after lobectomy for lung cancer: a Society of Thoracic Surgeons General Thoracic Surgery Database risk-adjustment model. 
  • Predictors of pulmonary toxicity in limited stage small cell lung cancer patients treated with induction chemotherapy followed by concurrent platinum-based chemotherapy and 70 Gy daily radiotherapy: CALGB 30904. 
  • Predictors of smoking relapse in patients with thoracic cancer or head and neck cancer. 
  • Preferential inhibition of Akt and killing of Akt-dependent cancer cells by rationally designed phosphatidylinositol ether lipid analogues. 
  • Preliminary Clinical and Molecular Analysis Results From a Single-Arm Phase 2 Trial of Brigatinib in Patients With Disease Progression After Next-Generation ALK Tyrosine Kinase Inhibitors in Advanced ALK+ NSCLC. 
  • Preliminary clinical evaluation of a 4D-CBCT estimation technique using prior information and limited-angle projections. 
  • Preoperative Evaluation and Indications for Pulmonary Metastasectomy. 
  • Preoperative chemotherapy versus preoperative chemoradiotherapy for stage III (N2) non-small-cell lung cancer. 
  • Preoperative exercise Vo2 measurement for lung resection candidates: results of Cancer and Leukemia Group B Protocol 9238. 
  • Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. 
  • Preoperative radiation therapy and chemotherapy for pulmonary blastoma: a case report. 
  • Pretreatment 18F-Fluorodeoxyglucose Positron Emission Tomography Standardized Uptake Values and Tumor Size in Medically Inoperable Nonsmall Cell Lung Cancer Is Prognostic of Overall 2-Year Survival After Stereotactic Body Radiation Therapy. 
  • Prevalence of pulmonary atypical alveolar cell hyperplasia in an autopsy population: a study of 100 cases. 
  • Prevention of lung cancer: summary of published evidence. 
  • Primary Pulmonary Lymphomas. 
  • Primary adenocarcinomas of the lung in nonsmokers show a distinct pattern of allelic imbalance. 
  • Primary and Secondary Prevention of Lung Cancer: an International Association for the Study of Lung Cancer workshop. 
  • Primary carcinoma of the upper urinary tract. Effect of primary and secondary therapy on survival. 
  • Primary malignant fibrous histiocytoma of the lung. A clinicopathologic and ultrastructural study of five cases. 
  • Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project. 
  • Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data. 
  • Proactive recruitment of cancer patients' social networks into a smoking cessation trial. 
  • Product liability forecasting for asbestos-related personal injury claims: a multidisciplinary approach. 
  • Prognostic Significance of Liver Metastasis in Durvalumab-Treated Lung Cancer Patients. 
  • Prognostic factors for recurrence after pulmonary resection of colorectal cancer metastases. 
  • Prognostic indicators for survival in stage I carcinoma of the lung: a histologic study of 47 surgically resected cases. 
  • Prognostic modeling in early stage lung cancer: an evolving process from histopathology to genomics. 
  • Prognostic significance of MCM2, Ki-67 and gelsolin in non-small cell lung cancer. 
  • Prognostic significance of a complement factor H autoantibody in early stage NSCLC. 
  • Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. 
  • Prognostic significance of functional capacity and exercise behavior in patients with metastatic non-small cell lung cancer. 
  • Prognostic significance of gelsolin expression level and variability in non-small cell lung cancer. 
  • Prognostic significance of mucin and p53 expression in stage IB non-small cell lung cancer: a laboratory companion study to CALGB 9633. 
  • Prognostic significance of plasma scatter factor/hepatocyte growth factor levels in patients with metastatic hormone- refractory prostate cancer: results from cancer and leukemia group B 150005/9480. 
  • Prognostic validation of the body mass index, airflow obstruction, dyspnea, and exercise capacity (BODE) index in inoperable non-small-cell lung cancer. 
  • Prognostic value of computed tomography texture features in non-small cell lung cancers treated with definitive concomitant chemoradiotherapy. 
  • Prognostic value of fluorine-18 fluorodeoxyglucose positron emission tomography imaging in patients with advanced-stage non-small-cell lung carcinoma. 
  • Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. 
  • Progress in the Management of Early-Stage Non-Small Cell Lung Cancer in 2017. 
  • Progression of disease despite good endoscopic local control of upper tract urothelial carcinoma. 
  • Projecting chronic disease prevalence. 
  • Proliferative potential and resistance to immune checkpoint blockade in lung cancer patients. 
  • Prophylactic cranial irradiation in elderly patients with small cell lung cancer: findings from a North Central Cancer Treatment Group pooled analysis. 
  • Prospective Multicentered Safety and Feasibility Pilot for Endobronchial Intratumoral Chemotherapy. 
  • Prospective Multisite Cohort Study to Evaluate Shared Decision-Making Utilization Among Individuals Screened for Lung Cancer. 
  • Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer. 
  • Prospective analysis of DNA damage and repair markers of lung cancer risk from the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. 
  • Prospective analysis of quality of life in elderly patients treated with adjuvant chemotherapy for non-small-cell lung cancer. 
  • Prospective investigation of positron emission tomography in lung nodules. 
  • Prospective phase II trial of preresection thoracoscopic mediastinal restaging after neoadjuvant therapy for IIIA (N2) non-small cell lung cancer: results of CALGB Protocol 39803. 
  • Protein expression and functional analysis of the FHIT gene in human tumor cells. 
  • Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. 
  • Protocol for the examination of specimens from patients with primary non-small cell carcinoma, small cell carcinoma, or carcinoid tumor of the lung. 
  • Protocol to evaluate an enterprise-wide initiative to increase access to lung cancer screening in the Veterans Health Administration. 
  • Pruritus in patients with solid tumors: an overlooked supportive care need. 
  • Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. 
  • Pten-null tumors cohabiting the same lung display differential AKT activation and sensitivity to dietary restriction. 
  • Pulmonary Granular Cell Tumors: A Study of 4 Cases Including a Malignant Phenotype. 
  • Pulmonary Open, Robotic, and Thoracoscopic Lobectomy (PORTaL) Study: An Analysis of 5721 Cases. 
  • Pulmonary abnormalities and PET data analysis: a retrospective study. 
  • Pulmonary blastoma: an ultrastructural and histochemical study. 
  • Pulmonary blastomycosis presenting as primary lung cancer. 
  • Pulmonary carcinomas with a sarcomatoid element: an immunocytochemical and ultrastructural analysis. 
  • Pulmonary fibrosis, carcinoma, and ferruginous body counts in amosite asbestos workers. A study of six cases. 
  • Pulmonary function testing after stereotactic body radiotherapy to the lung. 
  • Pulmonary lymphangioleiomyomatosis: CT findings. 
  • Pulmonary marginal zone lymphoma: a single centre experience and review of the SEER database. 
  • Pulmonary metastasectomy for metastatic malignant melanoma. 
  • Pulmonary metastasis from ameloblastoma of the mandible: report of case and review of the literature. 
  • Pulmonary nodules on multi-detector row CT scans: performance comparison of radiologists and computer-aided detection. 
  • Pulmonary nodules: computer-aided detection in digital chest images. 
  • Pulmonary segmentectomy by thoracotomy or thoracoscopy: reduced hospital length of stay with a minimally-invasive approach. 
  • Pulmonary septic emboli mimicking metastatic rhabdomyosarcoma. 
  • Pulmonary toxicity in Stage III non-small cell lung cancer patients treated with high-dose (74 Gy) 3-dimensional conformal thoracic radiotherapy and concurrent chemotherapy following induction chemotherapy: a secondary analysis of Cancer and Leukemia Group B (CALGB) trial 30105. 
  • Putative functional polymorphisms of MMP9 predict survival of NSCLC in a Chinese population. 
  • Quality of life and survival after II stage nonsmall cell carcinoma surgery: Video-assisted thoracic surgery versus thoracotomy lobectomy. 
  • Quality of life and trial adherence among participants in the prostate, lung, colorectal, and ovarian cancer screening trial. 
  • Quality of life outcomes are equivalent after lobectomy in the elderly. 
  • Quantification and minimization of uncertainties of internal target volume for stereotactic body radiation therapy of lung cancer. 
  • Quantification of Aortic Valve Calcifications Detected During Lung Cancer-Screening CT Helps Stratify Subjects Necessitating Echocardiography for Aortic Stenosis Diagnosis. 
  • Quantification of Minimum Detectable Difference in Radiomics Features Across Lesions and CT Imaging Conditions. 
  • Quantifying the safety benefits of wedge resection: a society of thoracic surgery database propensity-matched analysis. 
  • Quantitative CT: technique dependence of volume estimation on pulmonary nodules. 
  • Quantitative pulmonary single photon emission computed tomography for radiotherapy applications. 
  • RB-mediated tumor suppression of a lung cancer cell line is abrogated by an extract enriched in extracellular matrix. 
  • REV3L 3'UTR 460 T>C polymorphism in microRNA target sites contributes to lung cancer susceptibility. 
  • RNA Aptamer-targeted Inhibition of NF-κB Suppresses Non-small Cell Lung Cancer Resistance to Doxorubicin. 
  • RNA splicing and aggregate gene expression differences in lung squamous cell carcinoma between patients of West African and European ancestry. 
  • ROC curve estimation under test-result-dependent sampling. 
  • ROS1-fusion protein induces PD-L1 expression via MEK-ERK activation in non-small cell lung cancer. 
  • Racial Differences in Survival Among Advanced-stage Non-small-Cell Lung Cancer Patients Who Received Immunotherapy: An Analysis of the US National Cancer Database (NCDB). 
  • Racial Differences in Treatment and Survival among Veterans and Non-Veterans with Stage I NSCLC: An Evaluation of Veterans Affairs and SEER-Medicare Populations. 
  • Racial and Ethnic Differences in Lung Cancer Surgical Stage: An STS Database Study. 
  • Racial and ethnic inequities of palliative care use among advanced Non-Small cell lung cancer patients in the US. 
  • Racial differences in the perception of lung cancer: the 2005 Health Information National Trends Survey. 
  • Racial disparities among patients with lung cancer who were recommended operative therapy. 
  • Radiation Therapy Oncology Group. Research Plan 2002-2006. Cancer Prevention and Control Committee. 
  • Radiation dose from contemporary cardiothoracic multidetector CT protocols with an anthropomorphic female phantom: implications for cancer induction. 
  • Radiation therapy at the end of life in patients with incurable nonsmall cell lung cancer. 
  • Radiation therapy for oligometastatic non-small cell lung cancer. 
  • Radiation-induced lung damage in patients treated with stereotactic body radiotherapy after EGFR-TKIs: is there any difference from stereotactic body radiotherapy alone? 
  • Radiation-induced narrowing of the tracheobronchial tree: an in-depth analysis. 
  • Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer. 
  • Radiation-induced reductions in regional lung perfusion: 0.1-12 year data from a prospective clinical study. 
  • Radical Minimally Invasive Surgery After Immuno-chemotherapy in Initially-unresectable Stage IIIB Non-small cell Lung Cancer. 
  • Radiofrequency ablation followed by conventional radiotherapy for medically inoperable stage I non-small cell lung cancer. 
  • Radiofrequency ablation for primary lung cancer and pulmonary metastases. 
  • Radiogenomic Analysis of Locally Advanced Lung Cancer Based on CT Imaging and Intratreatment Changes in Cell-Free DNA. 
  • Radiographic imaging of bronchioloalveolar carcinoma: screening, patterns of presentation and response assessment. 
  • Radiologic Considerations and Standardization of Malignant Pleural Mesothelioma Imaging Within Clinical Trials: Consensus Statement from the NCI Thoracic Malignancy Steering Committee - International Association for the Study of Lung Cancer - Mesothelioma Applied Research Foundation Clinical Trials Planning Meeting. 
  • Radiologic findings of bronchogenic carcinoma with pulmonary metastases at presentation. 
  • Radiologic imaging of AIDS. 
  • Radiomics analysis using stability selection supervised component analysis for right-censored survival data. 
  • Radionuclide emission computed tomography of the head with 99mTc and a scintillation camera. 
  • Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. 
  • Radiotherapy and Small Cell Carcinoma With Paraneoplastic Polyneuropathy: A Case Report. 
  • Radon and lung cancer. 
  • Radon risk information and voluntary protection: evidence from a natural experiment. 
  • Randomized Phase II Trial Comparing Chemoradiotherapy with Chemotherapy for Completely Resected Unsuspected N2-Positive Non-Small Cell Lung Cancer. 
  • Randomized Pilot Trial of a Telephone Symptom Management Intervention for Symptomatic Lung Cancer Patients and Their Family Caregivers. 
  • Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study. 
  • Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. 
  • Randomized phase II multicenter trial of two schedules of lapatinib as first- or second-line monotherapy in patients with advanced or metastatic non-small cell lung cancer. 
  • Randomized phase II study of bortezomib alone and bortezomib in combination with docetaxel in previously treated advanced non-small-cell lung cancer. 
  • Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage IIIB non-small-cell lung cancer: cancer and leukemia group B study 9431. 
  • Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. 
  • Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. 
  • Randomized phase II trial of docetaxel plus cetuximab or docetaxel plus bortezomib in patients with advanced non-small-cell lung cancer and a performance status of 2: CALGB 30402. 
  • Randomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial. 
  • Randomized phase II trial of gemcitabine plus irinotecan or docetaxel in stage IIIB or stage IV NSCLC. 
  • Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. 
  • Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. 
  • Randomized phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. 
  • Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. 
  • Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. 
  • Randomized trial of chemotherapy and radiation therapy with or without warfarin for limited-stage small-cell lung cancer: a Cancer and Leukemia Group B study. 
  • Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer. 
  • Randomized trial of radiotherapy to the thorax in limited small-cell carcinoma of the lung treated with multiagent chemotherapy and elective brain irradiation: a preliminary report. 
  • Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. 
  • Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. 
  • Randomized, dose-escalation study of SD/01 compared with daily filgrastim in patients receiving chemotherapy. 
  • Rapamycin downregulates thymidylate synthase and potentiates the activity of pemetrexed in non-small cell lung cancer. 
  • Rapamycin prevents the development and progression of mutant epidermal growth factor receptor lung tumors with the acquired resistance mutation T790M. 
  • Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. 
  • Rare breast metastasis from adenoid cystic carcinoma of the submandibular gland. 
  • Rare codons capacitate Kras-driven de novo tumorigenesis. 
  • Rationale and Design of the Lung Cancer Screening Implementation. Evaluation of Patient-Centered Care Study. 
  • Rationale of technical requirements for NRG-BR001: The first NCI-sponsored trial of SBRT for the treatment of multiple metastases. 
  • Rb and p16INK4a expression in resected non-small cell lung tumors. 
  • Re: Akt phosphorylation and gefitinib efficacy in patients with advanced non-small-cell lung cancer. 
  • Re: The "Helsinki Criteria" for attribution of lung cancer to asbestos exposure: how robust are the criteria? 
  • Readiness for Implementation of Lung Cancer Screening. A National Survey of Veterans Affairs Pulmonologists. 
  • Readmission After Lobectomy for Lung Cancer: Not All Complications Contribute Equally. 
  • Rebuttal from drs Wahidi and Ernst. 
  • Recombinant human endostatin could eliminate the pro-angiogenesis priority of SP cells sorted from non-small cell lung cancer cells. 
  • Recommendations for Measuring Pulmonary Nodules at CT: A Statement from the Fleischner Society. 
  • Recommendations from the European Society of Thoracic Surgeons (ESTS) regarding computed tomography screening for lung cancer in Europe. 
  • Recurrence dynamics for non-small-cell lung cancer: effect of surgery on the development of metastases. 
  • Recurrent WNT pathway alterations are frequent in relapsed small cell lung cancer. 
  • Redistribution of health care costs after the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2005. 
  • Reduced DNA repair capacity in lung cancer patients. 
  • Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. 
  • Reducing scan angle using adaptive prior knowledge for a limited-angle intrafraction verification (LIVE) system for conformal arc radiotherapy. 
  • Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. 
  • Reduction in Tumor Volume by Cone Beam Computed Tomography Predicts Overall Survival in Non-Small Cell Lung Cancer Treated With Chemoradiation Therapy. 
  • Reduction of artifacts in T2 -weighted PROPELLER in high-field preclinical imaging. 
  • Reduction of oral mucositis by filgrastim (r-metHuG-CSF) in patients receiving chemotherapy. 
  • Refining Prognosis in Lung Cancer: A Report on the Quality and Relevance of Clinical Prognostic Tools. 
  • Refractory myasthenia gravis exacerbation triggered By pembrolizumab. 
  • Regional dose response to pulmonary irradiation using a manual method. 
  • Regional lung density changes after radiation therapy for tumors in and around thorax. 
  • Registration of lung nodules using a semi-rigid model: method and preliminary results. 
  • Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin. 
  • Regression of metastatic breast cancer in a patient treated with the anti-angiogenic drug TNP-470. 
  • Regulation of MUC5AC expression by NAD(P)H:quinone oxidoreductase 1. 
  • Regulation of local and metastatic host-mediated anti-tumour mechanisms by L-selectin and intercellular adhesion molecule-1. 
  • Relating radiation-induced regional lung injury to changes in pulmonary function tests. 
  • Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. 
  • Relationship of epithelial ovarian cancer to other malignancies within families. 
  • Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. 
  • Renal metastases. 
  • Renal metastasis of adenocarcinoma of the lung: massive hematuria managed by therapeutic embolization. 
  • Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. 
  • Repeat Annual Lung Cancer Screening After Baseline Screening Among Screen-Negative Individuals: No-Cost Coverage Is Not Enough. 
  • Repeatability of 18F-FDG PET/CT in Advanced Non-Small Cell Lung Cancer: Prospective Assessment in 2 Multicenter Trials. 
  • Repeatability of hypoxia PET imaging using [¹⁸F]HX4 in lung and head and neck cancer patients: a prospective multicenter trial. 
  • Reply to "Prognostic Value of Fluorodeoxyglucose-Positron Emission Tomography". 
  • Reply to M.S. Hofman et al. 
  • Reply to T.-H. Wang et al. 
  • Reply: Repeatability of Tumor SUV Quantification: The Role of Variable Blood SUV. 
  • Reply: To PMID 23545195. 
  • Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia. 
  • Representativeness of participants in the cancer care outcomes research and surveillance consortium relative to the surveillance, epidemiology, and end results program. 
  • Repressive coping style: relationships with depression, pain, and pain coping strategies in lung cancer outpatients. 
  • Reproducibility of histopathological diagnosis in poorly differentiated NSCLC: an international multiobserver study. 
  • Reproducibility of histopathological subtypes and invasion in pulmonary adenocarcinoma. An international interobserver study. 
  • Reproducibility of interfraction lung motion probability distribution function using dynamic MRI: statistical analysis. 
  • Reproducibility of tumor motion probability distribution function in stereotactic body radiation therapy of lung cancer. 
  • Reprogramming normal human epithelial tissues to a common, lethal neuroendocrine cancer lineage. 
  • Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non-Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown. 
  • Resistance to receptor tyrosine kinase inhibition in cancer: molecular mechanisms and therapeutic strategies. 
  • Resminostat, a histone deacetylase inhibitor, circumvents tolerance to EGFR inhibitors in EGFR-mutated lung cancer cells with BIM deletion polymorphism. 
  • Respiratory diseases among union carpenters: cohort and case-control analyses. 
  • Response and resistance to NF-κB inhibitors in mouse models of lung adenocarcinoma. 
  • Response of the secretory immune system to bronchogenic carcinoma of the lung. 
  • Response to Comment on "A National Analysis of Long-term Survival Following Thoracoscopic Versus Open Lobectomy for Stage I Nonsmall-cell Lung Cancer". 
  • Response to Letter to the Editor About Clinical Significance of Lung-RADS Category 3 Lesions. 
  • Response to comments on 'Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure' by Farioli et al. and Oddone et al. 
  • Response to comments on 'Malignant mesothelioma diagnosed at a younger age is associated with heavier asbestos exposure' by Farioli et al. and Oddone et al. 
  • Response. 
  • Responses to online GSTM1 genetic test results among smokers related to patients with lung cancer: a pilot study. 
  • Restrictive spirometry pattern among construction trade workers. 
  • Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer. 
  • Results of cancer and leukemia group B protocol 8935. A multiinstitutional phase II trimodality trial for stage IIIA (N2) non-small-cell lung cancer. Cancer and Leukemia Group B Thoracic Surgery Group. 
  • Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. 
  • Rethinking Autoantibody Signature Panels for Cancer Diagnosis. 
  • Retreatment of patients surviving cancer-free 2 or more years after initial treatment of small cell lung cancer. 
  • Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. 
  • Rhabdomyosarcoma in adult prostate. 
  • Right-Sided Versus Left-Sided Pneumonectomy After Induction Therapy for Non-Small Cell Lung Cancer. 
  • Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practice. 
  • Risk calculators are useful but.... 
  • Risk factors for atrial fibrillation after lung cancer surgery: analysis of the Society of Thoracic Surgeons general thoracic surgery database. 
  • Risk factors for morbidity after lobectomy for lung cancer in elderly patients. 
  • Risk of Each of the Five Lung Lobectomies: A Society of Thoracic Surgeons Database Analysis. 
  • Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy. 
  • Risk of occult irresectable disease at liver resection for hepatic colorectal cancer metastases: a contemporary analysis. 
  • Risk of thromboembolism in cisplatin versus carboplatin-treated patients with lung cancer. 
  • Risk perceptions and smoking decisions of adult Chinese men. 
  • Ritterazine B, a new cytotoxic natural compound, induces apoptosis in cancer cells. 
  • Rlf-Mycl Gene Fusion Drives Tumorigenesis and Metastasis in a Mouse Model of Small Cell Lung Cancer. 
  • Role of Adjuvant Therapy in a Population-Based Cohort of Patients With Early-Stage Small-Cell Lung Cancer. 
  • Role of FDG PET/CT in the Eighth Edition of TNM Staging of Non-Small Cell Lung Cancer. 
  • Role of computerized cranial tomography in the staging of small cell carcinoma of the lung. 
  • Role of dietary carbohydrates on risk of lung cancer. 
  • Role of serum tumor markers CA 125 and CEA in non-small cell lung cancer. 
  • Role of the Quantitative Imaging Biomarker Alliance in optimizing CT for the evaluation of lung cancer screen-detected nodules. 
  • Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer. 
  • Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. 
  • SAbR as an Alternative Boost Modality for Cervical Cancer: A Cautionary Exercise. 
  • SETDB1-mediated methylation of Akt promotes its K63-linked ubiquitination and activation leading to tumorigenesis. 
  • SIRPγ-expressing cancer stem-like cells promote immune escape of lung cancer via Hippo signaling. 
  • SMARCA4 and Other SWItch/Sucrose NonFermentable Family Genomic Alterations in NSCLC: Clinicopathologic Characteristics and Outcomes to Immune Checkpoint Inhibition. 
  • SOCS3 inhibiting migration of A549 cells correlates with PYK2 signaling in vitro. 
  • SOX2 expression is an early event in a murine model of EGFR mutant lung cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines. 
  • SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. 
  • STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment. 
  • STS database risk models: predictors of mortality and major morbidity for lung cancer resection. 
  • SWOG S1400B (NCT02785913), a Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-MAP Sub-Study). 
  • Safely and Effectively Evaluating Computed Tomography-detected Lung Lesions. Much Work to Be Done. 
  • Safety and Efficacy of 68Ga-DOTATATE PET/CT for Diagnosis, Staging, and Treatment Management of Neuroendocrine Tumors. 
  • Safety and Efficacy of a Five-Fraction Stereotactic Body Radiotherapy Schedule for Centrally Located Non-Small-Cell Lung Cancer: NRG Oncology/RTOG 0813 Trial. 
  • Safety and effectiveness of bevacizumab-containing treatment for non-small-cell lung cancer: final results of the ARIES observational cohort study. 
  • Safety and efficacy of weekly oral oltipraz in chronic smokers. 
  • Safety and feasibility of aerobic training on cardiopulmonary function and quality of life in postsurgical nonsmall cell lung cancer patients: a pilot study. 
  • Safety of topotecan in the treatment of recurrent small-cell lung cancer and ovarian cancer. 
  • Salud ocupacional. 
  • Sample size considerations of prediction-validation methods in high-dimensional data for survival outcomes. 
  • Sarcoidosis presenting as large pulmonary nodules. 
  • Sarcomatoid Peritoneal Mesothelioma: Clinicopathologic Correlation of 13 Cases. 
  • Schedule dependency of 21-day oral versus 3-day intravenous etoposide in combination with intravenous cisplatin in extensive-stage small-cell lung cancer: a randomized phase III study of the Cancer and Leukemia Group B. 
  • Sclerosing hemangioma of lung: A close cytologic mimicker of pulmonary adenocarcinoma. 
  • Screening for lung cancer. 
  • Screening for lung cancer. 
  • Screening for lung cancer. 
  • Screening for lung cancer: a review of the current literature. 
  • Screening for lung cancer: been there and done that. 
  • Secondary achalasia in a patient with brainstem metastases from lung carcinoma. 
  • Secondary analysis of RTOG 9508, a phase 3 randomized trial of whole-brain radiation therapy versus WBRT plus stereotactic radiosurgery in patients with 1-3 brain metastases; poststratified by the graded prognostic assessment (GPA). 
  • Segmentectomy and Lung Cancer: Why, When, How, and How Good? 
  • Selecting factors predictive of heterogeneity in multivariate event time data. 
  • Selection bias, phase II trials, and the FDA accelerated approval process. 
  • Self-assembled Lipid Nanoparticles for Ratiometric Codelivery of Cisplatin and siRNA Targeting XPF to Combat Drug Resistance in Lung Cancer. 
  • Self-efficacy for managing pain, symptoms, and function in patients with lung cancer and their informal caregivers: associations with symptoms and distress. 
  • Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. 
  • Sensitive and specific detection of the 4B5 antigen in bronchial lavage specimens from patients with primary bronchogenic carcinoma. 
  • Sensitivity to DNA damage induced by benzo(a)pyrene diol epoxide and risk of lung cancer: a case-control analysis. 
  • Sequence variations in DNA repair gene XPC is associated with lung cancer risk in a Chinese population: a case-control study. 
  • Sequential CT Findings in Patients With Non-small-cell Lung Cancer Receiving Nivolumab. 
  • Serum CYFRA 21-1 in advanced stage non-small cell lung cancer: an early measure of response. 
  • Serum inflammatory miRNAs predict radiation esophagitis in patients receiving definitive radiochemotherapy for non-small cell lung cancer. 
  • Serum protein expression predicts recurrence in patients with early-stage lung cancer after resection. 
  • Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial. 
  • Serum vascular endothelial growth factor and COX-2/5-LOX inhibition in advanced non-small cell lung cancer: Cancer and Leukemia Group B 150304. 
  • Severity of emphysema predicts location of lung cancer and 5-y survival of patients with stage I non-small cell lung cancer. 
  • Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. 
  • Sex differences in early outcomes after lung cancer resection: analysis of the Society of Thoracic Surgeons General Thoracic Database. 
  • Sex differences in risk of lung cancer associated with methylene-tetrahydrofolate reductase polymorphisms. 
  • Sexual concerns in lung cancer patients: an examination of predictors and moderating effects of age and gender. 
  • Shape "break-and-repair" strategy and its application to automated medical image segmentation. 
  • Shared heritability and functional enrichment across six solid cancers. 
  • Short Communication: Interim toxicity analysis for patients with limited stage small cell lung cancer (LSCLC) treated on CALGB 30610 (Alliance) / RTOG 0538. 
  • Signal transducer and activator of transcription 3 is required for the oncogenic effects of non-small-cell lung cancer-associated mutations of the epidermal growth factor receptor. 
  • Signaling levels mold the RAS mutation tropism of urethane. 
  • Signals leading to apoptosis-dependent inhibition of neovascularization by thrombospondin-1. 
  • Significance of percutaneous needle biopsy in patients with multiple pulmonary nodules and a single known primary malignancy. 
  • Similar outcomes between African American and non-African American patients with extensive-stage small-cell lung carcinoma: report from the Cancer and Leukemia Group B. 
  • Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies. 
  • Simulation of subtle lung nodules in projection chest radiography. 
  • Simultaneous thigh muscle metastasis from lung cancer and Escherichia coli gas producing myonecrosis. 
  • Single nucleotide polymorphism at rs1982073:T869C of the TGFbeta 1 gene is associated with the risk of radiation pneumonitis in patients with non-small-cell lung cancer treated with definitive radiotherapy. 
  • Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). 
  • Single-cell analyses reveal increased intratumoral heterogeneity after the onset of therapy resistance in small-cell lung cancer. 
  • Single-fraction SBRT for Early Stage NSCLC-A Viable Option in "These Uncertain Times"? 
  • Sintilimab, stereotactic body radiotherapy and granulocyte-macrophage colony stimulating factor as second-line therapy for advanced non-small cell lung cancer: safety run-in results of a multicenter, single-arm, phase II trial. 
  • Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells. 
  • Sleeve lobectomy for non-small cell lung cancer with N1 nodal disease does not compromise survival. 
  • Small Cell Lung Cancer Exhibits Frequent Inactivating Mutations in the Histone Methyltransferase KMT2D/MLL2: CALGB 151111 (Alliance). 
  • Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology. 
  • Small cell bladder cancer: should we consider prophylactic cranial irradiation? 
  • Small cell carcinoma of the lung. Results of combination chemotherapy and radiation therapy. 
  • Small cell lung cancer clinical practice guidelines in oncology. 
  • Small cell lung cancer presenting as a paraneoplastic syndrome characterized by recurrent episodic hypotension and bradycardia: case report. 
  • Small cell lung cancer. 
  • Small cell lung cancer. 
  • Small cell lung cancer. 
  • Small cell lung carcinoma cell lines express mRNA for calcitonin and alpha- and beta-calcitonin gene related peptides. 
  • Small neuroendocrine lesions in intrathoracic lymph nodes of patients with primary lung adenocarcinoma: real metastasis? 
  • Small-cell lung cancer: a review of clinical trials. 
  • Small-cell lung cancer: prognostic factors and changing treatment over 15 years. 
  • Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. 
  • Smoking Status and Survival Among a National Cohort of Lung and Colorectal Cancer Patients. 
  • Smoking cessation and the success of lung cancer surgery. 
  • Smoking history predicts for increased risk of second primary lung cancer: a comprehensive analysis. 
  • Smoking, DNA repair capacity and risk of nonsmall cell lung cancer. 
  • Smoking-adjusted lung cancer incidence among Asian-Americans (United States). 
  • Smoking-related genomic signatures in non-small cell lung cancer. 
  • Social Disparities in Lung Cancer Risk and Screening. 
  • Socioeconomic disparities in immunotherapy use among advanced-stage non-small cell lung cancer patients: analysis of the National Cancer Database. 
  • Solitary Fibrous Tumor of the Uterus Presenting With Lung Metastases: A Case Report. 
  • Solitary pulmonary metastases in high-risk melanoma patients: a prospective comparison of conventional and computed tomography. 
  • Solitary pulmonary nodules: Part I. Morphologic evaluation for differentiation of benign and malignant lesions. 
  • Solitary pulmonary nodules: Part II. Evaluation of the indeterminate nodule. 
  • Somatic mosaicism caused by monoallelic reversion of a mutation in T cells of a patient with ADA-SCID and the effects of enzyme replacement therapy on the revertant phenotype. 
  • Somatostatin receptor 2 signaling promotes growth and tumor survival in small-cell lung cancer. 
  • Sotorasib in KRAS p.G12C-Mutated Advanced Pancreatic Cancer. 
  • Sox2 cooperates with Lkb1 loss in a mouse model of squamous cell lung cancer. 
  • Spatial-temporal variability of radiomic features and its effect on the classification of lung cancer histology. 
  • Speed and convergence properties of gradient algorithms for optimization of IMRT. 
  • Spontaneous regression of squamous cell lung carcinoma with adrenal metastasis. 
  • Squamous non-small cell lung cancer as a distinct clinical entity. 
  • Stable RNA interference-mediated suppression of cyclophilin A diminishes non-small-cell lung tumor growth in vivo. 
  • Stage I NSCLC: elucidating the prognostic factors. 
  • Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence. 
  • Stage IA non-small cell lung cancer: a small proportion of cases in the general population. 
  • Stage III lung cancer: two or three modalities? The continued role of thoracic radiotherapy. 
  • Stage distribution in patients with a small (< or = 3 cm) primary nonsmall cell lung carcinoma. Implication for lung carcinoma screening. 
  • Stage migration, selection bias, and survival associated with the adoption of positron emission tomography among medicare beneficiaries with non-small-cell lung cancer, 1998-2003. 
  • Staging non-small cell carcinoma of the lung using technetium-99m-labeled monoclonal antibodies. 
  • Staging non-small cell lung cancer with whole-body PET. 
  • Staging techniques for lung cancer. 
  • Standardized beam bouquets for lung IMRT planning. 
  • State of the Art: Interventional Pulmonology. 
  • State of the Art: Toward Improving Outcomes of Lung and Liver Tumor Biopsies in Clinical Trials-A Multidisciplinary Approach. 
  • Statistical Considerations for Subgroup Analyses. 
  • Statistical Issues in Testing Conformance with the Quantitative Imaging Biomarker Alliance (QIBA) Profile Claims. 
  • Statistical considerations for analysis of microarray experiments. 
  • Statistically adjusted estimates of geographic mortality profiles. 
  • Stereotactic Body Radiation Therapy-Induced Abscopal Effect on Hepatocellular Carcinoma After Treatment for Lung Cancer: A Case Report. 
  • Stereotactic Body Radiotherapy Versus Delayed Surgery for Early-stage Non-small-cell Lung Cancer. 
  • Stereotactic body radiation therapy for early-stage non-small cell lung cancer: Executive Summary of an ASTRO Evidence-Based Guideline. 
  • Stereotactic body radiation therapy for treatment of primary and metastatic pulmonary malignancies. 
  • Stereotactic body radiation therapy versus sublobar resection for stage I NSCLC. 
  • Stereotactic body radiotherapy in patients with stage I non-small-cell lung cancer aged 75 years and older: retrospective results from a multicenter consortium. 
  • Stereotactic radiotherapy for pulmonary metastases. 
  • Stopping a clinical trial early: frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. 
  • Strain-specific spontaneous and NNK-mediated tumorigenesis in Pten+/- mice. 
  • Strategies for analysing ecological health data: models of the biological risk of individuals. 
  • Stromelysin-3 is overexpressed by stromal elements in primary non-small cell lung cancers and regulated by retinoic acid in pulmonary fibroblasts. 
  • Study Design and Rationale: A Multicenter, Prospective Trial of Electromagnetic Bronchoscopic and Electromagnetic Transthoracic Navigational Approaches for the Biopsy of Peripheral Pulmonary Nodules (ALL IN ONE Trial). 
  • Study protocol for a randomised trial evaluating the non-inferiority of stepped palliative care versus early integrated palliative care for patients with advanced lung cancer. 
  • Studying health histories of cancer: a new model connecting cancer incidence and survival. 
  • Subacute cutaneous lupus erythematosus and dermatomyositis associated with anti-programmed cell death 1 therapy. 
  • Subcutaneous interleukin-2 as initial therapy for patients with extensive small cell lung cancer: a phase II trial of Cancer and Leukemia Group B. 
  • Subcutaneous vaccination with irradiated, cytokine-producing tumor cells stimulates CD8+ cell-mediated immunity against tumors located in the "immunologically privileged" central nervous system. 
  • Sublobar Resection for Clinical Stage IA Non-small-cell Lung Cancer in the United States. 
  • Subtle lung nodules: influence of local anatomic variations on detection. 
  • Successful Outpatient Management of Diffuse Photosensitive Bullous Dermatitis Following Pembrolizumab Therapy. 
  • Successful bilateral lung transplantation for lymphangiomatosis. 
  • Sudden death in cancer patients receiving lithium. 
  • Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. 
  • Supportive Care in Lung Cancer: Improving Value in the Era of Modern Therapies. 
  • Suppression of Rev3, the catalytic subunit of Pol{zeta}, sensitizes drug-resistant lung tumors to chemotherapy. 
  • Suppression of tumorigenicity of A549 lung adenocarcinoma cells by human chromosomes 3 and 11 introduced via microcell-mediated chromosome transfer. 
  • Surgery Versus Optimal Medical Management for N1 Small Cell Lung Cancer. 
  • Surgery or ablative radiotherapy for breast cancer oligometastases. 
  • Surgery versus stereotactic body radiation therapy for operable stage I non-small cell lung cancer: Can we achieve equipoise? 
  • Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer: A comprehensive review. 
  • Surgical Evaluation in Patients Undergoing Radiation Therapy for Early-Stage Lung Cancer. 
  • Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases. 
  • Surgical Outcomes After Neoadjuvant Chemotherapy and Ipilimumab for Non-Small Cell Lung Cancer. 
  • Surgical management of pulmonary metastases. 
  • Surgical strategies and outcomes after induction therapy for non-small cell lung cancer. 
  • Surgical techniques and results of the pulmonary artery reconstruction for patients with central non-small cell lung cancer. 
  • Surgical techniques to avoid parenchymal injury during lung resection (fissureless lobectomy). 
  • Surgically Managed Clinical Stage IIIA-Clinical N2 Lung Cancer in The Society of Thoracic Surgeons Database. 
  • Surrogate endpoints for overall survival in chemotherapy and radiotherapy trials in operable and locally advanced lung cancer: a re-analysis of meta-analyses of individual patients' data. 
  • Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States. 
  • Survival after radiation for stage I and II non-small cell lung cancer with positive margins. 
  • Survival in the elderly after pneumonectomy for early-stage non-small cell lung cancer: a comparison with nonoperative management. 
  • Survivorship care planning and its influence on long-term patient-reported outcomes among colorectal and lung cancer survivors: the CanCORS disease-free survivor follow-up study. 
  • Susceptibility loci of CNOT6 in the general mRNA degradation pathway and lung cancer risk-A re-analysis of eight GWASs. 
  • Symptom Burden of Chronic Lung Disease Compared with Lung Cancer at Time of Referral for Palliative Care Consultation. 
  • Symptom management in patients with lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. 
  • Symptomatic pulmonary allograft Kaposi's sarcoma in two lung transplant recipients. 
  • Synchronous resection of esophageal cancer and other organ malignancies: A systematic review. 
  • Syndrome of inappropriate antidiuretic hormone secretion. 
  • Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. 
  • Systematic interrogation of 3q26 identifies TLOC1 and SKIL as cancer drivers. 
  • Systematic review of efficacy of dose-dense versus non-dose-dense chemotherapy in breast cancer, non-Hodgkin lymphoma, and non-small cell lung cancer. 
  • Systemic doxorubicin and intraarterial cisplatin preoperative chemotherapy plus postoperative adjuvant chemotherapy in patients with osteosarcoma. 
  • T1 lung cancers: sensitivity of diagnosis with fluorodeoxyglucose PET. 
  • TD-19, an erlotinib derivative, induces epidermal growth factor receptor wild-type nonsmall-cell lung cancer apoptosis through CIP2A-mediated pathway. 
  • TGFβ1 Polymorphisms Predict Distant Metastasis-Free Survival in Patients with Inoperable Non-Small-Cell Lung Cancer after Definitive Radiotherapy. 
  • TNFRSF1B +676 T>G polymorphism predicts survival of non-small cell lung cancer patients treated with chemoradiotherapy. 
  • TP53 and RAS mutations in metachronous tumors from patients with cancer of the upper aerodigestive tract. 
  • TP53, CDKN2A/P16, and NFE2L2/NRF2 regulate the incidence of pure- and combined-small cell lung cancer in mice. 
  • Tagging single nucleotide polymorphisms in MBD4 are associated with risk of lung cancer in a Chinese population. 
  • Tagging single nucleotide polymorphisms in excision repair cross-complementing group 1 (ERCC1) and risk of primary lung cancer in a Chinese population. 
  • Tagging single nucleotide polymorphisms in phosphoinositide-3-kinase-related protein kinase genes involved in DNA damage "checkpoints" and lung cancer susceptibility. 
  • Talking with patients about dying. 
  • Targeted cytotoxic analogue of bombesin/gastrin-releasing peptide inhibits the growth of H-69 human small-cell lung carcinoma in nude mice. 
  • Targeted therapy for non-small cell lung cancer. 
  • Targeting aberrant signal transduction pathways in lung cancer. 
  • Targeting anemia in patients with lung cancer. 
  • Targeting the Wnt-Regulatory Protein CTNNBIP1 by microRNA-214 Enhances the Stemness and Self-Renewal of Cancer Stem-Like Cells in Lung Adenocarcinomas. 
  • TbetaRIII suppresses non-small cell lung cancer invasiveness and tumorigenicity. 
  • Technical Aspects of Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration: CHEST Guideline and Expert Panel Report. 
  • Technical Note: Imaging dose resulting from optimized procedures with limited-angle intrafractional verification system during stereotactic body radiation therapy lung treatment. 
  • Techniques for virtual lung nodule insertion: volumetric and morphometric comparison of projection-based and image-based methods for quantitative CT. 
  • Technology evaluation: BLP-25, Biomira Inc. 
  • Temporal trends in the management of potentially resectable lung cancer. 
  • Ten years of respiratory cytopathology at Duke University Medical Center. I. The cytopathologic diagnosis of lung cancer during the years 1970 to 1974, noting the significance of specimen number and type. 
  • Ten years of respiratory cytopathology at Duke University Medical Center. II. The cytopathologic diagnosis of lung cancer during the years 1970 to 1974, with a comparison between cytopathology and histopathology in the typing of lung cancer. 
  • Tenascin-C, over expressed in lung cancer down regulates effector functions of tumor infiltrating lymphocytes. 
  • Testing different communication formats on responses to imagined risk of having versus missing the GSTM1 gene. 
  • The "High-Riding" superior pericardial recess: CT findings. 
  • The 2021 WHO Classification of Tumors of the Heart. 
  • The 2021 WHO Classification of Tumors of the Pleura: Advances Since the 2015 Classification. 
  • The ABL2 kinase regulates an HSF1-dependent transcriptional program required for lung adenocarcinoma brain metastasis. 
  • The Association of Intratumoral Germinal Centers with early-stage non-small cell lung cancer. 
  • The Biology of Pulmonary Metastasis. 
  • The Current and Evolving Role of PET in Personalized Management of Lung Cancer. 
  • The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. 
  • The Effect of Receiving Treatment Within a Clinical Trial Setting on Survival and Quality of Care Perception in Advanced Stage Non-Small Cell Lung Cancer. 
  • The Effect of Tumor Size and Histologic Findings on Outcomes After Segmentectomy vs Lobectomy for Clinically Node-Negative Non-Small Cell Lung Cancer. 
  • The Effect of Various Dose Normalization Strategies When Implementing Linear Boltzmann Transport Equation Dose Calculation for Lung Stereotactic Body Radiation Therapy Planning. 
  • The ErbB2ΔEx16 splice variant is a major oncogenic driver in breast cancer that promotes a pro-metastatic tumor microenvironment. 
  • The IASLC Lung Cancer Staging Project: proposals for revision of the M descriptors in the forthcoming (seventh) edition of the TNM classification of lung cancer. 
  • The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. 
  • The Impact of Adjuvant Hemithoracic Radiation on Outcomes in Patients With Stage I-III Malignant Pleural Mesothelioma: A Dual Registry Analysis. 
  • The Impact of Extended Delayed Surgery for Indolent Lung Cancer or Part-Solid Ground Glass Nodules. 
  • The International Association Study Lung Cancer (IASLC) Strategic Screening Advisory Committee (SSAC) response to the USPSTF recommendations. 
  • The International Association for the Study of Lung Cancer Early Lung Imaging Confederation. 
  • The Lineage-Defining Transcription Factors SOX2 and NKX2-1 Determine Lung Cancer Cell Fate and Shape the Tumor Immune Microenvironment. 
  • The National Lung Screening Trial: overview and study design. 
  • The Oldest Old: A National Analysis of Outcomes for Patients 90 Years or Older With Lung Cancer. 
  • The Optimal Treatment for Stage IIIA-N2 Non-Small Cell Lung Cancer: A Network Meta-Analysis. 
  • The PAX3-FKHR fusion gene of rhabdomyosarcoma cooperates with loss of p16INK4A to promote bypass of cellular senescence. 
  • The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. 
  • The Pseudocavitation Sign of Lung Adenocarcinoma: A Distinguishing Feature and Imaging Biomarker of Lepidic Growth. 
  • The Quality of Peer-Reviewed Publications on Surgery for Early Stage Lung Cancer Within the Veterans Health Administration. 
  • The Ras-related protein AGS1/RASD1 suppresses cell growth. 
  • The Reference Image Database to Evaluate Response to therapy in lung cancer (RIDER) project: a resource for the development of change-analysis software. 
  • The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of Potentially Curable Non-Small Cell Lung Cancer. 
  • The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma: An Analysis of 1991 Patients. 
  • The Shared Genetic Architectures Between Lung Cancer and Multiple Polygenic Phenotypes in Genome-Wide Association Studies. 
  • The So-called Short-Fiber Controversy: Literature Review and Critical Analysis. 
  • The Society of Thoracic Surgeons Composite Score Rating for Pulmonary Resection for Lung Cancer. 
  • The Society of Thoracic Surgeons Composite Score for Rating Program Performance for Lobectomy for Lung Cancer. 
  • The Society of Thoracic Surgeons Lung Cancer Resection Risk Model: Higher Quality Data and Superior Outcomes. 
  • The Use of Radiation Therapy for the Treatment of Malignant Pleural Mesothelioma: Expert Opinion from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. 
  • The VAMPIRE challenge: A multi-institutional validation study of CT ventilation imaging. 
  • The Value of FDG PET/CT in Treatment Response Assessment, Follow-Up, and Surveillance of Lung Cancer. 
  • The addition of anti-angiogenic tyrosine kinase inhibitors to chemotherapy for patients with advanced non-small-cell lung cancers: A meta-analysis of randomized trials. 
  • The addition of erlotinib to gemcitabine and cisplatin does not appear to improve median survival in metastatic pancreatic cancer. 
  • The approach to the patient with single and multiple liver metastases, pulmonary metastases, and intra-abdominal metastases from colorectal carcinoma. 
  • The best that surgery has to offer. 
  • The cell of origin and subtype of K-Ras-induced lung tumors are modified by Notch and Sox2. 
  • The chemokine CX3CL1 regulates NK cell activity in vivo. 
  • The chemopreventive agent myoinositol inhibits Akt and extracellular signal-regulated kinase in bronchial lesions from heavy smokers. 
  • The chest radiograph in acquired immunodeficiency syndrome. 
  • The complexity of chronic disease at later ages: practical implications for prospective payment and data collection. 
  • The correlation evaluation of a tumor tracking system using multiple external markers. 
  • The diagnostic distinction between malignant mesothelioma of the pleura and adenocarcinoma of the lung as defined by a monoclonal antibody (B72.3). 
  • The differential diagnosis between pleural sarcomatoid mesothelioma and spindle cell/pleomorphic (sarcomatoid) carcinomas of the lung: evidence-based guidelines from the International Mesothelioma Panel and the MESOPATH National Reference Center. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effect of extent of resection on outcomes in patients with limited stage small cell lung cancer. 
  • The effect of lithium carbonate administration in patients with advanced small cell bronchogenic carcinoma receiving combination chemotherapy and radiotherapy. 
  • The effect of patient-specific factors on radiation-induced regional lung injury. 
  • The effect of prior androgen synthesis inhibition on outcomes of subsequent therapy with docetaxel in patients with metastatic castrate-resistant prostate cancer: results from a retrospective analysis of a randomized phase 3 clinical trial (CALGB 90401) (Alliance). 
  • The effect of prior pneumonectomy or lobectomy on subsequent lung transplantation. 
  • The effect of respiratory motion variability and tumor size on the accuracy of average intensity projection from four-dimensional computed tomography: an investigation based on dynamic MRI. 
  • The effects of ambient lighting in chest radiology reading rooms. 
  • The efficacy of full-lung tomography in the detection of early metastatic disease from melanoma. 
  • The evolving role of radiotherapy in treatment of oligometastatic NSCLC. 
  • The feasibility of online genetic testing for lung cancer susceptibility: uptake of a web-based protocol and decision outcomes. 
  • The hOGG1 Ser326Cys polymorphism and lung cancer risk: a meta-analysis. 
  • The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons. 
  • The impact of Filgrastim schedule variation on hematopoietic recovery post-chemotherapy. 
  • The impact of induction chemotherapy and the associated tumor response on subsequent radiation-related changes in lung function and tumor response. 
  • The impact of pre-radiotherapy surgery on radiation-induced lung injury. 
  • The impact of pulmonary hypertension on morbidity and mortality following major lung resection. 
  • The impact of respiratory gating on improving volume measurement of murine lung tumors in micro-CT imaging. 
  • The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. 
  • The impact of tumor size on the association of the extent of lymph node resection and survival in clinical stage I non-small cell lung cancer. 
  • The importance of chemotherapy dose intensity in lung cancer. 
  • The incomplete border sign. 
  • The influence of adjuvant therapy on survival in patients with indeterminate margins following surgery for non-small cell lung cancer. 
  • The investigation on the location effect of external markers in respiratory-gated radiotherapy. 
  • The landscape of EGFR pathways and personalized management of non-small-cell lung cancer. 
  • The lung cancer exercise training study: a randomized trial of aerobic training, resistance training, or both in postsurgical lung cancer patients: rationale and design. 
  • The management of patients with stage IIIA non-small cell lung cancer with N2 mediastinal node involvement. 
  • The markerless lung target tracking AAPM Grand Challenge (MATCH) results. 
  • The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. 
  • The past, present, and future management of brain metastases in EGFR-mutant non-small cell lung cancer. 
  • The problem of benign pulmonary nodules in children receiving cytotoxic chemotherapy. 
  • The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. 
  • The prognostic value of interleukin-17 in lung cancer: A systematic review with meta-analysis based on Chinese patients. 
  • The prognostic value of pre-diagnosis health-related quality of life on survival: a prospective cohort study of older Americans with lung cancer. 
  • The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. 
  • The rexinoid LG100268 and the synthetic triterpenoid CDDO-methyl amide are more potent than erlotinib for prevention of mouse lung carcinogenesis. 
  • The role of DNA repair capacity in susceptibility to lung cancer: a review. 
  • The role of hematopoietic growth factors in support of ifosfamide/carboplatin/etoposide chemotherapy. 
  • The role of immunotherapy in fusion-driven lung cancer. 
  • The role of stem cells in airway repair: implications for the origins of lung cancer. 
  • The role of surgery for patients with metastatic melanoma. 
  • The role of the Akt/mTOR pathway in tobacco carcinogen-induced lung tumorigenesis. 
  • The role of thoracoscopic pneumonectomy in the management of non-small cell lung cancer: A multicenter study. 
  • The role of three dimensional functional lung imaging in radiation treatment planning: the functional dose-volume histogram. 
  • The roles of MASPIN expression and subcellular localization in non-small cell lung cancer. 
  • The secondary pulmonary lobule: normal and abnormal CT appearances. 
  • The shared genetic architecture between epidemiological and behavioral traits with lung cancer. 
  • The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using a single-source antibody with a review of the literature. 
  • The surgical management of lung cancer. 
  • The surgical management of metastatic melanoma. 
  • The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase. 
  • The synthetic phosphagen cyclocreatine phosphate inhibits the growth of a broad spectrum of solid tumors. 
  • The synthetic triterpenoids CDDO-methyl ester and CDDO-ethyl amide prevent lung cancer induced by vinyl carbamate in A/J mice. 
  • The time course of radiation therapy-induced reductions in regional perfusion: a prospective study with >5 years of follow-up. 
  • The toxicity of Upstate New York talc. 
  • The use of Grade of Membership analysis to evaluate and modify diagnosis-related groups. 
  • The use of a panel of monoclonal antibodies in ultrastructurally characterized small cell carcinomas of the lung. 
  • The use of convex probe endobronchial ultrasound-guided transbronchial needle aspiration in a pediatric population: a multicenter study. 
  • The use of electrocautery as the primary ablation modality for malignant and benign airway obstruction. 
  • The use of lithium carbonate to reduce infection and leukopenia during systemic chemotherapy. 
  • The utility of SPECT lung perfusion scans in minimizing and assessing the physiologic consequences of thoracic irradiation. 
  • The utility of non-axial treatment beam orientations for lower lobe lung cancers. 
  • The value of radionuclide bone imaging in selected patients with osteogenic sarcoma metastatic to lung. 
  • Therapeutic bronchoscopy for malignant central airway obstruction: success rates and impact on dyspnea and quality of life. 
  • Therapeutic effect of infused Fluosol-DA/carbogen with ephedrine, flunarizine, or nitroprusside. 
  • Therapy choices among older patients with lung carcinoma: an evaluation of two trials of the Cancer and Leukemia Group B. 
  • Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate. 
  • Thioredoxin-mediated denitrosylation regulates cytokine-induced nuclear factor κB (NF-κB) activation. 
  • Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. 
  • Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032. 
  • Thoracic FDG PET: state of the art. 
  • Thoracic Radiotherapy for Renal Cell Carcinoma Metastases: Local Control for the Management of Lung and Mediastinal Disease in the Modern Era. 
  • Thoracic imaging. 
  • Thoracic nodal staging with PET imaging with 18FDG in patients with bronchogenic carcinoma. 
  • Thoracic radiation therapy added to chemotherapy for small-cell lung cancer: an update of Cancer and Leukemia Group B Study 8083. 
  • Thoracic spiral CT: influence of subsecond gantry rotation on image quality. 
  • Thoracoscopic Lobectomy for Non-small Cell Lung Cancer. 
  • Thoracoscopic approach to lobectomy for lung cancer does not compromise oncologic efficacy. 
  • Thoracoscopic lobectomy facilitates the delivery of chemotherapy after resection for lung cancer. 
  • Thoracoscopic lobectomy for the management of non-small cell lung cancer. 
  • Thoracoscopic lobectomy has increasing benefit in patients with poor pulmonary function: a Society of Thoracic Surgeons Database analysis. 
  • Thoracoscopic lobectomy is a safe and versatile procedure: experience with 500 consecutive patients. 
  • Thoracoscopic lobectomy is associated with acceptable morbidity and mortality in patients with predicted postoperative forced expiratory volume in 1 second or diffusing capacity for carbon monoxide less than 40% of normal. 
  • Thoracoscopic lobectomy is associated with lower morbidity compared with thoracotomy. 
  • Thoracoscopic lobectomy is associated with lower morbidity than open lobectomy: a propensity-matched analysis from the STS database. 
  • Thoracoscopic lobectomy: a safe and effective strategy for patients receiving induction therapy for non-small cell lung cancer. 
  • Thoracoscopic lobectomy: a safe and effective strategy for patients with stage I lung cancer. 
  • Thoracoscopic lobectomy: evolving and improving. 
  • Thoracoscopic lobectomy: the gold standard for early-stage lung cancer? 
  • Thoracoscopic segmentectomy for lung cancer. 
  • Thoracoscopic segmentectomy: technical considerations and outcomes. 
  • Three-dimensional simulation of lung nodules for paediatric multidetector array CT. 
  • Time to diagnosis and treatment of lung cancer: A systematic overview of risk factors, interventions and impact on patient outcomes. 
  • Time-To-Event Data: An Overview and Analysis Considerations. 
  • Time-to-Treatment-Failure and Related Outcomes Among 1000+ Advanced Non-Small Cell Lung Cancer Patients: Comparisons Between Older Versus Younger Patients (Alliance A151711). 
  • Timing of local and distant failure in resected lung cancer: implications for reported rates of local failure. 
  • Tirapazamine: a hypoxia-activated topoisomerase II poison. 
  • Tobacco carcinogen-induced cellular transformation increases Akt activation in vitro and in vivo. 
  • Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. 
  • Tobacco components stimulate Akt-dependent proliferation and NFkappaB-dependent survival in lung cancer cells. 
  • Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade. 
  • Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. 
  • Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. 
  • Total and Out-of-Pocket Costs of Procedures After Lung Cancer Screening in a National Commercially Insured Population: Estimating an Episode of Care. 
  • Toxicity Related to Radiotherapy Dose and Targeting Strategy: A Pooled Analysis of Cooperative Group Trials of Combined Modality Therapy for Locally Advanced Non-Small Cell Lung Cancer. 
  • Toxicity of definitive and post-operative radiation following ipilimumab in non-small cell lung cancer. 
  • Tracheobronchial mucoid pseudotumors. 
  • Trajectory of overall health from self-report and factors contributing to health declines among cancer survivors. 
  • Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers. 
  • Translating biomarkers into clinical practice: prognostic implications of cyclophilin A and macrophage migratory inhibitory factor identified from protein expression profiles in non-small cell lung cancer. 
  • Translating genomics into clinical practice: applications in lung cancer. 
  • Transmission of cancer with cadaveric donor organs. 
  • Transplanted carcinoma in an immunosuppressed patient. 
  • Transthoracic fine needle aspiration biopsy. Sensitivity in relation to guidance technique and lesion size and location. 
  • Treating triple-negative breast cancer by a combination of rapamycin and cyclophosphamide: an in vivo bioluminescence imaging study. 
  • Treatment at Integrated Centers Might Bridge the Academic-Community Survival Gap in Patients With Metastatic Non-Small Cell Carcinoma of the Lung. 
  • Treatment of Lung Cancer in Medically Compromised Patients. 
  • Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. 
  • Treatment planning based on lung functional avoidance is not ready for clinical deployment. 
  • Treatment with Imatinib in NSCLC is associated with decrease of phosphorylated PDGFR-beta and VEGF expression, decrease in interstitial fluid pressure and improvement of oxygenation. 
  • Treatment with imatinib improves drug delivery and efficacy in NSCLC xenografts. 
  • Treatment with the nitric oxide synthase inhibitor L-NAME provides a survival advantage in a mouse model of Kras mutation-positive, non-small cell lung cancer. 
  • Treatment-related acute esophagitis for patients with locoregionally advanced non-small cell lung cancer treated with involved-field radiotherapy and concurrent chemotherapy. 
  • Trends in the outcomes for patients with limited stage small cell lung cancer: An analysis of the Surveillance, Epidemiology, and End Results database. 
  • Tuberous sclerosis 1 promotes invariant NKT cell anergy and inhibits invariant NKT cell-mediated antitumor immunity. 
  • Tumor Size, Histology, and Survival After Stereotactic Ablative Radiotherapy and Sublobar Resection in Node-negative Non-small Cell Lung Cancer. 
  • Tumor acquisition for biomarker research in lung cancer. 
  • Tumor heterogeneity. 
  • Tumor infiltrating Foxp3+ regulatory T-cells are associated with recurrence in pathologic stage I NSCLC patients. 
  • Tumor infiltrating lymphocyte therapy for metastatic melanoma: analysis of tumors resected for TIL. 
  • Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. 
  • Tumor lysis syndrome and acute renal failure after treatment of non-small-cell lung carcinoma with combination irinotecan and cisplatin. 
  • Tumor multiplicity, DNA adducts and K-ras mutation pattern of 5-methylchrysene in strain A/J mouse lung. 
  • Tumor necrosis and cavitation after stereotactic body radiation therapy. 
  • Tumor necrosis factor induces neuroendocrine differentiation in small cell lung cancer cell lines. 
  • Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. 
  • Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer. 
  • Tumor-dendritic cell fusion as a basis for cancer immunotherapy. 
  • Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial. 
  • Typical and atypical carcinoid tumors of the lung: a clinicopathological correlation of 783 cases with emphasis on histological features. 
  • U19/Eaf2 knockout causes lung adenocarcinoma, B-cell lymphoma, hepatocellular carcinoma and prostatic intraepithelial neoplasia. 
  • Ultrasound: the pulmonologist's new best friend. 
  • Uncertainties in the dosimetric heterogeneity correction and its potential effect on local control in lung SBRT. 
  • Uncertainties of 4-dimensional computed tomography-based tumor motion measurement for lung stereotactic body radiation therapy. 
  • Unexpected observations on tumor size and survival in stage IA non-small cell lung cancer. 
  • Uniportal video-assisted thoracic surgery: a call for better evidence, not just more evidence. 
  • Univent tube provides a new technique for jet ventilation. 
  • Up-regulation of proline-rich tyrosine kinase 2 in non-small cell lung cancer. 
  • Update in non-small cell lung cancer. 
  • Update: vinorelbine (navelbine) in non-small cell lung cancer. 
  • Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. 
  • Urinary cyclic adenosine monophosphate as an aid in the diagnosis of hyperparathyroidism. 
  • Use and Outcomes of Minimally Invasive Lobectomy for Stage I Non-Small Cell Lung Cancer in the National Cancer Data Base. 
  • Use and impact of adjuvant chemotherapy in patients with resected non-small cell lung cancer. 
  • Use of bioluminescence imaging to detect enhanced hepatic and systemic tumor growth following partial hepatectomy in mice. 
  • Use of fertility preservation services in female reproductive-aged cancer patients. 
  • Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study. 
  • Use of pulmonary function test demographic data to identify high-risk patients for lung cancer screening. 
  • Use of trastuzumab in the treatment of metastatic endometrial cancer. 
  • Usefulness of collecting routine cytologic specimens during fiberoptic bronchoscopy for endoscopically visible and nonvisible lung carcinoma. 
  • Using FDG-PET activity as a surrogate for tumor cell density and its effect on equivalent uniform dose calculation. 
  • Using immunotherapy to target EGF in patients with NSCLC. 
  • Using patient data similarities to predict radiation pneumonitis via a self-organizing map. 
  • Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation. 
  • Utilization of Lung Cancer Screening in the Medicare Fee-for-Service Population. 
  • VATS and Minimally Invasive Resection in Early-Stage NSCLC. 
  • VATS lobectomy has better perioperative outcomes than open lobectomy: CALGB 31001, an ancillary analysis of CALGB 140202 (Alliance). 
  • VATS versus open surgery for lung cancer resection: moving toward a minimally invasive approach. 
  • Vaccine therapy in non-small-cell lung cancer. 
  • Validation and real-world assessment of the Functional Assessment of Anorexia-Cachexia Therapy (FAACT) scale in patients with advanced non-small cell lung cancer and the cancer anorexia-cachexia syndrome (CACS). 
  • Validation of Progression-Free Survival as a Surrogate Endpoint for Overall Survival in Malignant Mesothelioma: Analysis of Cancer and Leukemia Group B and North Central Cancer Treatment Group (Alliance) Trials. 
  • Validation of cancer-type-dependent benefit from immune checkpoint blockade in TMB-H tumors identified by the FoundationOne CDx assay. 
  • Validation of interobserver agreement in lung cancer assessment: hematoxylin-eosin diagnostic reproducibility for non-small cell lung cancer: the 2004 World Health Organization classification and therapeutically relevant subsets. 
  • Validation of lesion simulations in clinical CT data for anonymized chest and abdominal CT databases. 
  • Validation of survival prognostic models for non-small-cell lung cancer in stage- and age-specific groups. 
  • Validation of the Patient Care Monitor (Version 2.0): a review of system assessment instrument for cancer patients. 
  • Validation of two models to estimate the probability of malignancy in patients with solitary pulmonary nodules. 
  • Value of intraoperative pleural lavage in staging non-small cell lung cancer. 
  • Variability in the treatment of elderly patients with stage IIIA (N2) non-small-cell lung cancer. 
  • Variable apoptotic response of NSCLC cells to inhibition of the MEK/ERK pathway by small molecules or dominant negative mutants. 
  • Variation in Definitive Therapy for Localized Non-Small Cell Lung Cancer Among National Comprehensive Cancer Network Institutions. 
  • Variations in the functional visual field for detection of lung nodules on chest computed tomography: Impact of nodule size, distance, and local lung complexity. 
  • Variations in use of PET among Medicare beneficiaries with non-small cell lung cancer, 1998-2007. 
  • Veliparib and nivolumab in combination with platinum doublet chemotherapy in patients with metastatic or advanced non-small cell lung cancer: A phase 1 dose escalation study. 
  • Veliparib in combination with carboplatin/paclitaxel-based chemoradiotherapy in patients with stage III non-small cell lung cancer. 
  • Venous thromboembolism risk in patients with cancer receiving chemotherapy: a real-world analysis. 
  • Video-assisted thoracic surgery lobectomy: report of CALGB 39802--a prospective, multi-institution feasibility study. 
  • Video-assisted thoracoscopic surgery lobectomy at 20 years: a consensus statement. 
  • Video-assisted thoracoscopic surgery versus robot-assisted thoracoscopic surgery versus thoracotomy for early-stage lung cancer. 
  • Video-assisted wedge resection and local radiotherapy for peripheral lung cancer in high-risk patients: the Cancer and Leukemia Group B (CALGB) 9335, a phase II, multi-institutional cooperative group study. 
  • Videothoracoscopic mediastinal lymphadenectomy. 
  • Vinorelbine (Navelbine) in non-small cell lung cancer: future directions. 
  • Vinorelbine (Navelbine)/carboplatin combination therapy: dose intensification with granulocyte colony-stimulating factor. 
  • Vinorelbine tartrate (Navelbine): drug profile and nursing implications of a new vinca alkaloid. 
  • Virtual bronchoscopy for directing transbronchial needle aspiration of hilar and mediastinal lymph nodes: a pilot study. 
  • Virtual reality: a distraction intervention for chemotherapy. 
  • Vitamin E succinate decreases lung cancer tumor growth in mice. 
  • Volume Pledge is Not Associated with Better Short-Term Outcomes After Lung Cancer Resection. 
  • Volumetric CT in lung cancer: an example for the qualification of imaging as a biomarker. 
  • Volumetric quantification of lung nodules in CT with iterative reconstruction (ASiR and MBIR). 
  • Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B. 
  • Weight loss over time and survival: a landmark analysis of 1000+ prospectively treated and monitored lung cancer patients. 
  • Weight loss, fatigue, and mediastinal and hilar adenopathy in a 67-year-old man. 
  • What bothers lung cancer patients the most? A prospective, longitudinal electronic patient-reported outcomes study in advanced non-small cell lung cancer. 
  • What's New in 10 Years? A Revised Cardiothoracic Curriculum for Diagnostic Radiology Residency with Goals and Objectives Related to General Competencies. 
  • What's next for immunotherapy in locally advanced NSCLC? 
  • When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis. 
  • Whole Exome Sequencing Identifies Frequent Somatic Mutations in Cell-Cell Adhesion Genes in Chinese Patients with Lung Squamous Cell Carcinoma. 
  • Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma. 
  • Why do cancer patients die in the emergency department?: an analysis of 283 deaths in NC EDs. 
  • X-ray irradiation induced Disabled-2 gene promoter de-methylation enhances radiosensitivity of non-small-cell lung carcinoma cells. 
  • XPA polymorphism associated with reduced lung cancer risk and a modulating effect on nucleotide excision repair capacity. 
  • Yield of Malignant Pleural Effusion for Detection of Oncogenic Driver Mutations in Lung Adenocarcinoma. 
  • Yield of brain 18F-FDG PET in evaluating patients with potentially operable non-small cell lung cancer. 
  • Young smokers' interpretations of the estimated lung cancer risk associated with a common genetic variant of low penetrance. 
  • Ziv-aflibercept: binding to more than VEGF-A--does more matter? 
  • [A study of E-cadherin and beta-catenin expression and their correlation with prognosis of nonsmall cell lung carcinoma]. 
  • [Experimental studies on human lung cancer gene-therapy with HSV-TK/GCV system]. 
  • [Human chromosome 8p11 (CHRNB3-CHRNA6) region gene polymorphisms and susceptibility to lung cancer in Chinese Han population]. 
  • [PCNA expression and AgNORs image analysis as factors in judging the prognosis of lung cancer]. 
  • [The relationship between drug sensitivity and expression of drug resistance gene mutations in non-small cell lung cancer]. 
  • [Variation of mortality risk among cancer patients and individualized therapy]. 
  • c-MYC antisense phosphosphorodiamidate morpholino oligomer inhibits lung metastasis in a murine tumor model. 
  • c-Maf: a bad influence in the education of macrophages. 
  • miR-126 and miR-126* repress recruitment of mesenchymal stem cells and inflammatory monocytes to inhibit breast cancer metastasis. 
  • microRNA-214 promotes epithelial-mesenchymal transition and metastasis in lung adenocarcinoma by targeting the suppressor-of-fused protein (Sufu). 
  • p53 and MDM2 immunostaining in pulmonary blastomas and bronchogenic carcinomas. 
  • p73 G4C14-to-A4T14 polymorphism and risk of lung cancer. 
  • xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. 
• 

  Keywords of People

  • Badea, Cristian Tudorel, Professor in Radiology, Biomedical Engineering
  • Berchuck, Andrew, James M. Ingram Distinguished Professor of Gynecologic Oncology, Obstetrics and Gynecology, Gynecologic Oncology
  • Chitneni, Satish K., Associate Professor in Radiology, Radiology
  • Craciunescu, Oana, Professor of Radiation Oncology, Radiation Oncology
  • Dement, John McCray, Professor Emeritus in Family Medicine and Community Health, Family Medicine & Community Health,Occupational & Environmental Medicine
  • Driehuys, Bastiaan, Professor of Radiology, Biomedical Engineering
  • Hogan, Brigid L. M., Research Professor of Cell Biology, Cell Biology
  • Hyslop, Terry, Adjunct Professor in the Department of Biostatistics & Bioinformatics, Duke Cancer Institute
  • Jowell, Paul Simon, Professor of Medicine, Medicine, Gastroenterology
  • LeBlanc, Thomas William, Associate Professor of Medicine, Duke Cancer Institute
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Muir, Kelly Walton, Associate Professor of Ophthalmology, Ophthalmology, Glaucoma
  • O'Daniel, Jennifer Colleen, Assistant Professor of Radiation Oncology, Radiation Oncology
  • Palmer, Gregory M., Associate Professor of Radiation Oncology, Radiation Oncology
  • Pang, Herbert, Adjunct Assistant Professor in the Department of Biostatistics & Bioinformatics, Biostatistics & Bioinformatics
  • Patz Jr., Edward F., James and Alice Chen Distinguished Professor of Radiology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Sullivan, Daniel Carl, Professor Emeritus of Radiology, Radiology
  • Turkington, Timothy Garvey, Associate Professor in Radiology, Radiology
  • Zhong, Xiaoping, Professor of Pediatrics, Integrative Immunobiology